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General introduction
Opioids comprise one of the most powerful groups of drugs available for the 
symptomatic treatment of both severe acute and chronic pain. In anesthesia a 
variety of opioids (remifentanil, fentanyl, sufentanil, morphine etc.) are 
administered by a variety of routes (oral, subcutaneous, intramuscular, 
intravenous, epidural, intrathecal) to manage acute, per- and postoperative pain.1 
For cancer pain the use of strong opioids (especially oral morphine) is 
recommended as “step 3” in the classic World Health Organization (WHO) 
Analgesic Ladder (ﬁ rst published in 1986 and updated in 1996) only after step 1 
(paracetamol/non-steroidal anti-inﬂ ammatory drugs (NSAID’s)) and step 2 
(weak opioids such as codeine) drugs fail to provide adequate relief.2 Opioids are 
also increasingly prescribed in the management of chronic non-cancer pain.3 
Several pain societies have developed guidelines with recommendations 
regarding opioid treatment for chronic non-cancer pain syndromes.4,5
The International Narcotics Control Board 6 reported that the stock of opiate raw 
materials, which are used to manufacture opioids destined for medical use, 
continues to grow at the global level. In spite of this growth, the availability and 
consumption of opioids for pain treatment remain extremely low in many 
countries worldwide: ten Western countries account for almost 90% of the total 
world consumption of morphine. It is anticipated that with time, the global 
consumption of opioids for the treatment of pain will increase, especially among 
developing countries, so that the gap in opioid use between developing and 
developed countries will decrease.
It is clear then, that in many developed Western countries, opioids are widely 
used for both acute and chronic pain management. However, opioids are not 
always prescribed or administered in the appropriate way or dose in both acute 
and chronic pain patients.7-11 This can only be solved by education of the 
prescriber (“the doctor”), the person who has to administer the prescribed drug 
(e.g. “the nurse”) and also the patient. This educational effort has to be combined 
with further development of protocols and guidelines. 
It is well recognized that opioids are the analgesic of choice for the treatment of 
moderate to severe pain and are generally quite effective. In spite of their 
beneﬁ ts, opioids are not wonder drugs and a number of problems may be 
encountered with their actual use:
1. Opioid induced tolerance and opioid induced hyperalgesia
It is generally known that the chronic administration of opioids can lead to 
the development of tolerance. The classical deﬁ nition of tolerance to opioids 
is the progressive reduction of their effects resulting in increased dose 
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requirements to achieve the same level of pain relief as before. In a review of 
the clinical experience of over 750 patients who received epidural and 
intrathecal opioids, it was found that tolerance developed to different degrees 
among patients; the need for increased dosage seemed to be related not only 
to changes in receptor sensitivity but also to changes in pain mechanisms.12 
The rate of development of tolerance is also variable between patients, but 
may be as rapid as a few days after the beginning of therapy.13 In neonates, 
tolerance is believed to develop more rapidly with continuous infusions of 
opioids (rather than intermittent doses) and with the use of synthetic opioids 
(e.g. fentanyl).14 
More recently it has been shown that tolerance can also develop after acute 
administration of the more novel and potent opioids. Vinik and Kissin 15 
showed that in humans, tolerance to analgesia during remifentanil infusion 
was profound and developed very rapidly. A comparable outcome was 
observed after the use of high dose fentanyl during surgery.16 
A growing body of evidence shows that opioids can also induce a state of 
abnormal pain experience.17,19 This is typically characterized by increased pain 
in response to a painful stimulus (hyperalgesia). This can in some cases 
explain the reduction of the opioid analgesic effects normally typically 
ascribed to tolerance. The development of an abnormal pain sensation 
following chronic exposure to opioids was reported by Brodner and Taub as 
early as 1978.20 More recently hyperalgesia was also described following the 
acute exposure to remifentanil.21,22
2. Opioid insensitivity
For both cancer and chronic non-cancer pain it was demonstrated that the 
pain experience may originate from different mechanisms each of which can 
have a differential sensitivity to opioids.23,24 Most notably, neuropathic pain 
has always been considered to be least responsive to opioids. However recent 
studies have shown that some opioid formulations can be of value in the 
treatment of neuropathic pain.25,26 Despite the promising results from these 
studies, the use of opioids in the treatment of neuropathic pain still remains a 
daily, clinical problem. For example, patients with peripheral neuropathic 
pain seem to be more responsive to opioids than those with pain from central 
lesions, and opioids appear to selectively reduce only some (but not all) of the 
symptoms of neuropathic pain.27
3. Opioid adverse effects
Opioids can be the cause of a number of troublesome adverse effects of 
which respiratory depression, sedation, nausea and vomiting, urinary 
retention and constipation or ileus are the most frequent and best known. The 
occurrence of these adverse effects can necessitate a reduction, or even 
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termination, of the use of opioids with increased pain as a consequence. For 
example, patient-controlled postoperative use of opioids can result in 
incidences of postoperative nausea and vomiting as high as 50%.28 These 
adverse effects can be equally, if not more, distressing to the patient than the 
pain itself; some patients may decide to stop self-administering opioids by 
patient-controlled analgesia (PCA) in order to reduce nausea and vomiting 
and are therefore forced to accept inadequate analgesia as a result.29
Several different approaches have been adopted to address the above-mentioned 
problems with the use of opioids. 
Additional drugs may be given to treat the adverse effect of opioids (such as anti-
emetics to treat or prevent nausea and vomiting). Another option is to try to 
reduce the use of opioids by co-administering drugs acting on other signalling 
pathways than opioids within the pain transmission system. There are several 
possibilities in this respect, such as the use of NSAIDs, paracetamol, local 
anesthetics, alpha-adrenergic drugs, etc.30,31 
A speciﬁ c option is to use drugs that have antagonistic activity at the N-methyl-
D-aspartate (NMDA) receptor. This NMDA receptor has been the subject of 
numerous studies in the last two decades. The following sections deal with the 
role of the NMDA receptor in pain and nociception.
The NMDA receptor
Glutamate, and its cogener aspartate, are considered to be the major signalling 
excitatory amino acids in the mammalian central nervous system (CNS).32 
Excitatory amino acid activity has been implicated in learning and memory, 
synaptic plasticity, nociception as well as a number of neurological and 
psychiatric disorders such as stroke, neurotrauma, Alzheimer’s disease, 
Huntington’s chorea, epilepsy, and schizophrenia.33
The higher concentration of glutamate in the dorsal versus ventral spinal cord 
was the main observation supporting its role in neurotransmission. Various 
studies showed that a large proportion of sensory ﬁ bers (including both small and 
large diameter ﬁ bers) contain glutamate and aspartate.34-37 Valtschanoff and 
coworkers 38 provided direct anatomical evidence that nerve terminals of primary 
afferent ﬁ bers, terminating in spinal laminae, appear to use excitatory amino 
acids as neurotransmitters. Glutamate has by now satisﬁ ed the main criteria for 
classiﬁ cation as a neurotransmitter.39-41
Two subgroups of glutamate receptors have been identiﬁ ed: ionotropic and 
metabotropic receptors (for reviews see Lodge 42 and Hudspith 43). Ionotropic 
receptors are ligand-operated ion channels which means that ﬁ rst a ligand must 
bind to the receptor before the ion channel can open. The ionotropic receptor 
family can be subdivided into three subtypes:
• The N-methyl-D-aspartate (NMDA) receptor, sensitive to glutamate and 
12
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NMDA.
• The alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) 
receptor, sensitive to glutamate, quisqualate (from the Cambodian quisquala 
tree), kainate and to AMPA.
• The kainate receptor, sensitive to glutamate and kainate.
The metabotropic receptors are linked to membrane G-proteins that modulate a 
variety of intracellular signal transduction pathways generating slow synaptic 
responses. Several metabotropic receptor subtypes have been identiﬁ ed.44
The NMDA receptor is well characterised within the group of glutamate 
receptors. NMDA receptors are composed of NR1, NR2 (A, B, C and D) and 
NR3 (A and B) subunits. It is not clear how many subunits are present in a native 
complex, although most models favor structures with 4 or 5 subunits. Functional 
NMDA receptors are formed by a combination of at least the NR1-subunit and 
one of four NR2-subunits. Co-expression studies have shown that many 
properties of the NR1/NR2 NMDA receptors depend on the type of NR2 subunit 
in the receptor complex. Accumulating evidence has suggested that especially the 
NR2B subunit is important for pain and nociception.45 Much less is known about 
the functional role of the NR3 subunits and no studies have been performed 
related to the role of NR3 subunits in pain mechanisms.
The NMDA receptor consists of an ion channel which is highly permeable to 
Ca2+. At resting potential this channel is blocked by Mg2+, and this block shows 
marked voltage dependence. So, unlike most ion channel complexes, the NMDA 
receptor is both voltage- and ligand-gated. 
Noxious stimulation and/or peripheral tissue injury give rise to release of 
glutamate and neurokinins (especially substance P) in the spinal cord from nerve 
terminals of A- and C-ﬁ bers. The release of glutamate activates the AMPA 
receptor (and probably also the kainate receptor 46) and the release of substance P 
activates the neurokinin (NK)1 receptor. This results in the depolarization of 
dorsal horn cells and the activation of the central pathways. If the depolarization 
caused by the activation of AMPA and NK1 receptors is of sufﬁ cient duration 
and magnitude, the Mg2+-block of the NMDA receptor will be removed. Before 
the NMDA receptor can be further activated, the binding of glycine to the 
receptor is required. Glycine acts as a co-agonist for glutamate and binds at a 
receptor site on the NR1 subunit, while the receptor site for glutamate is on the 
NR2 subunit (see Figure 1).47,48 After release of the Mg2+ block and the binding of 
glycine and glutamate, the NMDA receptor is activated and Ca2+ moves into the 
cell from the extracellular space. The rise in intracellular calcium activates Ca2+ 
second and third messenger signalling pathways, which leads to increased 
intracellular concentration of protein kinase C (PKC). PKC has an important role 
in the further sensitization of the postsynaptic cell; it catalyses phosphorylation 
of the NMDA receptor, leading to enhancement of the NMDA mediated 
glutamate responses and to long term potentiation of synaptic transmission (also 
see The NMDA receptor and central sensitization).49,50 There is also evidence that 
the NMDA receptor is involved in longer-lasting changes by stimulating new 
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gene expression (e.g. c-fos).51,52
In 1987 both Dickenson and Sullivan 53 and Davies and Lodge 54 provided ﬁ rst 
evidence on the role of the NMDA receptor in pain and nociception. Since then, 
many animal and clinical studies have conﬁ rmed that the NMDA receptors and 
NMDA receptor (ant)agonists play important roles in pain and nociception (for 
reviews see Parsons 55, Petrenko et al.45 and McCartney et al.56). Some of these 
roles will now be discussed in more detail. 
 
The NMDA receptor, opioid tolerance and opioid induced hyperalgesia
There is accumulating evidence indicating that opioid tolerance and opioid 
induced hyperalgesia are related features which share the same mechanisms. A 
number of factors (such as the presence of anti-opioid peptides (cholecystokinin, 
orphanin FQ/nociceptin, dynorphin),19 activation of different neuroimmune 
factors (glia, cytokines),57 activation of the NMDA receptor 58,59) have been 
identiﬁ ed which indeed are involved in the development of opioid induced 
Figure 1. Schematic diagram of the molecular structure of the NMDA receptor. The receptor consists 
of ﬁ ve subunits surrounding a central ion channel permeable for Ca2+ (and, to a lesser degree, for Na+ 
and K+). One of the subunits has been removed to allow a view inside the ion channel, in which the 
binding site for Mg2+ () is located. Glycine () acts as a co-agonist for glutamate and binds at a 
receptor site on the NR1 subunit, while the receptor site for glutamate () is on the NR2 subunit.
(Adapted from Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg 
1988;87:1186-93)
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tolerance as well as the development of opioid induced hyperalgesia. Of these 
various factors, the role of the NMDA receptor is the best studied. Opioids 
activate NMDA dependent, pronociceptive processes which are involved in the 
development of tolerance after acute administration of opioids,60,61 development 
of tolerance after chronic administration 62,63 and in the development of 
hyperalgesia.64 It is however unclear how the activation of the NMDA receptors 
could be initiated after opioid administration. Mu-opioid receptor occupation 
stimulates the activation of NMDA receptors by increasing intracellular protein 
PKC.49,65 Celerier et al.50 showed that PKC (and especially the gamma isoform 
(PKC)) is probably the key factor relating the NMDA receptor to opioid 
induced tolerance and opoid induced hyperalgesia. Recent animal data has also 
provided evidence for a possible important role of the postsynaptic density 
protein-95 and postsynaptic density protein-93 in NMDA receptor mediated pain 
and opioid tolerance.66,67 More research is needed to unravel the molecular 
mechanisms implicated in the interaction between opioids and NMDA receptors.
 
The NMDA receptor and central sensitization
Some patients who undergo surgery continue to complain of pain long after 
healing of the surgical wounds.68 Usually there is hyperalgesia (increased 
response to noxious stimuli) and spread of pain and hyperalgesia to areas outside 
the surgical scars (secondary hyperalgesia). The fact that this pathological pain 
persists long after healing of the tissues suggests that changes have occurred in 
the nociceptive pathways of the CNS. There is now indeed a large body of 
evidence supporting the concept that peripheral injury can produce central 
changes which are maintained even after the noxious inputs are removed or the 
injury has healed. This plasticity of the CNS, often referred to as central 
sensitization, is important in the transition from acute to chronic pain.18,69,70
Activation of the NMDA receptor plays a crucial role in central sensitization. If 
nociceptive input has led to channel opening, activation of PKC and 
phosphorylation of the NMDA receptor (also see The NMDA receptor), the 
excitability of the receptor is increased.71 Thus, nociceptive input can lead to 
changes in the way the CNS responds to subsequent inputs and central 
sensitization is established. The role of the NMDA receptor is further highlighted 
by ﬁ ndings that central sensitization could be prevented or reversed by 
substances which antagonize the NMDA receptor.18 
The NMDA receptor, pre-emptive and preventive analgesia
The ﬁ nding that nociception from peripheral injury can lead to central 
sensitization (which ampliﬁ es pain) led to the concept of pre-emptive analgesia. 
In this concept the establishment of central sensitization is prevented by using an 
antinociceptive intervention (for example by administering a NMDA receptor 
antagonist) started before the beginning of the acute nociceptive stimulation. This 
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also implies that starting the antinociceptive intervention after the beginning of 
the acute nociceptive stimulation should have no (or a signiﬁ cantly lesser) 
effect.69,72
Although evidence from basic animal experimental work strongly supports the 
concept that pre-treatment with a NMDA receptor antagonist before versus after 
painful stimulation can prevent central sensitization, the result of studies 
regarding its clinical value are still controversial.73,74 Based on the ﬁ ndings that 
opioids can induce (acute) tolerance and/or hyperalgesia and that central 
sensitization is not only induced during surgery but also postoperatively by 
inﬂ ammatory injury, it was suggested that the preventive use of NMDA receptor 
antagonists (i.e. administration of a NMDA receptor antagonist before induction 
of anesthesia (preferably before the opioid is given) with continuation into the 
postoperative period) might lead to better clinically results.75,76 The clinical value 
of pre-emptive analgesia and the newer concept of preventive analgesia is further 
discussed in Chapter 2 and 3 of this thesis.
The NMDA receptor and neuropathic pain
It is now recognized that the process of central sensitization also plays a key role 
in the induction of development of neuropathic pain syndromes. Neuropathic 
pain is caused by nerve damage, which can originate from metabolic, traumatic, 
ischaemic, infectious or immune-mediated factors. Neuropathic pain consist of 
stimulus-independent (persistent, paroxysmal, shooting, lancinating or burning 
pain) as well as stimulus-dependent pain with hyperalgesia as the key feature. 
Hyperalgesia is also a key feature of central sensitization and there is evidence 
that central sensitization mechanisms play an important role in neuropathic 
pain.77 This is supported by ﬁ ndings from a number of studies showing that 
NMDA receptor antagonists can abolish different aspects of the abnormal pain 
sensations in patients with neuropathic pain.78-81 Animal studies have 
demonstrated that the application of a NMDA receptor antagonist improves the 
effectiveness of opioids in neuropathic pain.82,83 The combined use of opioids and 
NMDA receptor antagonists might thus be of value in the treatment of 
neuropathic pain.  
Aim of the thesis
This thesis aims to enhance knowledge about the effects of combining opioids 
with clinically available NMDA receptor antagonists in the treatment of pain. 
The objective of this thesis is based on the following ﬁ ndings:
• Even the short term use of opioids can lead to the development of opioid 
induced tolerance and/or a state of abnormal pain sensation (hyperalgesia) 
which lessens the effectiveness of opioids.
• In certain types of pains (e.g. (central) neuropathic pain) opioids possess 
limited efﬁ cacy.
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• Use of opioids can result in adverse effects which can be troublesome and 
hinder the effective use of these drugs.
• The NMDA receptor plays a key role in the development of opioid induced 
tolerance, opioid induced hyperalgesia, central sensitization and neuropathic 
pain syndromes. Furthermore, NMDA receptor antagonists have been shown 
in certain instances to prevent or reverse these phenomena. 
Based on these considerations, it is likely that administering opioids together 
with NMDA receptor antagonists might combine the beneﬁ ts of both drugs and 
in this way improve the treatment of pain.
Clinically available drugs with NMDA receptor antagonist 
properties
There are a number of clinically available drugs with NMDA receptor antagonist 
properties which could potentially be used as co-analgesic drugs in combination 
with opioids. In the Netherlands the following drugs are available:
• ketamine, a racemic mixture of two enantiomers, s(+)- and r(-)-ketamine (in 
August 2000 the racemate was replaced by the s(+)-enantiomer) 
• dextromethorpan
• magnesium
• amantadine
• methadone
• memantine (available since September 2002) 
In most studies concerning the use of clinically available NMDA receptor 
antagonists (racemic) ketamine, magnesium and dextromethorphan have been 
used.56,84,85 Other drugs such as s(+)-ketamine, amantadine and methadone have 
attracted much less attention. 
Although the NMDA receptor antagonist properties of these drugs are 
emphasized in this thesis, it is also pointed out that these drugs can mediate 
effects through interactions with other receptors.
Research questions
Both animal experimental and clinical studies were performed. Three clinically 
available substances with NMDA receptor antagonist properties were used and 
the following research questions addressed:
For ketamine
• Does pre-emptive analgesia using intravenous fentanyl plus low dose 
(racemic) ketamine, versus intravenous fentanyl alone, for radical 
prostatectomy under general anesthesia produce short term or long term 
reductions in pain or analgesic use? (Chapter 2) 
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• What is the effect of preventive analgesia by using intra- and postoperative 
low dose s(+)-ketamine plus morphine on postoperative pain and analgesic 
consumption after radical prostatectomy? (Chapter 3)
• Can a continuous parenteral infusion of low dose (racemic) ketamine 
effectively be used in the treatment of neuropathic pain (uncontrolled by high 
doses of opioids) in terminal cancer patients? (Chapter 6a)
For amantadine
• What is the effect on postoperative pain and opioid consumption of 
amantadine given orally over the perioperative period in patients undergoing 
radical prostatectomy? (Chapter 4)
• What are the effects of pre-treatment with amantadine on morphine induced 
antinociception during second phase formalin responses in rats? (Chapter 5)
For methadone
• Can methadone effectively be used in the treatment of phantom limb pain? 
(Chapter 6b) 
18
General introduction, aim of the thesis and research questionsChapter 1
References
1. Bowdle TA. Pharmacology of analgesia. In: Wylie and Churchill-Davidson’s - A practice of 
anesthesia, 7th Edition. Edited by Healy TE, Knight PR. London, Arnold, 2003:543-63.
2.  WHO. Cancer pain relief with a guide to opioid availability, 2nd Edition. Geneva, World Health 
Organization, 1996.
3.  Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003;349:1943-53.
4.  Jovey RD, Ennis J, Gardner-Nix J, Goldman B, Hays H, Lynch M, Moulin D. Use of opioid 
analgesics for the treatment of chronic noncancer pain-A consensus statement and guidelines 
from the Canadian Pain Society, 2002. Pain Res Manag 2003;8 (Suppl A):3A-28A.
5.  Kalso E, Allan L, Dellemijn PL, Faura CC, Ilias WK, Jensen TS, Perrot S, Plaghki LH, Zenz M. 
Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003;7:381-6.
6. International Narcotics Control Board. Report of the international narcotics control board for 
2003. New York, United Nations, 2004. 
7. Dolin SJ, Cashman JN, Bland JM. Effectiveness of acute postoperative pain management:
 I. Evidence from published data. Br J Anaesth 2002;89:409-23.
8. Shvartzman P, Friger M, Shani A, Barak F, Yoram C, Singer Y. Pain control in ambulatory cancer 
patients-Can we do better? J Pain Symptom Manag 2003;26:716-22.
9. Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeland CS, Uchitomi Y. Adequacy 
of cancer pain management in a Japanese Cancer Hospital. Jpn J Clin Oncol 2004;34:37-42.
10. Di Maio M, Gridelli C, Gallo C, Manzione L, Brancaccio L, Barbera S, Robbiati SF, Ianniello 
GP, Ferrau F, Piazza E, Frontini L, Rosetti F, Carrozza F, Bearz A, Spatafora M, Adamo V, Isa L, 
Iaffaioli RV, Di Salvo E, Perrone F. Prevalence and management of pain in Italian patients with 
advanced non-small-cell lung cancer. Br J Cancer 2004;90:2288-96.
11.  Cascinu S, Giordani P, Agostinelli R, Gasparini G, Barni S, Beretta GD, Pulita F, Iacorossi L, 
Gattuso D, Mare M, Munao S, Labianca R, Todeschini R, Camisa R, Cellerino R, Catalano G. 
Pain and its treatment in hospitalized patients with metastatic cancer.
 Support Care Cancer 2003;11:587-92.
12. Arner S, Rawal N, Gustafsson LL. Clinical experience of long-term treatment with epidural and 
intrathecal opioids-A nationwide survey. Acta Anaesthesiol Scand 1988;32:253-9.
13.  Foley KM. Misconceptions and controversies regarding the use of opioids in cancer pain.
 Anticancer Drugs 1995;6 (Suppl 3):4-13.
19
Chapter 1General introduction, aim of the thesis and research questions
14.  Suresh S, Anand KJ. Opioid tolerance in neonates: mechanisms, diagnosis, assessment, and 
management. Semin Perinatol 1998;22:425-33.
15.  Vinik HR, Kissin I. Rapid development of tolerance to analgesia during remifentanil infusion in 
humans. Anesth Analg 1998;86:1307-11.
16.  Chia YY, Liu K, Wang JJ, Kuo MC, Ho ST. Intraoperative high dose fentanyl induces 
postoperative fentanyl tolerance. Can J Anaesth 1999;46:872-7.
17.  Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current 
view of their possible interactions. Pain 1995;62:259-74.
18.  Eide PK. Wind-up and the NMDA receptor complex from a clinical perspective.
 Eur J Pain 2000;4:5-15.
19.  Simonnet G, Rivat C. Opioid-induced hyperalgesia: abnormal or normal pain?
 Neuroreport 2003;14:1-7.
20.  Brodner RA, Taub A. Chronic pain exacerbated by long-term narcotic use in patients with 
nonmalignant disease: clinical syndrome and treatment. Mt Sinai J Med 1978;45:233-7.
21. Hood DD, Curry R, Eisenach JC. Intravenous remifentanil produces withdrawal hyperalgesia in 
volunteers with capsaicin-induced hyperalgesia. Anesth Analg 2003;97:810-5.
22. Angst MS, Koppert W, Pahl I, Clark DJ, Schmelz M. Short-term infusion of the mu-opioid 
agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain 2003;106:49-57.
23. Arner S, Arner B. Differential effects of epidural morphine in the treatment of cancer-related 
pain. Acta Anaesthesiol Scand 1985;29:32-6.
24. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms 
of pain. Pain 1988;33:11-23.
25. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for 
chronic peripheral and central neuropathic pain. N Engl J Med 2003;348:1223-32.
26. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuro-
 pathy: a randomized controlled trial. Neurology 2003;60:927-34.
27. Attal N, Guirimand F, Brasseur L, Gaude V, Chauvin M, Bouhassira D. Effects of IV morphine 
in central pain: a randomized placebo-controlled study. Neurology 2002;58:554-63.
28. Tramer MR, Walder B. Efﬁ cacy and adverse effects of prophylactic antiemetics during patient-
controlled analgesia therapy: a quantitative systematic review. Anesth Analg 1999;88:1354-61.
20
General introduction, aim of the thesis and research questionsChapter 1
29.  Taylor NM, Hall GM, Salmon P. Patients’ experiences of patient-controlled analgesia.
 Anaesthesia 1996;51:525-8.
30.  Dahl V, Raeder JC. Non-opioid postoperative analgesia.
Acta Anaesthesiol Scand 2000;44:1191-203.
31.  McNicol E, Strassels S, Goudas L, Lau J, Carr D. Nonsteroidal anti-inﬂ ammatory drugs, alone or 
combined with opioids, for cancer pain: a systematic review. J Clin Oncol 2004;22:1975-92.
32.  Headley PM, Grillner S. Excitatory amino acids and synaptic transmission: the evidence for a 
physiological function. Trends Pharmacol Sci 1990;11:205-11.
33.  Palfreyman MG. Glutamate receptors and their regulators - an overview. In: Direct and allosteric 
control of glutamate receptors. Edited by Palfreyman MG, Reynolds IJ, Skolnick P. Boca Raton, 
CRC Press, 1994:1-19.
34.  Battaglia G, Rustioni A. Coexistence of glutamate and substance P in dorsal root ganglion 
neurons of the rat and monkey. J Comp Neurol 1988;277:302-12.
35.  Maxwell DJ, Christie WM, Short AD, Storm-Mathisen J, Ottersen OP. Central boutons of 
glomeruli in the spinal cord of the cat are enriched with L-glutamate-like immunoreactivity.
 Neuroscience 1990;36:83-104.
36.  Clements JR, Magnusson KR, Hautman J, Beitz AJ. Rat tooth pulp projections to spinal 
trigeminal subnucleus caudalis are glutamate-like immunoreactive.
J Comp Neurol 1991;309:281-8.
37.  Merighi A, Polak JM, Theodosis DT. Ultrastructural visualization of glutamate and aspartate 
immunoreactivities in the rat dorsal horn, with special reference to the co-localization of 
glutamate, substance P and calcitonin-gene related peptide. Neuroscience 1991;40:67-80.
38.  Valtschanoff JG, Phend KD, Bernardi PS, Weinberg RJ, Rustioni A. Amino acid 
immunocytochemistry of primary afferent terminals in the rat dorsal horn.
J Comp Neurol 1994;346:237-52.
39.  Cotman CW, Kahle JS, Miller E, Ulas J, Bridges RJ. Excitatory amino acid neurotransmission. 
In: Psychopharmacology: the fourth generation of progress. Edited by Bloom FE, Kupfer. New 
York, Raven Press, 1995:75-85.
40.  Cooper JR, Bloom FE, Roth RH. Amino acids transmitters. In: The biochemical basis of 
neuropharmacology, 7th Edition. Edited by Cooper JR, Bloom FE, Roth RH. New York, Oxford 
University Press, 1996:126-93.
21
Chapter 1General introduction, aim of the thesis and research questions
41.  Malandro MS, Kilberg MS. Molecular biology of mammalian amino acid transporters.
Annu Rev Biochem 1996;65:305-36.
42.  Lodge D. Subtypes of glutamate receptors. In: The ionotropic glutamate receptors. Edited by 
Monaghan DT, Wenthold RJ. Totowa, Humana Press, 1997:1-38.
43.  Hudspith MJ. Glutamate: a role in normal brain function, anaesthesia, analgesia and CNS injury. 
Br J Anaesth 1997;78:731-47.
44.  Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and functions.
 Neuropharmacology 1995;34:1-26.
45.  Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA) 
receptors in pain: a review. Anesth Analg 2003;97:1108-16.
46.  Li P, Wilding TJ, Kim SJ, Calejesan AA, Huettner JE, Zhuo M. Kainate-receptor-mediated 
sensory synaptic transmission in mammalian spinal cord. Nature 1999;397:161-4.
47.  Hirai H, Kirsch J, Laube B, Betz H, Kuhse J. The glycine binding site of the N-methyl-D-
aspartate receptor subunit NR1: identiﬁ cation of novel determinants of co-agonist potentiation in 
the extracellular M3-M4 loop region. Proc Natl Acad Sci U S A 1996;93:6031-6.
48. Laube B, Hirai H, Sturgess M, Betz H, Kuhse J. Molecular determinants of agonist 
discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B 
subunit. Neuron 1997;18:493-503.
49.  Chen L, Huang LY. Protein kinase C reduces Mg2+ block of NMDA-receptor channels as a 
mechanism of modulation. Nature 1992;356:521-3.
50.  Celerier E, Simonnet G, Maldonado R. Prevention of fentanyl-induced delayed pronociceptive 
effects in mice lacking the protein kinase C gene. Neuropharmacology 2004;46:264-72.
51.  Wilcox GL. Excitatory neurotransmitters and pain. In: Proceedings of the VIth World Congress on 
Pain. Edited by Bond MR, Charlton JE, Woolf CJ. Amsterdam, Elsevier Science Publishers B.V., 
1991:97-117.
52. Munglani R, Hunt SP. Molecular biology of pain. Br J Anaesth 1995;75:186-92.
53.  Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency 
dependent potentiation of deep rat dorsal horn nociceptive neurones following C ﬁ bre 
stimulation. Neuropharmacology 1987;26:1235-8.
54.  Davies SN, Lodge D. Evidence for involvement of N-methylaspartate receptors in ‘wind-up’ of 
class 2 neurones in the dorsal horn of the rat. Brain Res 1987;424:402-6.
22
General introduction, aim of the thesis and research questionsChapter 1
55.  Parsons CG. NMDA receptors as targets for drug action in neuropathic pain.
 Eur J Pharmacol 2001;429:71-8.
56.  McCartney CJ, Sinha A, Katz J. A qualitative systematic review of the role of N-methyl-D-
aspartate receptor antagonists in preventive analgesia. Anesth Analg 2004;98:1385-400.
57.  Deleo JA, Tanga FY, Tawﬁ k VL. Neuroimmune activation and neuroinﬂ ammation in chronic pain 
and opioid tolerance/hyperalgesia. Neuroscientist 2004;10:40-52.
58.  Price DD, Mayer DJ, Mao J, Caruso FS. NMDA-receptor antagonists and opioid receptor 
interactions as related to analgesia and tolerance. J Pain Symptom Manag 2000;19:S7-11.
59.  Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy.
 Pain 2002;100:213-7.
60.  Celerier E, Laulin J, Larcher A, Le Moal M, Simonnet G. Evidence for opiate-activated NMDA 
processes masking opiate analgesia in rats. Brain Res 1999;847:18-25.
61.  Celerier E, Rivat C, Jun Y, Laulin JP, Larcher A, Reynier P, Simonnet G. Long-lasting 
hyperalgesia induced by fentanyl in rats: preventive effect of ketamine.
Anesthesiology 2000;92:465-72.
62.  Laulin JP, Celerier E, Larcher A, Le Moal M, Simonnet G. Opiate tolerance to daily heroin 
administration: an apparent phenomenon associated with enhanced pain sensitivity.
 Neuroscience 1999;89:631-6.
63.  Celerier E, Laulin JP, Corcuff JB, Le Moal M, Simonnet G. Progressive enhancement of delayed 
hyperalgesia induced by repeated heroin administration: a sensitization process. 
 J Neurosci 2001;21:4074-80.
64.  Rivat C, Laulin JP, Corcuff JB, Celerier E, Pain L, Simonnet G. Fentanyl enhancement of 
carrageenan-induced long-lasting hyperalgesia in rats: prevention by the N-methyl-D-aspartate 
receptor antagonist ketamine. Anesthesiology 2002;96:381-91.
65.  Chen L, Huang LY. Sustained potentiation of NMDA receptor-mediated glutamate responses 
through activation of protein kinase C by a mu opioid. Neuron 1991;7:319-26.
66.  Tao YX, Rumbaugh G, Wang GD, Petralia RS, Zhao C, Kauer FW, Tao F, Zhuo M, Wenthold RJ, 
Raja SN, Huganir RL, Bredt DS, Johns RA. Impaired NMDA receptor-mediated postsynaptic 
function and blunted NMDA receptor-dependent persistent pain in mice lacking postsynaptic 
density-93 protein. J Neurosci 2003;23:6703-12.
23
Chapter 1General introduction, aim of the thesis and research questions
67.  Liaw WJ, Zhang B, Tao F, Yaster M, Johns RA, Tao YX. Knockdown of spinal cord postsynaptic 
density protein-95 prevents the development of morphine tolerance in rats.
 Neuroscience 2004;123:11-5.
68.  Perkins FM, Kehlet H. Chronic pain as an outcome of surgery. A review of predictive factors. 
Anesthesiology 2000;93:1123-33.
69.  Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to 
pathological pain: review of clinical and experimental evidence. Pain 1993;52:259-85.
70.  Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000;288:1765-9.
71.  Woolf CJ. Central mechanisms of acute pain. In: Proceedings of the VIth World Congress on Pain. 
Edited by Bond MR, Charlton JE, Woolf CJ. Amsterdam, Elsevier Science Publishers B.V., 
1991:25-34.
72.  Woolf CJ, Chong MS. Preemptive analgesia-Treating postoperative pain by preventing the 
establishment of central sensitization. Anesth Analg 1993;77:362-79.
73.  Wilder-Smith OH. Pre-emptive analgesia and surgical pain. Prog Brain Res 2000;129:505-24.
74.  Moiniche S, Kehlet H, Dahl JB. A qualitative and quantitative systematic review of preemptive 
analgesia for postoperative pain relief: the role of timing of analgesia.
 Anesthesiology 2002;96:725-41.
75.  Kissin I, Bright CA, Bradley EL. The effect of ketamine on opioid-induced acute tolerance: can 
it explain reduction of opioid consumption with ketamine-opioid analgesic combinations?
 Anesth Analg 2000;91:1483-8.
76.  Katz J. Timing of treatment and pre-emptive analgesia. In: Clinical management of pain. Edited 
by Rice AS, Warﬁ eld CA, Justins D, Eccleston C. London, Arnold, 2003:113-62.
77.  Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. 
Lancet 1999;353:1959-64.
78.  Eide PK, Jorum E, Stubhaug A, Bremnes J, Breivik H. Relief of post-herpetic neuralgia with the 
N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison 
with morphine and placebo. Pain 1994;58:347-54.
79.  Felsby S, Nielsen J, Arendt-Nielsen L, Jensen TS. NMDA receptor blockade in chronic 
neuropathic pain: a comparison of ketamine and magnesium chloride. Pain 1996;64:283-91.
24
General introduction, aim of the thesis and research questionsChapter 1
80.  Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose oral dextromethorphan 
versus placebo in painful diabetic neuropathy and postherpetic neuralgia.
Neurology 1997;48:1212-8.
81.  Jorum E, Warncke T, Stubhaug A. Cold allodynia and hyperalgesia in neuropathic pain: the effect 
of N-methyl-D-aspartate (NMDA) receptor antagonist ketamine - a double-blind, cross-over 
comparison with alfentanil and placebo. Pain 2003;101:229-35.
82.  Yamamoto T, Yaksh TL. Studies on the spinal interaction of morphine and the NMDA antagonist 
MK-801 on the hyperesthesia observed in a rat model of sciatic mononeuropathy.
 Neurosci Lett 1992;135:67-70.
83.  Pelissier T, Laurido C, Kramer V, Hernandez A, Paeile C. Antinociceptive interactions of 
ketamine with morphine or methadone in mononeuropathic rats.
Eur J Pharmacol 2003;477:23-8.
84.  Weinbroum AA, Rudick V, Paret G, Ben Abraham R. The role of dextromethorphan in pain 
control. Can J Anaesth 2000;47:585-96.
85.  Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. 
Anesth Analg 2003;97:1730-9.
 
25
Chapter 2Pre-emptive analgesia using intravenous fentanyl plus low dose ketamine...
Chapter 2
Pre-emptive analgesia using intravenous fentanyl plus low 
dose ketamine for radical prostatectomy under  general 
 anesthesia does not produce short term or long term 
 reductions in pain or analgesic use 
Katz J, Schmid R, Snijdelaar DG, Coderre TJ, McCartney CJ, 
Wowk A
Pain 2004;110:707-18
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Introduction
Ketamine hydrochloride operates on multiple receptor systems.1 However, its 
property as a non-competitive NMDA receptor antagonist generated a new focus 
of research activity once this receptor-ion channel complex was found to play a 
critical role in the induction and maintenance of central sensitization and 
pathological pain.2,3 The mechanism by which pain and analgesic consumption 
are reduced after pre-emptive administration of local anesthetics and opioids is 
believed to involve the prevention of NMDA-mediated sensitization of spinal 
cord dorsal horn neurons.4,5 Thus, the NMDA channel blocker ketamine has been 
of particular interest in evaluating the hypothesis that ketamine administration 
before surgery would reduce pain and analgesic consumption relative to saline 
administration or to ketamine administration after incision.
Studies of pre-emptive analgesia using intravenous low dose ketamine have 
yielded mixed results.1,6,7 This is in part due to the large inter-study variability in 
surgical procedure, patient population, dose of ketamine, use of additional 
analgesic agents intraoperatively and study design. One of the aims of the present 
study was to evaluate the effects on postoperative pain and morphine 
consumption of pre-incisional versus post-incisional intravenous (i.v.) 
administration of the mu-opioid agonist fentanyl plus low dose ketamine. Use of 
these two agents together would be expected to capitalize on their combined 
actions in reducing nociceptive input and central sensitization.8,9 We hypothesized 
that morphine consumption would be lower in the pre-incisional group compared 
with the post-incisional group. 
Debate about the efﬁ cacy of pre-emptive analgesia stems in part from a 
fundamental misconception about its deﬁ nition.5,6 The typical two-group design 
that compares administration of an agent before versus after incision or surgery 
fails to control for the possibility that early and late noxious intraoperative 
stimuli contribute equally to postoperative central sensitization. Two group 
studies that do not show a signiﬁ cant difference in outcome leave open the 
question of whether the absence of an effect reﬂ ects the relative efﬁ cacy of 
postoperative blockade or the inefﬁ cacy of pre-operative blockade in reducing 
central sensitization.6,10 
Therefore, the second aim of the present study was to evaluate postoperative pain 
and analgesic use after pre-operative or postincisional i.v. fentanyl plus low dose 
i.v. ketamine versus a standard treatment control condition consisting of i.v. 
fentanyl but not ketamine. Men undergoing radical prostatectomy under general 
anesthesia were randomly assigned in a double-blinded manner to one of three 
groups: (1) i.v. fentanyl plus low dose i.v. ketamine (bolus plus infusion) before 
incision and i.v. fentanyl plus i.v. saline (bolus plus infusion) after incision;
(2) i.v. fentanyl plus i.v. saline (bolus plus infusion) before incision and i.v. 
fentanyl plus low dose i.v. ketamine (bolus plus infusion) after incision; or
(3) i.v. fentanyl plus i.v. saline (bolus plus infusion) before and after incision.
We hypothesized that postoperative pain and morphine consumption would be 
28
Pre-emptive analgesia using intravenous fentanyl plus low dose ketamine...Chapter 2
lowest in the pre-incision group and highest in the control group.
Materials and methods
Approval to carry out the study was obtained from The Toronto Hospital 
Research Ethics Board. All patients gave their written informed consent to 
participate before entering the study.
Patients scheduled for radical prostatectomy for prostate cancer were eligible for 
recruitment into the study. Inclusion criteria were American Society of 
Anesthesiologists (ASA) physical status I-II, age between 19 and 75 years and 
able to speak and read English. Exclusion criteria were contraindications to (i.v.) 
patient-controlled analgesia (PCA) with morphine, ASA physical status > II, 
history of major psychiatric disorder and chronic opioid use.
Randomization and blinding procedures
A randomization schedule was computer-generated 11 and provided to the 
hospital pharmacist who prepared and dispensed the study drug. The 
randomization schedule speciﬁ ed the group (1, 2, or 3) to which each prospective 
patient would be allocated upon entry into the trial. An opaque envelope 
containing the patient number and group assignment was prepared, sealed and 
numbered for each patient by the hospital pharmacist. 
All patients and personnel involved in patient management and data collection 
were unaware of the group to which the patient had been allocated. The 
anesthesiologist in charge of the case was also unaware of group allocation.
Drug preparation
A standard volume of ketamine hydrochloride and normal saline was prepared in 
two separate 60 ml syringes, coded for blinding purposes and dispensed by the 
hospital pharmacy on the day of surgery. The syringes were labeled “pre-
incision” and “post-incision”. For group 1 and group 2 patients, one syringe 
contained 60 ml ketamine hydrochloride (1 mg ml-1); the second contained 60 ml 
normal saline. For group 3 patients, both syringes contained 60 ml normal saline. 
The pharmacist who dispensed the study medications was not involved in any 
other aspect of the study. 
Pain assessment instruments
Visual analogue scale (VAS)
The VAS provides a simple, efﬁ cient and minimally intrusive measure of pain 
intensity that has been used widely in research settings where a quick index of 
pain is required and to which a numerical value can be assigned.12 The VAS 
consists of a 10 cm horizontal line with the two endpoints labeled “no pain” and 
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“worst possible pain”, respectively. The patient is required to mark the 10 cm line 
at a point that corresponds to the level of pain intensity he presently feels. The 
distance in cm from the low end of the VAS and the patient’s mark is used as a 
numerical index of pain intensity. Pain was assessed with patients at rest
(VAS-R) and after standard mobilization (VAS-M) by asking patients to roll from 
a supine to a side-lying position and perform two maximal inspirations before 
rating their pain. 
McGill Pain Questionnaire (MPQ)
The MPQ was developed by Melzack 13 to obtain quantitative and qualitative 
measures of the experience of pain. The MPQ yields two global scores, the pain 
rating index (PRI) and the present pain intensity (PPI), which have been found to 
provide valid and reliable measures of pain.12,13 The PRI is the sum of the rank 
values of the words chosen from 20 sets of qualitative words, each set containing 
two to six adjectives that describe the sensory, affective and evaluative properties 
of pain. The lists of pain descriptors are read to the patients who are asked to 
choose the word in each category that best describes their pain at the moment. 
The PPI is rated on a scale of 0-5 as follows: 0 = none, 1 = mild,
2 = discomforting, 3 = distressing, 4 = horrible and 5 = excruciating. 
von Frey ﬁ laments
Secondary mechanical hyperalgesia to punctate stimulation applied to the skin 
was assessed using von Frey ﬁ laments (Smith & Nephew Rolyan Inc., 
Menomonee Falls, WI, USA) that consist of a set of 20 individual nylon 
ﬁ laments of equal length (38 mm) ranging from 0.06 to 1.14 mm in diameter. 
Each ﬁ lament has been assigned a value that represents the logarithm of the force 
(in mg) required to bend it maximally when pressed against the skin. To 
minimize the assessment burden on the patients, we used every other ﬁ lament 
beginning with the smallest (0.06 mm). On each trial, a ﬁ lament was applied to 
the designated point on the skin for approximately one second. Trials were 
separated by an interval ranging from ﬁ ve to ﬁ fteen seconds in order to reduce 
the likelihood of anticipatory responses. Filaments were applied in ascending 
serial order. Touch threshold (TT) was deﬁ ned by the value (force in log mg) 
associated with the ﬁ lament that patients ﬁ rst reported a sensation of touch. Pain 
threshold (PT) was deﬁ ned by the value (force in log mg) associated with the 
ﬁ lament that patients ﬁ rst reported as being uncomfortable or painful. PTs were 
obtained from two regions of the body: a control site on the inner forearm and a 
test site approximately 10 cm from the wound dressing. 
Measures of psychosocial functioning
Mental Health Inventory (MHI)
The MHI 14 is a self-administered questionnaire that measures symptoms of 
psychological distress and well-being. The present study used an 18-item version 
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of the MHI that consists of a total score and ﬁ ve subscales: anxiety, depression, 
loss of behavioral/emotional control, positive affect and interpersonal ties.15 
Subjects responded to each of the 18 statements on the basis of how often “in the 
past month” they have experienced each symptom. Each statement is 
accompanied by a six choice response set ranging from 1 = all of the time to
6 = none of the time. The total score, which we report in the present study, ranges 
from 0 to 108 with higher scores indicative of better mental health. The MHI was 
administered prior to surgery. Internal reliability of the MHI subscales by 
Cronbach’s alpha ranged from 0.10 (loss of behavioral/emotional control) to 0.85 
(depression). 
Spielberger State-Trait Anxiety Inventory (STAI)
The STAI 16 is composed of two forms, each of which measures separate 
dimensions of anxiety. The STAI-S consists of 20 statements and measures “state 
anxiety”. The patients are required to respond on the basis of how they are 
feeling “right now” (i.e., at the moment when completing the form). The STAI-T 
measures anxiety as an enduring personality trait and consists of another 20 
statements that pertain to how the patients “generally feel”. The STAI-S has been 
shown to be sensitive to psychological manipulations that alter anxiety level. 
Test-re-test reliability coefﬁ cients of the STAI-T have been reported to be 
relatively high, reaching approximately 0.70 after a 3-month interval and 
increasing with decreasing time between testings. The STAI has also shown 
relatively high correlations with other well known measures of anxiety. Only the 
STAI-S was used in the present study. Internal reliability of the STAI-S by 
Cronbach’s alpha was 0.90.
Follow-Up Pain Questionnaire (FUPQ)
The FUPQ is a brief inventory designed to assess the presence, intensity, 
location, frequency and quality of long term postsurgical pain. Items also assess 
pain interference in daily life, methods of pain relief sought, medication use and 
aggravating and relieving factors. The FUPQ was modeled after similar pain 
assessment measures including the MPQ and a follow-up interview form used to 
assess long term pain after surgery.17 The FUPQ was administered at the six 
month postsurgical interview.
Procedures
Preoperative assessment
A member of the research team approached prospective patients who were 
informed of the nature of the study, screened for eligibility and recruited if 
interested. Following informed written consent, patients completed the MHI and 
STAI-S. Patients were familiarized with the VAS rating scales and were shown a 
PCA pump and instructed in its use. 
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Pre-incisional and post-incisional administration of ketamine and saline
On the morning of surgery a research nurse drew up the appropriate volumes 
(based on the patient’s weight) from the two 60 ml coded syringes that had been 
prepared and dispensed by the pharmacy. The ﬁ rst and second syringes, labeled 
“pre-incision” and “post-incision”, respectively, contained ketamine (1 mg ml-1) 
and saline for group 1, saline and ketamine (1 mg ml-1) for group 2 and saline and 
saline for group 3.
All patients received i.v. fentanyl (1 µg kg-1, 25 µg ml-1) every 80 minutes starting 
approximately 5 minutes before induction of general anesthesia (Figure 1 and 
Table 1).
Approximately 10 minutes before skin incision and after induction of general 
anesthesia, all patients received a bolus dose of i.v. fentanyl (0.5 µg kg-1). This 
was followed immediately by an i.v. bolus dose (0.2 ml kg-1) and an i.v. infusion 
(0.0025 ml kg-1 min-1) from the ﬁ rst syringe labeled “pre-incision”. Seventy 
minutes after incision, the ﬁ rst infusion was stopped and all patients received a 
bolus dose of i.v. fentanyl (0.5 µg kg-1). This was followed immediately by an i.v. 
bolus dose (0.2 ml kg-1) and an i.v. infusion (0.0025 ml kg-1 min-1) from the 
second syringe labeled “post-incision”. The second infusion was stopped after 80 
minutes, approximately 150 minutes after incision.
 
General anesthesia
Patients received midazolam 1-2 mg i.v. as premedication approximately one 
hour before surgery. General anesthesia was induced with thiopental 4-6 mg kg-1. 
Intubation followed the administration of d-tubo curarine (3.0-4.5 mg) and 
succinylcholine 1.0-1.5 mg kg-1. General anesthesia was maintained with 60% 
N2O in O2 and isoﬂ urane. Pancuronium was used for neuromuscular blockade. 
Induction Incision End surgery
TA1 TB1 TA2 TB2 TA3
Start 1st infusion Start 2nd infusion Stop 2nd infusion
Stop 1st infusionGroup
Fb/Sb/SiFb Fb/Kb/Ki Fb Fb1
Fb/Kb/KiFb Fb/Sb/Si Fb Fb2
Fb/Sb/SiFb Fb/Sb/Si Fb Fb3
bolus bolus bolus
Figure 1. Flow chart showing timing of drug administration relative to speciﬁ c preoperative and 
intraoperative events. To ensure comparability among groups, time intervals TA1, TA2, TA3 and time 
intervals TB1, TB2 were designed to be of equal duration, respectively. See Table 1 for actual duration 
of each interval. Abbreviations: F, fentanyl; K, ketamine; S, saline; subscript b, bolus; subscript i, 
infusion.
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Vasoactive agents (beta-blockers, vasodilators and vasopressors) were used as 
required to maintain hemodynamic parameters within ± 20% of mean 
preoperative baseline values. At the conclusion of the surgery, neuromuscular 
blockade was reversed with neostigmine 0.05 mg kg-1 and glycopyrrolate 0.02 
mg kg-1. The trachea was extubated after emergence and upon resumption of 
spontaneous breathing. Patients received supplemental O2 by mask and were 
transported to the Post Anesthesia Care Unit (PACU).
Intraoperative monitoring
All patients were continuously monitored with an arterial line (systolic, mean, 
diastolic blood pressure), electrocardiogram (heart rate and rhythm), pulse 
oximeter, nasal temperature probe and end-tidal monitor (anesthetic gas and 
carbon dioxide levels). Intra-operative hemodynamics and end-tidal isoﬂ urane 
were recorded every minute for the ﬁ rst 5 minutes after skin incision and every 
15 minutes thereafter until the end of surgery.
Postoperative analgesia
Patients were assessed immediately upon arrival in the PACU and were 
connected to a PCA pump system (Abbott Life Care Infuser, Abbott 
Laboratories, Chicago, IL, USA). If patients complained of pain, a research nurse 
blind to group allocation administered a loading dose of 2-4 mg morphine. Every 
5 minutes, patients were asked whether they were in need of pain relief. An 
Table 1. Timing of drug administration relative to intraoperative events (mean ± SD).
Time interval 
(See Fig. 1)
Interval between intraoperative events Group 1 Group 2 Group 3
--- Min between pre-induction dose of fentanyl and induction of 
general anesthesia
4.6 ± 3.7 4.8 ± 3.9 4.8 ± 3.5
TA1 Min between pre-induction dose of fentanyl and start of 
infusion 1
22.6 ± 6.1 25.1 ± 7.0 23.2 ± 8.2
--- Min between start of infusion 1 and incision 9.9 ± 6.4 9.2 ± 2.6 9.7 ±3.3
TB1 Min between start of infusion 1 and 1st post-incisional dose 
of fentanyl
58.6 ± 3.8 58.9 ± 3.4 59.4 ± 3.3
TA2 Min between 2nd post-incisional dose of fentanyl and start of 
infusion 2
22.6 ± 6.7 25.4 ± 7.3 23.2 ± 8.2
TB2 Min between start of infusion 2 and 3rd post-incisional dose 
of fentanyl
58.2 ± 5.2 59.0 ± 4.0 59.4 ± 3.3
TA3 Min between 3rd post-incisional dose of fentanyl and end of 
infusion 2
23.1 ± 7.8 26.6 ± 17.8 23.0 ± 8.4
TB1 + TA2 Duration in min of ﬁ rst infusion 81.2 ± 8.3 84.2 ± 7.9 82.6 ± 8.3
TB2 + TA3 Duration in min of second infusion 81.3 ± 8.0 85.5 ± 17.7 82.4 ± 8.8
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afﬁ rmative response was followed by a 1.0-1.5 mg i.v. bolus of morphine. This 
procedure was repeated until the patients were alert enough to begin self-
administration using the PCA pump button. The PCA pump was set to deliver a 
1.0-1.5 mg i.v. bolus dose of morphine with a lock-out time of 5 minutes, a 
maximum dose of 40 mg in any 4 hours period and no continuous background 
infusion. This regimen was overseen by the Acute Pain Service and was 
continued on the ward for 72 hours during which time no other analgesics were 
administered. Morphine consumption in milligrams was calculated on an hourly 
basis from hard copy records (Abbott TRW Printer, Model TP 40, Abbott 
Laboratories, Chicago, IL, USA) of the 72 hours study period.
Measurement of postoperative pain and von Frey thresholds
VAS-R was measured 3, 6, 12, 24, 48 and 72 hours after surgery. VAS-M, MPQ, 
von Frey TT and PT were measured at 24, 48 and 72 hours after surgery.
Two week follow-up
Patients were seen in the hospital on their ﬁ rst visit post-discharge approximately 
two weeks after surgery. An assessment of pain status since discharge was 
obtained and von Frey touch (TT) and pain (PT) thresholds were measured as 
previously described.
Six month follow-up
Patients were contacted by telephone approximately six months from the date of 
surgery and administered the post surgical follow-up questionnaire. A maximum 
of ﬁ ve attempts was made to contact each patient by telephone. 
Sample size calculation
Sample size estimation was performed using data from an earlier study of men 
undergoing radical prostatectomy who received pre-incisional or post-incisional 
lumbar epidural bupivacaine.18 In that study, mean cumulative PCA morphine 
was 55 mg for the pre-incisional group and 71 mg for the post-incisional groups 
with a standard deviation of 28 mg. The 16 mg difference in morphine 
consumption represented a savings of 30% in favor of the pre-incisional group. 
Using a Type I error rate of 0.05 we estimated that we would require 45 patients 
per group to detect a mean difference of 16 mg (SD = 28 mg) with a power of 
~80%.19 Two Monte Carlo simulations 20 of 10,000 trials each were then 
performed under the following two conditions assuming 45 patients per group 
and a standard deviation of 28 mg: (1) pre-incision mean = 55 mg, post-incision 
mean = 71 mg, control mean = 85 mg; and (2) pre-incision mean = 55 mg, post-
incision mean = control mean = 71 mg. Comparisons between pairs of means 
were undertaken when the omnibus F test was statistically signiﬁ cant
(i.e.,  = 0.05, two tailed). The Monte Carlo simulations indicated that a sample 
size of 45 patients per group provided a power of 80% under condition 1 and 
99% under condition 2. 
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Data entry and veriﬁ cation
Data were keyed in twice. One of the data sets was checked for errors manually 
by two research assistants/nurses. After correcting any errors, the two data sets 
were compared ﬁ eld by ﬁ eld by an in-house computer program. Discrepancies 
between matching records in the two data sets were corrected by referring back 
to the raw data.
Statistical analysis
Data were analysed using the Statistical Package for the Social Sciences (SPSS 
for Windows, release 11.0.1, Chicago, IL, USA) and Primer of Biostatistics: The 
Program (Version 4.0, McGraw Hill, New York, NY, USA).21 Background 
demographic data and clinical variables were compared using ANOVA for 
parametric data and chi-square test for nominal data. 
Primary outcome variable. Cumulative morphine consumption at 72 hours after 
surgery was analysed by one-way ANOVA followed by directional comparisons 
between pairs of means.
Secondary outcome variables. Visual analogue pain scores at rest (VAS-R), after 
mobilization (VAS-M) and von Frey touch (TT) and pain thresholds (PT) were 
analysed by 2-way between-within ANOVA using group as the between subjects 
factor and time after surgery as the within subjects factor. The regression lines 
relating time and cumulative morphine consumption on day 3 after surgery 
(between 49 and 72 hours) were compared pair wise by one-way ANOVA by ﬁ rst 
testing the overall coincidence of the regression lines.21 If the overall coincidence 
differed, the slopes and intercepts were compared by t-test using the Bonferroni 
Type I error rate correction for multiple comparisons ( = 0.05/number of 
comparisons). MPQ pain rating indexes (PRIs) and MPQ present pain intensity 
(PPI) were analysed by non-parametric Kruskal-Wallis ANOVA of ranks. MHI 
and STAI-S scores were analysed by one-way ANOVA. 
All data presented are mean ± SD unless otherwise speciﬁ ed. P ≤ 0.05 is 
considered statistically signiﬁ cant. 
Results
Recruitment and patient withdrawals
Between June 1994 and October 1997, 168 patients were recruited into the study. 
In total 25 patients were withdrawn for the following reasons. 
Pre-randomization dropouts (n = 8): Procedure cancelled on the day of surgery
(n = 2); pharmacy did not prepare the drugs in time for the surgery (n = 2); 
personnel not available to run the case (n = 4). 
Intraoperative withdrawals (n = 10): Excessive bleeding and/or change in 
operative procedure (n = 4); administration of additional analgesic agents (n = 3); 
problems with the infusion pump (n = 2); anaphylactic reaction to general 
anesthesia (n = 1). 
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Postoperative withdrawals (n = 7): bleeding (n = 1); faulty PCA equipment
(n = 1); severe bladder spasms requiring additional analgesics (n = 3); alcohol 
withdrawal/delirium tremens (n = 1); excessive drowsiness precluding data 
collection (n = 1). 
There were no signiﬁ cant differences among groups in the proportion of patients 
withdrawn (n = 7, 6 and 4 for groups 1 to 3, respectively).
In total, one hundred and forty three patients completed the study; 47 in group 1, 
50 in group 2 and 46 in group 3.
Timing of drug administration relative to intraoperative events
Table 1 and Figure 1 show the intervals between speciﬁ c intraoperative events as 
they relate to the time of administration of fentanyl, ketamine and saline. As 
designed, there were no signiﬁ cant group differences between any of the 
intervals; including, the time between the pre-induction dose of fentanyl and 
induction, the time between the start of the ﬁ rst infusion and incision and the 
duration of the ﬁ rst and second infusions.
Demographic, psychosocial and intraoperative variables
There were no signiﬁ cant differences among the groups in demographic or 
clinical data (Table 2) or preoperative MHI and STAI-S scores (Table 3). The 
groups did not differ signiﬁ cantly in the total dose of i.v. fentanyl. Groups 1 and 
2 did not differ signiﬁ cantly in the total dose of ketamine received.
Figures 2 and 3 show mean percent end tidal isoﬂ urane and the mean change 
from preoperative baseline level in heart rate and mean blood pressure across the 
surgical procedure. There were no signiﬁ cant differences among the three groups 
in any of these parameters.
Table 2. Demographic and clinical variables. Data are mean ± SD unless otherwise stated.
Demographic/clinical measure Group 1 Group 2 Group 3
Age (years) 62 ± 5.8 62 ± 6.2 61 ± 6.7
Height (cm) 175 ± 8.3 178 ± 7.9 176 ± 6.1
Weight (kg) 81 ± 9.5 84 ± 17.1 84 ± 16.8
Frequency of ASA status (1:2) 25:21 18:32 23:23
Surgery duration (min) 180 ± 30.9 181 ± 30.7 182 ± 45.2
Blood loss (ml) 1507 ± 983.5 1770 ± 1217.7 1603 ± 1015.7
Total fentanyl (µg) 364.8 ± 59.66 365.1 ± 61.84 369.9 ± 87.24
Total ketamine (mg) 31.9 ± 4.21 32.2 ± 3.9 0.0 ± 0.0
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PCA morphine consumption
Although cumulative PCA morphine consumption at 72 hours was lower in 
group 1 (92.3 ± 45.9 mg) than group 2 (107.2 ± 58.4 mg) and group 3 (103.6 ± 
50.4 mg), comparisons between the means did not reach the conventional 0.05 
level of signiﬁ cance (p = 0.08 for group 1 versus group 2 and p = 0.08 for group 
1 versus group 3). The number of PCA requests that did not result in a bolus of 
morphine (i.e., requests made during the 5-minute lock-out period) did not differ 
signiﬁ cantly among the groups (data not shown). Table 4 shows PCA morphine 
consumption between intervals when pain at rest was assessed. Morphine 
consumption did not differ signiﬁ cantly during any of the intervals. 
Psychosocial measure Group 1 Group 2 Group 3
STAI-S 38.1 ± 9.63 35.8 ± 10.87 34.8 ± 8.77
MHI – anxiety 24.4 ± 3.33 24.2 ± 4.42 25.4 ± 3.63
MHI – depression 20.9 ± 2.40 21.1 ± 3.28 21.5 ± 2.70
MHI - loss of control 22.1 ± 2.12 22.1 ± 1.95 22.2 ± 1.94
MHI - positive affect 18.7 ± 3.09 18.4 ± 3.12 19.3 ± 2.34
MHI - total score 91.5 ± 10.45 91.3 ± 11.64 93.9 ± 9.04
Table 3. Scores (mean ± SD) on the Spielberger State-Trait Anxiety Inventory (STAI-S) and Mental Health 
Inventory (MHI) obtained the evening before surgery.
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Figure 2. Percent end-tidal isoﬂ urane shown for the three groups during the ﬁ rst and second 
intraoperative i.v. infusions. Downward pointing arrow at zero on the x-axis corresponds to time of 
skin incision.
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Figure 4 shows cumulative morphine consumption for the three groups across 
the 72 hours study period. Also shown are the best-ﬁ tting linear regression lines 
relating cumulative morphine consumption and time for each group across the 
ﬁ nal 24 hours period (day 3: 49-72 hours). On day 3, the hourly rate (mean ± 
SEM) of morphine consumption in group 1 (0.61 ± 0.013 mg h-1) was 
signiﬁ cantly lower (p < 0.0009) than that in group 2 (0.86 ± 0.011 mg h-1) and 
group 3 (0.89 ± 0.008 mg h-1). Groups 2 and 3 did not differ signiﬁ cantly.
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Figure 3. Change from baseline in mean blood pressure and heart rate shown for the three groups 
during the ﬁ rst and second intraoperative i.v. infusions. Downward pointing arrow at zero on the x-
axis corresponds to time of skin incision.
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Hours after surgery
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Figure 4. An hour-by-hour plot of cumulative PCA morphine consumption for each 
group showing the best-fitting, least squares regression line calculated for day 3 (49 to 
72 hours after surgery). Each regression line accounts for at least 95% (r2) of the total 
variance. The hourly rate of morphine consumption on day 3 was significantly lower for 
group 1 versus group 2 and for group 1 versus group 3 reflecting the benefit of pre-
operative ketamine. Bonferroni corrected significance tests of the regression line slope 
comparing group 1 versus group 2 and group 1 versus group 3 on day 3, *p < 0.0009.
Time interval after surgery Group 1 Group 2 Group 3
0 – 3 h 14.5 ± 7.9 14.7 ± 9.1 15.2 ± 7.4
 3 – 6 h 5.7 ± 5.0 7.4 ± 5.4 5.7 ± 3.9
 6 – 12 h 7.8 ± 4.9 9.1 ± 7.1 8.7 ± 6.6
 12 – 24 h 20.2 ± 11.3 24.1 ± 15.2 22.7 ± 14.9
 24 – 48 h 28.1 ± 16.4 30.1 ± 20.1 29.8 ± 17.3
 48 – 72 h 16.0 ± 15.7 21.7 ± 20.0 21.5 ± 18.9
Table 4. PCA morphine consumption (mg) within intervals bounded by times when pain at rest was assessed. Data 
are mean ± SD.
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Figure 5. Visual analogue scale (VAS) pain scores at rest (R) and after standardized mobilization (M). 
Data are mean ± SD.
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Figure 6. von Frey touch and pain thresholds obtained 10 cm from the wound dressing and at a 
control site on the forearm. Data are mean ± SD. 
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Follow-up measure Group 1 Group 2 Group 3
Days since surgery (mean ± SD) 18.9 ± 4.4 19.7 ± 10.7 19.6 ± 4.6
VAS pain at rest (mean ± SD) 2.8 ± 1.5 3.0 ± 1.7 2.9 ± 1.9
Pain-free on discharge 25 (62.5%) 24 (55.8%) 25 (61.0%)
Pain since discharge 23 (57.5%) 30 (69.8%) 26 (63.4%)
Scar tender to touch 21 (52.5%) 23 (53.5%) 22 (53.7%)
Table 6. Data [n (%)] from two week post-discharge follow-up.
Postoperative pain and von Frey thresholds
There were no signiﬁ cant differences among the groups in VAS pain scores 
(Figure 5), MPQ pain rating indexes (Table 5), or von Frey touch or pain 
thresholds measured near the wound and at the control site on the inner forearm 
(Figure 6).
Complications/adverse events
The following complications/adverse events occurred intraoperatively: excessive 
bleeding in two patients (one in group 1 and one in group 3); anaphylactic 
reaction to the general anesthetic in one patient (group 2). The following 
complications/adverse events occurred postoperatively: vivid dreams in one 
patient (group 2); agitation in two patients (one in group 1 and one in group 3); 
drowsiness in two patients (group 1); alcohol withdrawal/delirium tremens in one 
patient (group 2); and hypotension and bleeding in one patient (group 3).
Two-week follow-up assessment
One hundred and twenty-ﬁ ve of the 143 patients (87.4%) were assessed at the 
hospital approximately two weeks after discharge (n = 40, n = 43, n = 42 in
groups 1 to 3, respectively). The overall incidence of pain was 55.2% (n = 79). 
The pain intensity was in the mild to moderate range. Von Frey touch and pain 
thresholds are shown in Figure 6. There were no signiﬁ cant differences among 
the three groups in any of the variables measured (Table 6). 
Six month follow-up interview
One hundred and eight of the 143 patients (75.5%) were reached by telephone 
six months after surgery (n = 34, n = 36, n = 38 in groups 1 to 3, respectively). 
The groups did not differ signiﬁ cantly in the most intense pain they remembered 
having experienced after surgery (Table 7) which was a remarkably accurate 
reﬂ ection of their 24 hours VAS-M pain scores (Figure 5).
The overall incidence of pain was 10.5% (n = 15) with no signiﬁ cant difference 
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among the three groups (Table 7). The pain was described as sharp, burning or 
aching and as originating in deep tissue and at the scar. In general, the intensity 
of pain was mild and all 15 patients reported not taking analgesic medication for 
the pain. One patient in group 2 reported that the pain interfered “slightly” with 
his everyday activities; the remaining 14 reported no interference at all.
Discussion
The results of the present study do not support the hypothesis that pre-operative 
i.v. administration of the NMDA receptor antagonist ketamine results in a 
clinically meaningful reduction in pain or morphine consumption when 
compared with a saline control condition or post-incisional administration of i.v. 
ketamine. In the present study, a bolus dose of 0.2 mg kg-1 ketamine followed by 
continuous infusion of 2.5 µg kg-1 min-1 for 80 minutes was started 10 minutes 
before or 70 minutes after incision. This amounted to a total of approximately 30 
mg ketamine administered over the duration of the three-hour procedure. There 
was no evidence that postoperative pain or analgesic use differed as a function of 
pre-operative or post-incisional administration of ketamine. Nor did this regimen 
reduce postoperative cumulative morphine consumption or pain compared with a 
saline control group that did not receive ketamine. 
Follow-up measure Group 1 Group 2 Group 3
Follow up time in days 201.8 ± 17.8 204.7 ± 19.3  205.2 ± 25.2
Most intense pain after surgery
 PPI (0-5) 2.1 ± 0.6 2.1 ± 0.7 2.0 ± 0.9
 VRS (0-10) 5.1 ± 1.9 5.6 ± 2.2 5.1 ± 2.5
Has pain at site of surgery [n (%)] 6 (17.6%) 2 (5.6%) 7 (8.4%)
Taking medication [n] 0 0 0
Pain interference in daily activities
 Not at all [n (%)] 6 (100%) 1 (50%) 7 (100%)
 Slightly [n (%)] 0 (0%) 1 (50%) 0 (0%)
VRS-Rest pain 2.3 ± 1.2 2.8 ± 1.1 3.4 ± 3.0
McGill Pain Questionnaire scores
 PRI-sensory 2.4 ± 2.1 2.0 ± 1.4 3.9 ± 2.7
 PRI-affective 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
 PRI-evaluative 0.6 ± 0.5 1.0 ± 0.0 0.4 ± 0.5
 PRI-total 3.0 ± 2.1 3.0 ± 1.4 4.9 ± 2.8
 Present pain intensity 1.4 ± 0.5 1.0 ± 0.0 1.7 ± 1.5
 Number of words chosen 2.2 ± 1.3 2.5 ± 0.7 3.1 ± 1.5
Table 7. Six month follow-up data. Follow-up time and most intense pain (present pain intensity (PPI) and 
verbal rating scale (VRS)) are reported for all 108 patients reached. The remaining variables show data only 
for patients reporting pain. Data are mean ± SD unless otherwise stated. PRI: pain rating index.
43
Chapter 2Pre-emptive analgesia using intravenous fentanyl plus low dose ketamine...
However, between group comparisons of the regression line slopes relating 
morphine and time gives some support for the idea that preoperative ketamine is 
associated with a late reduction in the rate of morphine consumption beginning at 
49 hours after surgery and extending to the end of the study, 72 hours after 
surgery. The difference in the rate of morphine consumption between group 1 
and the other two groups on day 3 was approximately 0.25 mg h-1 (Figure 4) 
amounting to 6 mg less of morphine over 24 hours. Since this effect was 
observed two days after ketamine administration (> 15 ketamine half lives 22) in 
groups 1 and 2, it is likely not related to the ongoing actions of the drug but 
rather to a possible reduction in central sensitization. 
The difference in the rate of morphine consumption in favor of the pre-incisional 
group supports the idea that early and late noxious intraoperative stimuli 
contribute differentially to the establishment of central sensitization.6,10 In the 
present study, it appears that the noxious events during the early intraoperative 
period including incision and the following 70 minutes contribute to a greater 
extent to central sensitization than do noxious late intraoperative or postoperative 
stimuli. Furthermore, given the absence of a difference in rate of morphine 
consumption between groups 2 and 3, it would appear that the most important 
contribution to central sensitization in the present study originates in the effects 
of the barrage of noxious impulses arising from incision and subsequent noxious 
events. Nevertheless, the clinical signiﬁ cance of this effect is small and the 
somewhat lower morphine consumption was not accompanied by differences in 
pain hypersensitivity as measured by von Frey ﬁ laments, by pain scores at rest or 
after mobilization, or in the incidence and intensity of pain two weeks and six 
months after surgery.
The present design thus compared an early versus late intraoperative start to 
NMDA receptor blockade by a low dose of ketamine. The timing of 
administration of the ketamine infusions and total dose of ketamine were 
designed to reduce the incidence of adverse reactions. Because of reports of 
psychotomimetic and emergence reactions associated with ketamine,23,24 we 
planned to stop the second infusion approximately 20-30 minutes before the end 
of surgery so as to minimize the potential occurrence of these adverse effects, 
especially in group 2 patients. We anticipated the mean duration of the radical 
prostatectomy procedure to be three hours as in our earlier study 18 so that 
running the two infusions for approximately 80 minutes each translated into 
stopping the second infusion on average 30 minutes before the end of surgery 
(Table 1 and Figure 1). Emergence reactions were not observed; nor were 
hallucinations or other psychotomimetic effects although one patient in group 2 
reported having had vivid dreams. 
The low dose of ketamine also appeared to have no effect on intraoperative heart 
rate or blood pressure in contrast to the results reported by Roytblat et al.25 
showing a marked reduction in intraoperative hemodynamics associated with a 
single preoperative bolus dose of 0.15 mg kg-1 ketamine i.v.. As shown in Figures 
2 and 3 isoﬂ urane requirements and hemodynamic responses did not signiﬁ cantly 
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differ among the three groups, nor between the ﬁ rst and second infusions within 
groups 1 and 2. To our knowledge, the only other study to compare low dose 
ketamine (0.15 mg kg-1) and saline also reported no signiﬁ cant differences in 
intraoperative heart rate and blood pressure.26
There are several possibilities that alone, or in various combinations, may explain 
the lack of a clinically signiﬁ cant pre-emptive or preventive effect of the fentanyl 
and ketamine used in the present study. The ﬁ rst has to do with the related issues 
of timing of ketamine administration relative to incision and duration of NMDA 
receptor blockade. Central sensitization is not only induced during surgery but 
also postoperatively by inﬂ ammatory inputs.5,6 As discussed above, neither group 
1 nor group 2 received the ketamine infusion for the duration of the surgical 
procedure and no ketamine was given in the postoperative period. Thus, the 
modest effects in rate of morphine consumption we observed might have been 
enhanced had we started the infusion before surgery and continued it throughout 
the procedure into the postoperative period. 
Secondly, the dose of ketamine used in the present study may have been too 
small. Studies of abdominal surgery patients have reported signiﬁ cant effects 
using bolus doses that ranged between 0.15 mg kg-1 and 2 mg kg-1 and infusion 
rates between ~8 µg kg-1 min-1 and 20 µg kg-1 min-1.25,27-30 Negative results have also 
been reported after abdominal hysterectomy using a total ketamine dose 
approximating the 30 mg used in the present study.31 Other surgical procedures 
have produced mixed results: the same small bolus dose of 0.15 mg kg-1 ketamine 
produced an early opposite effect in favor of the post-incision group after 
mastectomy 32 and signiﬁ cantly lower postoperative morphine requirements 48 
hours after anterior cruciate ligament repair in patients treated with ketamine 
before or after surgery compared with a placebo control group.33 In addition, a 
considerable amount of blood loss occurred in all three groups (Table 2) which, 
together with the associated ﬂ uid management, may have reduced further the 
serum concentration of the intravenously ketamine in groups 1 and 2. It is 
possible that a larger dose of ketamine combined with a continuous intravenous 
infusion would have resulted in more clinically signiﬁ cant results in the present 
study. 
A third reason for the lack of a clinically signiﬁ cant effect may have to do with 
the co-administration of fentanyl with ketamine and more generally, the role of 
ketamine in potentiating opioid analgesia by preventing or reducing central 
sensitization. Our expectation was that adding low dose ketamine to a standard 
general anesthetic regimen using fentanyl would produce enhanced 
antinociceptive effects due to the combined actions of the two agents operating at 
different receptor sites,8,9 and in particular by preventing or obtunding the 
NMDA-mediated state of pain hypersensitivity that normally ensues following 
tissue damage.9 However, the results of a recent rat study in which epidural 
ketamine was combined with various doses of morphine and fentanyl suggests 
that the effects of ketamine may depend on the speciﬁ c mu-opioid agonist.34 
Whereas ketamine potentiated the antinociceptive effects of morphine, it 
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antagonized the effects of fentanyl at several doses. The mechanism by which 
this antagonistic effect occurred is not known but may involve competition for 
active blood-brain barrier transport proteins due to the high lipophilicity of both 
ketamine and fentanyl, competition between ketamine and fentanyl for the mu-
receptor, drug differences in mu-receptor subtype binding, or intracellular 
differences in phosphorylation associated with speciﬁ c opioid-ketamine 
combinations.34 
To date six studies have evaluated pre-emptive or preventive effects of i.v. 
ketamine in combination with an opioid. The clinical data do not point to a
clear-cut relationship between the relative efﬁ cacy of ketamine when 
administered with various opioid agonists although Hoffmann et al.34 suggested 
that lipophilicity may be a factor. The two studies that administered ketamine in 
combination with morphine found a signiﬁ cant opioid sparing effect,27,29 and a 
signiﬁ cant reduction in postoperative pain 27 compared with a control group. The 
only other study to have administered preoperative ketamine with fentanyl also 
found a signiﬁ cant opioid sparing effect in favor of the ketamine treated patients 
compared with a saline control group.25 The remaining three studies did not ﬁ nd a 
pre-emptive or preventive effect when ketamine was administered in combination 
with the fast-acting opioids sufentanil 32,33 or alfentanil.35 Interestingly,
co-administration of ketamine and alfentanil before or after surgery resulted in 
greater pain intensity when compared with a saline control group that received 
alfentanil alone.35 These results were opposite in direction to what was predicted 
and are consistent with the suggestion that ketamine may have antagonized the 
antinociceptive effects of the opioid.34 Further studies are required to determine 
the relative efﬁ cacy of ketamine in combination with various opioid agonists.
The literature contains two competing hypotheses that may, in part, help to 
explain the negative ﬁ ndings of the present study. On the one hand, it is possible 
that the fentanyl and other agents (e.g., nitrous oxide), administered as part of the 
general anesthetic regimen, exerted subtle, additive pre-emptive effects, which 
may have attenuated the central sensitizing effects of surgery in all patients 
thereby minimizing the effect size when comparing groups 1 and 2 with the 
control group.  
On the other hand, recent evidence showing that under certain conditions opioids 
activate pronociceptive systems associated with acute opioid tolerance and 
opioid-induced hyperalgesia.36-39 These phenomena are derived from an NMDA 
receptor mediated mechanism similar to that which occurs following tissue 
damaging injury. Mu-opioid receptor agonists produce a sustained increase in 
NMDA-activated currents by activating intracellular protein kinase C which 
potentiates the NMDA response by reducing the voltage-dependent Mg2+ block of 
NMDA receptor channels. In rats, pretreatment with ketamine prior to opioid 
administration and followed by repeated ketamine injections prevented opioid-
induced hyperalgesia and acute tolerance to opioids.40 It is possible that in the 
present study, the administration of fentanyl to all patients may have activated a 
pronociceptive system thereby minimizing later inter-groups differences in 
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postoperative pain and morphine consumption. The subsequent administration of 
ketamine to groups 1 and 2 after the fentanyl had been given may have been too 
late to prevent opioid-induced NMDA receptor activation. 
Taken together, these results suggest that clinically signiﬁ cant reductions in 
postoperative pain and analgesic use are more likely to be found when ketamine 
is administered preventively 6,7 before induction of anesthesia (prior to an opioid; 
preferably morphine) and continuously throughout the operation.
In addition, use of the s(+)-isomer of ketamine may produce more substantial 
results. The s(+)-isomer has been shown to be 3 to 4 times more potent than the 
r(-)-isomer in producing anti-nociceptive effects and, in equianalgesic doses, 
possibly to induce fewer psychotomimetic effects.41-43 These suggestions appear 
to be supported by preliminary results.44
In summary, preoperative i.v. fentanyl plus a low dose i.v. ketamine infusion did 
not reduce cumulative morphine consumption or pain, to a clinically signiﬁ cant 
extent, when compared with the same regimen initiated 70 minutes after the start 
of surgery or a fentanyl plus saline control condition. Although the rate of 
morphine consumption on day 3 was signiﬁ cantly lower in group 1 than in 
groups 2 and 3, by two weeks and six months after surgery the three groups did 
not differ signiﬁ cantly in pain incidence or intensity. Extending the duration of 
the infusion to cover a longer period of nociceptive activity, use of the
s(+)-isomer of ketamine and co-administering it in combination with morphine 
may produce more clinically meaningful results.
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Introduction
There is a large body of evidence indicating that noxious stimulation and frank 
injury may have profound effects on the central neural processes involved in pain 
transmission, including the establishment of central sensitization and the 
transition of acute, time-limited pain to chronic, pathological pain.1,2 It is now 
well established that the N-methyl-D-aspartate (NMDA) receptor-ion channel 
complex plays a critical role in the development of central sensitization.3,4 This 
has led to renewed interest in the pain-relieving properties of clinically available 
NMDA receptor antagonists such as ketamine for use in humans undergoing 
major surgery.5
More recently, NMDA receptor activation has also been linked to the 
development of acute opioid tolerance and opioid-induced hyperalgesia.6,7 
Furthermore it is now recognized that the process of central sensitization is not 
only induced during surgery but also postoperatively by inﬂ ammatory injuries.8,9 
In the clinical setting this suggests that for optimal effect, NMDA receptor 
antagonists need to be administered before induction of anesthesia (before the 
opioids are given) and continued during surgery and well into the postoperative 
period. To evaluate this possibility we compared the effects of intraoperative low 
dose s(+)-ketamine versus saline given intravenously (started before induction of 
anesthesia) followed by intravenous postoperative patient-controlled low dose 
s(+)-ketamine plus morphine, versus morphine alone, on postoperative pain and 
analgesic consumption after radical prostatectomy.
Methods
Approval to carry out the study was obtained from the institutional ethics 
committee at the University Medical Centre, Nijmegen. Eligible patients were 
men scheduled for radical retropubic prostatectomy. Inclusion criteria were 
ability to speak Dutch, 18-75 years of age, ASA class 1-3, stable or no signiﬁ cant 
central nervous system, respiratory, cardiac, hepatic, renal or endocrine 
dysfunction and/or any signiﬁ cant sequelae, no history of signiﬁ cant 
psychopathology, chronic pain or chronic use of opioid or non-opioid analgesics, 
no previous allergies or adverse reactions to opioid analgesics, no ingestion of 
antitussive medication (dextromethorphan) within 48 hours of surgery, no history 
of alcohol or drug dependency or abuse and body weight 60-100 kg with a body 
mass index ≤ 30 kg m-2. 
All patients were told about the study and screened for suitability and interest 
during the visit to the Preoperative Assessment Clinic approximately 2-4 weeks 
before surgery. At that time patients were informed about the nature and purpose 
of the study and were sent home with a consent form describing the study 
purpose, procedures and risks. One week later, the patient was telephoned at 
home to answer any questions and to obtain verbal informed consent. On the day 
before surgery, after admission to the hospital, patients who had verbally 
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consented were visited on the ward to obtain written, informed consent. Patients 
were then introduced to the Visual Analogue Scale (VAS), the patient-controlled 
analgesia (PCA) pump and pressure algometry. A baseline VAS pain score was 
taken with the patient in a resting position. On the day before surgery, patients 
were randomly assigned to one of two groups: ketamine/morphine or saline/
morphine. Two syringes were prepared for each patient; one contained either 50 
ml s(+)-ketamine 1 mg ml-1 or saline for intraoperative administration and the 
other 50 ml s(+)-ketamine 1 mg ml-1 plus morphine 2 mg ml-1 or morphine 2 mg 
ml-1 alone for postoperative use in the PCA pump. Study syringes were prepared 
and dispensed by the Pharmacy of the University Medical Centre Nijmegen on 
the basis of a predetermined randomisation schedule (using the random function 
of Microsoft EXCEL 97). The syringes were coded and prepared in a blinded 
fashion for each patient and retained by the pharmacy department.
Premedication consisted of oral midazolam 7.5 mg (administered 45-60 min 
before the expected time of induction of general anesthesia). An additional 2 mg 
midazolam was given intravenously after insertion of a venous line. Five minutes 
before induction with propofol (2 mg kg-1) and fentanyl (2 g kg-1), patients 
received a bolus injection of 0.1 ml kg-1 s(+)-ketamine (ketamine/morphine 
group) or saline (saline/morphine group), followed by a continuous infusion of 
0.002 ml kg-1 min-1 of the same agent. For patients in the ketamine/morphine 
group, this amounted to a bolus dose of 100 µg kg-1 s(+)-ketamine and a 
continuous infusion of 2 µg kg-1 min-1 s(+)-ketamine. After induction, 0.6 mg kg-1 
rocuronium was given to facilitate tracheal intubation. Anesthesia was 
maintained with isoﬂ urane in N2O/O2 (60%/40%) aiming at an end expiratory 
concentration of isoﬂ urane of 0.7 %. Further rocuronium 0.1-0.2 mg kg-1 was 
given when necessary. Morphine in a dose of 50 µg kg-1 was given when there 
were signs of inadequate analgesia (increase in blood pressure or heart rate above 
10% of baseline value). The continuous infusion of s(+)-ketamine (ketamine/
morphine group) or saline (saline/morphine group) was stopped at skin closure. 
At the conclusion of surgery, neuromuscular blockade was reversed (when 
necessary) with neostigmine (0.05 mg kg-1) and atropine (0.01-0.02 mg kg-1).
Immediately on arrival in the Post Anesthesia Care Unit (PACU) the PCA pump 
(SIMS Graseby 3300 PCA Pump, Watford, Herts, UK), loaded with the coded 
syringes, was attached to the patient’s intravenous cannula. The PCA system was 
programmed to deliver a bolus of 0.5 ml, corresponding to a bolus dose of 0.5 
mg s(+)-ketamine plus 1 mg of morphine for the ketamine/morphine group and 1 
mg morphine for the saline/morphine group. The lock-out time was set at 5 
minutes. No background infusion was delivered. If the patient complained of 
pain in the PACU but was too drowsy to use the PCA pump, the attending nurse 
was permitted to push the PCA pump button. PCA was continued until the end of 
the study, 48 hours after surgery. No other analgesics were administered during 
the study period. When required, bladder spasm pain was treated with 5 mg 
oxybutynin three times daily. After transfer to the ward, pain management was 
supervised by the researchers and the Acute Pain Service. If a patient required 
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intravenous analgesia beyond the 48-hour study period, the study syringes were 
removed and the patient was treated according to the hospital’s Acute Pain 
Service protocol for managing pain. Nausea and vomiting were treated with 
ondansetron 4 mg given intravenously.
Pain was assessed with patients at rest (VAS-R) at 1, 2, 3, 4, 8, 12, 18, 24, 30, 36, 
42 and 48 hours after surgery. The VAS pain scale consists of a 10-cm horizontal 
line with the two endpoints labeled “no pain” and “worst possible pain”. Pain 
was also assessed after standard mobilization (VAS-M) at 24 and 48 hours by 
asking patients to perform two maximal inspirations before rating their pain. 
Sensitivity to mechanical pressure around the surgical wound was assessed using 
a Pressure Threshold Meter (Pain Diagnostics and Thermography Inc, Great 
Neck, NY, USA), a force gauge with a rubber tip (1 cm2 in diameter) and a 10-kg 
range in 0.1-kg divisions. The pain perception threshold was determined by 
applying pressure and recording in kg cm-2 the level at which the patient ﬁ rst 
reported pain. The patient then rated, on a 10-cm VAS, the intensity of the pain at 
this threshold. After surgery, pain perception thresholds were obtained 5 cm from 
the left and right edges of the surgical wound (halfway between umbilicus and 
pubic symphysis) at 24 and 48 hours after surgery.
Subjective reports of dreams (0 = none, 1 = pleasant, 2 = unpleasant,
3 = nightmare), hallucinations (0 = no, 1 = yes) and other adverse effects were 
documented for all patients at 24 and 48 hours after surgery. The latter effects 
included drowsiness, dizziness, confusion and feelings of unreality (0 = none,
1 = mild, 2 = moderate, 3 = severe). Postoperative sedation was assessed at 1, 2, 
3, 4, 8, 12, 18, 24, 30, 36, 42 and 48 hours after surgery using a 5-point modiﬁ ed 
sedation scale (0 = alert and orientated, 1 = awake but drowsy, 2 = sleeping but 
arousable by verbal commands, 3 = sleeping but arousable by tactile stimuli and 
4 = comatose).10 Postoperative nausea and vomiting were assessed at 1, 2, 3, 4, 8, 
12, 18, 24, 30, 36, 42 and 48 hours after surgery. Nausea was measured using a 
10-cm horizontal VAS with endpoints labeled “no nausea” and “extreme nausea”. 
Vomiting was assessed as present or absent. Postoperative pruritus was assessed 
at 1, 2, 3, 4, 8, 12, 18, 24, 30, 36, 42 and 48 hours after surgery using a 10-cm 
horizontal VAS with endpoints labelled “no itching” and “extreme itching”.
Before the start of the study we estimated that a total sample size of 22 patients 
would be required (11 per group), This was based on a type-I error rate of 0.05 
and power of 0.90 using 48-hour mean cumulative morphine consumption used 
by patients in the study by Adriaenssens et al.,11 with ability to detect a mean 
difference of ~27 mg (27 mg versus 54 mg) with a standard deviation of 20 mg. 
Based on an anticipated attrition rate of 20-25% due to prerandomisation drop-
outs, complications, adverse effects, protocol violations and withdrawals, a total 
of 28 patients were recruited. Data were analysed using the Statistical Package 
for the Social Sciences (SPSS for WINDOWS, release 10.0, Chicago, IL, USA). 
Clinical variables and cumulative morphine consumption were compared using 
independent t-tests for continuous data and Fisher’s exact test for categorical 
data. The primary outcome measure, cumulative morphine consumption at 48 
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hours after surgery, was compared by independent samples t-test. The VAS-R 
pain scores at set intervals (see above) and PCA morphine consumption between 
these intervals, were each analysed by two-way repeated measures ANOVA using 
group as the independent samples factor and time as the repeated measures 
factor. Area under the curve was also computed for the two groups for morphine 
consumption and VAS-R pain scores and compared between the groups by 
independent samples t-test.12 Visual analogue pain scores after mobilization 
(VAS-M), pressure pain threshold and magnitude of side-effects were analysed 
by Mann-Whitney U-test and incidence of adverse effects by Chi-squared test. 
Statistical signiﬁ cance was set at p < 0.05. No intent-to-treat analysis was 
planned; only a per protocol analysis was performed.
Results
Of the 28 patients enrolled in the study, three were excluded: one in the 
ketamine/morphine group because of protocol violation on the ﬁ rst postoperative 
day (he was given a sedative by the attending urologist) and two in the saline/
morphine group (one because of surgery lasting more than 6 hours with the need 
for postoperative ventilation and another because of development of a large 
wound hematoma on the ﬁ rst postoperative day). Baseline characteristics and 
clinical variables are shown in Table 1. Although mean end-expiratory isoﬂ urane 
concentration differed signiﬁ cantly between the groups this was not considered 
clinically signiﬁ cant.
Mean (SD) total cumulative morphine consumption was signiﬁ cantly lower
(p = 0.049) in the ketamine/morphine group (47.9 (26.2) mg) compared with the 
saline/morphine group (73.4 (34.8) mg) at the end of the study, 48 hours after 
surgery; cumulative consumption over time is shown in Figure 1. Results of the 
Ketamine/morphine
(n = 13)
Saline/morphine
(n = 12)
Age; years 60.1 (4.7) 61.7 (4.7)
Weight; kg 83.1 (13.6) 79.9 (12.2)
Height; cm 179 (5.8) 180 (8.3)
Preoperative VAS* for pain; cm 0.0 (0.0) 0.0 (0.0)
Total intraoperative morphine; mg 8.5 (6.3) 10.0 (6.1)
Mean end-expiratory isoﬂ urane concentration; % 0.65 (0.07)† 0.71 (0.04)†
Blood loss; ml 1472 (752) 1518 (856)
Duration of surgery; min 148 (23) 158 (25)
Table 1. Baseline and pre- and intraoperative data in patients receiving ketamine/morphine or saline/
morphine. Values are as mean (SD). * VAS; visual analogue scale. † p = 0.009.
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Ketamine/morphine
(n = 13)
Saline/morphine
(n = 12) p-value
VAS-R; cm
  1 h 3.3 (1.6 [0.9-6.1]) 4.9 (1.5 [2.7-8.4]) 0.01*
  2 h 2.4 (1.8 [0-5.8]) 4.2 (1.8 [0.8-6.9])
  3 h 1.7 (1.2 [0-3.8]) 3.3 (1.4 [1.3-6.1])
  4 h 1.4 (1.2 [0-2.9]) 2.9 (1.6 [0.8-5.5])
  8 h 1.8 (1.4 [0-4.9]) 2.2(1.3 [0-4.0])
12 h 1.2 (1.2 [0-4.0]) 2.1 (1.5 [0-5.0])
18 h 1.5 (1.4 [0-4.8]) 2.8 (1.2 [1.3-4.8])
24 h 1.2 (1.0 [0-3.1]) 2.0 (1.4 [0-5.4])
30 h 1.6 (2.2 [0-8.6]) 1.8 (2.0 [0-6.8])
36 h 0.6 (0.8 [0-2.0]) 1.5 (1.4 [0-5.0])
42 h 1.1 (1.9 [0-5.0]) 1.4 (1.3 [0-4.0])
48 h 0.8 (0.8 [0-2.5]) 0.9 (0.8 [0-2.1])
Area under the 
curve†
61.2 (29.2 [7.9-109]) 92.4 (44.9 [42.2-204.8]) 0.049
VAS-M; cm
24 h 2.7 (2.5 [0.0-7.3]) 2.8 (2.6 [0.0-9.0]) NS
48 h 1.1 (1.2 [0-3.7]) 0.5 (0.4 [0-1.1]) NS
Table 2. Postoperative pain scores at rest (VAS-R) and after standard mobilization (VAS-M) in patients 
receiving ketamine/morphine or saline/morphine. Data are mean (SD [range]).
* For ANOVA across whole 48-hour study period. † Area under the curve for VAS-R 1-48 hours.
Figure 1. Cumulative PCA-morphine consumption in patients receiving ketamine/morphine (solid) or 
saline/morphine (clear). Values are mean (SD). Overall consumption was less in the ketamine/
morphine group than in the saline/morphine group (p = 0.049).
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ANOVA indicated that over the 48-hour study period patients in the ketamine/
morphine group consistently self-administered signiﬁ cantly less morphine
(p = 0.049) than those in the saline/morphine group and consistent with this, the 
area under the curve for morphine consumption in the ketamine/morphine group 
was also less (p = 0.037). Pain scores at rest analysed by ANOVA and by 
comparison of area under the curve also revealed signiﬁ cant differences between 
the groups (Table 2). Signiﬁ cant differences were not found for VAS-M pain 
scores (Table 2), nor for the number of patients needing oxybutynin for bladder 
spasm pain or pressure pain thresholds at 24 or 48 hours after surgery (Table 3).
No signiﬁ cant differences were found in the incidence or extent of morphine or 
s(+)-ketamine related side-effects. No hallucinations were reported at any time 
point. One patient in each group reported “pleasant” dreams at 24 hours, but no 
dreams were reported at 48 hours. All other side effects are presented in Table 4.
Discussion
The results of this study show that low dose s(+)-ketamine given during and after 
radical prostatectomy reduces PCA morphine consumption by 34% at 48 hours 
after surgery and lower pain scores at rest compared with a standard treatment 
control group that did not receive s(+)-ketamine. 
Ketamine belongs to the group of non-competitive NMDA receptor antagonists 
that bind to the recognition site in the NMDA receptor operated ion channel.13 
Although there is evidence for the interaction of ketamine with opioid receptors, 
monoaminergic receptors, nicotinic and muscarinic cholinergic receptors, Ca2+ 
channels, GABA receptors and Na+ channels, ketamine has the highest afﬁ nity 
for the NMDA receptor.14,15 Ketamine is a racemic mixture of two enantiomers, 
Ketamine/morphine
(n = 13)
Saline/morphine
(n = 12)
Oxybutynin required
 24 h
 48 h
1 (8%)
1 (8%)
0
1 (8%)
PPT; kg cm-2
 24 h
 48 h
1.7 (1.2 [0-6.0])
1.9 (0.7 [0.5-3.2])
1.2 (0.6 [0.1-2.2])
2.0 (0.9 [0.2-4.7])
VAS* at PPT; cm
 24 h
 48 h
4.9 (1.8 [2.2-7.7])
4.6 (2.4 [0.3-8.6])
3.9 (2.3 [0.4-8.0])
4.2 (2.6 [0.1-8.9])
Table 3. Need for oxybutynin for bladder spasm pain and pressure pain thresholds (PPT) at 24 and 48 h after 
surgery, in patients receiving ketamine/morphine or saline/morphine. Values are number (proportion) or 
mean (SD [range]). No signiﬁ cant differences between groups. * VAS; visual analogue scale
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s(+)- and r(-)-ketamine. S(+)-ketamine shows an afﬁ nity for the NMDA receptor 
that is four times higher than that of r(-)-ketamine.16 In a study of healthy 
volunteers, ketamine isomers induced less fatigue and cognitive impairment than 
equianalgesic low dose racemic ketamine. In addition, s(+)-ketamine produced 
less decline in concentration capacity and primary memory.17 Because of its 
higher potency (about twice that of racemic ketamine) and more favorable 
adverse effects proﬁ le, s(+)-ketamine is an attractive alternative to the racemate 
for perioperative use in humans.
For low dose ketamine to be an effective (co)analgesic and morphine-sparing 
agent in the surgical patient, two recently evolved concepts are of major 
Ketamine/morphine
(n = 13)
Saline/morphine
(n = 12)
Drowsiness*
24 h
48 h
1 / 4 / 7 / 1
4 / 5 / 3 / 1
1 / 4 / 6 / 1
5 / 6 / 1 / 0
Dizziness*
24 h
48 h
10 / 2 / 1 / 0
8 / 4 / 1 / 0
12 / 0 / 0 / 0
9 / 3 / 0 / 0
Confusion*
24 h
48 h
11 / 1 / 1 / 0
13 / 0 / 0 / 0
10 / 1 / 1 / 0
11 / 1 / 0 / 0
Feelings of unreality*
24 h
48 h
12 / 1 / 0 / 0
11 / 2 / 0 / 0
10 / 2 / 0 / 0
12 / 0 / 0 / 0
Sedation†
24 h
48 h
13 / 0 / 0 / 0 / 0
12 / 0 / 1 / 0 / 0
11 / 1 / 0 / 0 / 0
12 / 0 / 0 / 0 / 0
Nausea VAS; cm
24 h
48 h
1.1 (2.1 [0-6.9])
0.1 (0.4 [0-1.4])
0.4 (0.6 [0-2.0])
0.4 (1.0 [0-3.6])
Vomitting; Y / N
24 h
48 h
0 / 13
0 / 13
1 / 11
1 / 11
Pruritus VAS; cm
24 h
48 h
0 (0 [0-0.1])
0.1 (0.3 [0-1.2])
0 (0 [0-0.1])
0.1 (0.3 [0-1.0])
Table 4. Adverse effects in patients receiving ketamine/morphine or saline/morphine. Values are number or mean 
(SD [range]). No signiﬁ cant differences between groups.
* None / mild / moderate / severe
† Alert and orientated / awake but drowsy / sleeping but rousable by verbal commands / sleeping but rousable by 
tactile stimuli / comatose
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importance. First, it has been shown that opioids activate not only antinociceptive 
systems but also pronociceptive systems, causing acute opioid tolerance and 
opioid-induced hyperalgesia.6,7 These phenomena seem to stem from a common 
NMDA receptor dependent mechanism; use of mu-opioid receptor agonists 
causes a sustained increase in NMDA-activated currents by activating 
intracellular protein kinase C. In turn, protein kinase C potentiates the NMDA 
response by reducing the voltage-dependent Mg2+ block of NMDA receptor 
channels.18  In rats, pretreatment with ketamine (before opioid administration) and 
subsequent repeated ketamine injections prevented opioid-induced hyperalgesia 
and acute tolerance to opioids.19 Second, it is now recognized that central 
sensitization is not only induced during surgery (by incisional injury) but also 
postoperatively by inﬂ ammatory injuries.8,9 This means that efforts to prevent the 
development of central sensitization must be continued well into the 
postoperative period and should not be limited to the duration of the surgical 
procedure. The practical consequences of both of these concepts are that 
ketamine should be administered before induction of anesthesia (especially 
before the opioids are given) and continued during surgery and into the 
postoperative period. As suggested by the results of the present study, this leads 
to lower postoperative morphine consumption and also to lower postoperative 
pain scores. Further study is required to ascertain the practical importance, in the 
clinical setting, of the need to give ketamine before the opioids, by comparing 
the administration of ketamine before and after the opioids.
We did not ﬁ nd signiﬁ cant differences in the sensitivity to mechanical pressure 
applied around the surgical wound. Tverskoy et al.20 used pressure algometry on 
the wound to show that the use of a rather high dose of racemic ketamine (bolus 
dose of 2 mg kg-1 during induction followed by a continuous infusion of
20 µg kg-1 min-1 until the end of surgery) decreased wound sensitivity in patients 
after abdominal hysterectomy. Kopert et al.21 used von Frey ﬁ laments to show 
that a mean dose of 0.4 mg kg-1 of s(+)-ketamine (administered over 20 minutes) 
was capable of inhibiting the development of secondary hyperalgesia in 
experimentally electrically induced pain. The use of higher doses of
s(+)-ketamine might have yielded more signiﬁ cant differences in sensitivity to 
mechanical pressure around the surgical wound in the present study.
To date only one other published study has described the use of intravenously 
low dose s(+)-ketamine in the surgical patient. In contrast to the results of the 
present study, Jaksch et al.22 did not ﬁ nd evidence for improved postoperative 
analgesia when s(+)-ketamine was used in patients undergoing arthroscopic 
anterior cruciate ligament repair. There are three obvious differences between our 
study and that of Jaksch et al.: starting the s(+)-ketamine after opioids were 
given; discontinuation of s(+)-ketamine 2 hours after surgery; and the type of 
surgery. As discussed, the ﬁ rst differences can possibly lead to a reduced 
effectiveness of low dose s(+)-ketamine. Most importantly, the study by Jaksh et 
al. examined the effect of perioperative s(+)-ketamine on later postoperative pain 
since they stopped the ketamine infusion 2 hours after surgery but continued to 
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look for effects over the following ﬁ ve days. In contrast, we examined the effect 
on postoperative use of morphine and postoperative pain of starting a low dose of 
s(+)-ketamine before induction with continuation during surgery and for 48 hours 
thereafter. Another difference between studies concerns the patient populations 
and surgical procedures. Compared with the major surgery (radical 
prostatectomy) in the present study, the arthroscopic knee surgery used in the 
study of Jaksch et al. is a relatively minor type of surgery. It is clear that 
arthroscopic surgery causes less tissue trauma which may lead to a lower 
postoperative pain intensity. Finally, patients in the study by Jaksch et al. were 
substantially younger (30 (8) years and 33 (7) years) than the patients in the 
present study (60.1 (4.7) years and 61.2 (4.7) years). This raises the possibility 
that the opioid-sparing effects of s(+)-ketamine may be age related; however, 
further research is required to evaluate this possibility. 
There are several limitations to the present study. First concerns the relatively 
small number of patients studied. This might explain why despite the 34% 
reduction in 48-hour morphine consumption in the ketamine/morphine group, no 
differences in morphine related side effects were found. Second, patients in this 
study were only followed up to 48 hours after surgery. The study cannot address 
the question of whether perioperative s(+)-ketamine inﬂ uences pain and 
analgesic consumption in the longer term. Third, although we did not ﬁ nd 
differences in psychomimetic side effects, a larger study is needed to assess this 
properly. A larger study is also needed to assess whether the favorable 
postoperative effects of s(+)-ketamine makes a difference in clinical outcomes 
such as time to ambulation, resumption of dietary intake and discharge from 
hospital.
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Chapter 4
Effects of perioperative oral amantadine on postoperative 
pain and morphine consumption in patients after radical 
prostatectomy: results of a preliminary study
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Introduction
Currently, a large body of evidence indicates that inadequate treatment of acute 
pain can have long-lasting effects. Brief noxious stimulation and frank injury 
may have profound effects on the central nervous system that long outlast the 
injury.1 Intraoperative as well as postoperative pain results in a “barrage” of nerve 
impulses entering the spinal cord and the release, from small diameter afferent C 
ﬁ bers, of excitatory amino acids and neuropeptides which induce a state of 
hyperexcitability in spinal dorsal horn neurons, leading to prolonged 
postoperative pain. This central nervous system plasticity, resembling a sort of 
“pain memory”, is referred to as central sensitization and may contribute to 
persistent pain. 
The N-methyl-D-aspartate (NMDA) receptor plays an important role in the 
process of central sensitization.2,3 Excitatory amino acids, such as glutamate and 
aspartate activate the NMDA receptor leading to an increase in intracellular 
calcium and activation of second messengers, which stimulate protein kinases 
and modify neuronal excitability. NMDA receptor activation may also produce 
longer-lasting changes by stimulating new gene expression. 
The role of the NMDA receptor in the development of central sensitization, acute 
opioid tolerance and opioid-induced hyperalgesia has led to renewed interest in 
NMDA receptor antagonists for clinical use in humans.1,4,5 Ketamine (for review 
see Schmid et al.6) and dextromethorphan7,8 have been studied almost to the 
exclusion of other clinically available substances that antagonize the NMDA 
receptor-ion channel complex. 
One of these substances is amantadine (1-aminoadamantane). Amantadine has 
been in clinical use for more than 20 years and is primarily used for the treatment 
of Parkinson’s disease and as an antiviral drug. Evidence shows amantadine to be 
a non-competitive NMDA receptor antagonist.9,10 Therefore, amantadine may be 
useful in decreasing pain and analgesic requirements, possibly by preventing 
postsurgical central sensitization, acute opioid tolerance and opioid induced 
hyperalgesia. This randomised, double-blind, placebo-controlled pilot study was 
designed to evaluate the postoperative analgesic and opioid sparing effects of 
amantadine given orally over the perioperative period in patients undergoing 
radical prostatectomy. 
Methods
Selection and randomization of patients
Approval to carry out the study was obtained from the Toronto Hospital 
Committee for Research on Human Subjects (Toronto, Ontario, Canada). 
Eligible individuals were men booked for radical retropubic prostatectomy. 
Inclusion criteria were ability to speak English; 18-75 years; American Society 
of Anesthesiologists physical status class I-III; stable or no signiﬁ cant central 
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nervous system, respiratory, cardiac, hepatic, renal or endocrine dysfunction and/
or any signiﬁ cant sequelae; no history of signiﬁ cant psychopathology; no history 
of chronic pain or chronic use of opioid and non-opioid analgesics; no previous 
allergies or adverse reactions to amantadine or opioid analgesics; no ingestion of 
antitussive medication (dextromethorphan) within 48 hours of surgery; no history 
of alcohol or drug dependency/abuse; and a body weight between 60 and 90 kg 
with a body mass index of 30 kg m-2 or less. 
A member of the Acute Pain Research Unit saw all eligible patients in the 
preadmission clinic, where they were screened for suitability and interest. 
Patients were informed of the nature of the study and introduced to the visual 
analogue scale (VAS), the patient-controlled analgesia (PCA) pump and pressure 
algometry.
For the purpose of this preliminary study, it was decided to recruit 20 patients. 
Based on an anticipated attrition rate of 15-20% due to complications, adverse 
effects, protocol violations and patient withdrawal, a total of 24 patients were 
recruited.
Patients were randomly assigned to one of two groups based on a pre-determined 
randomization schedule.11 Patients in the amantadine group received amantadine 
in a dose of 200 mg the evening before surgery; 200 mg at 1 hour before surgery; 
and 100 mg 8, 20 and 32 hours after surgery. Patients in the placebo group 
received placebo capsules at the same time as the patients in the amantadine 
group. Amantadine and placebo capsules were prepared by the Toronto General 
Hospital Pharmacy. One whole amantadine 100 mg capsule (Lot: 9AD0721; 
exp.: November 2001; Endo Pharmaceuticals, Chadds Ford, PA, USA) was 
inserted into a No. 2 empty red gelatin capsule. For placebo capsules, No. 2 
empty red gelatin capsules were ﬁ lled with Lactose powder (Lot: 127665/12243; 
Bio-Health, Dawson Traders Limited, Toronto, Ontario, Canada). The 
amantadine and placebo capsules were coded and dispensed on a patient-by-
patient basis by the pharmacy along with a sealed, opaque envelope containing 
the patient’s number and group allocation. If the attending anesthetist/Acute Pain 
Service physician determined it to be necessary for optimal patient management, 
the envelope was to be opened and the code was to be broken.
The study was double blind in that all patients and personnel involved in patient 
care, data collection, scoring and entry were unaware of the group to which the 
patient had been assigned.
General anesthesia
Midazolam, 1-2 mg, was administered intravenously to all patients 10 minutes 
before the anticipated time of induction of general anesthesia. A dosage of
2.5 µg kg-1 fentanyl was administered 60 seconds before induction with thiopental 
(3-5 mg kg-1). Muscle relaxation and tracheal intubation were facilitated with 
rocuronium bromide (0.6-0.9 mg kg-1). Anesthesia was maintained with 
60%/40% N2O/O2 and isoﬂ urane aimed at an end-tidal concentration of 0.6%. 
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Muscle relaxant was given as necessary. Morphine (75 µg kg-1) was given 
intravenously to maintain blood pressure and heart rate within 10% of baseline 
values. At the conclusion of surgery, neuromuscular blockade was reversed 
(when necessary) with neostigmine (0.05 mg kg-1) and glycopyrrolate
(0.01 mg kg-1). During the surgical procedure, patients were continuously 
monitored with an electrocardiogram, a pulse oximeter, a temperature probe and 
an end-tidal carbon dioxide and end-tidal gas analyser. 
Postoperative pain management
Immediately upon arrival in the Post Anesthesia Care Unit (PACU), the PCA-
pump (Abbott Life Care Infuser; Abbott Laboratories, Chicago, IL, USA), loaded 
with morphine, was attached to the patient’s intravenous access. When the patient 
reported pain, a loading dose of 50 µg kg-1 morphine was given through the PCA 
pump by the attending nurse. If the patient continued to experience pain, further 
increments of 50 µg kg-1 were given through the PCA pump until the patient was 
comfortable. Every 10 min during the patient’s stay in the PACU, the patient was 
asked whether he needed pain relief. An afﬁ rmative response was followed by 
administration of another 50 µg kg-1 bolus of morphine. This procedure was 
continued until the patient no longer requested pain relief and/or was alert 
enough to use the PCA pump himself.
The PCA pump was programmed to administer a bolus of 1 mg of morphine with 
a lockout time of 5 minutes and a 4-hourly maximum dose of 40 mg. No 
background infusion was delivered. PCA was continued until the end of the 
study, 48 hours after surgery. After the patient was transferred from the PACU to 
the ward, the PCA pump was the sole method of providing pain relief and was 
overseen by the research team and the Acute Pain Service of the Department of 
Anesthesia. No other analgesics were administered during the study period. If the 
patient rated his pain as 6 or higher on a VAS for a period of 1 hour, the PCA 
bolus dose was increased to 1.5 mg of morphine. When required, bladder spasm 
pain was treated with oxybutynin 5 mg three times a day.
If a patient required intravenous analgesia beyond the 48 hours study period, 
PCA morphine was continued as per the Acute Pain Service protocol.
Pain assessment instruments
Visual analogue scale (VAS)
The VAS provides a simple, efﬁ cient and minimally intrusive measure of pain 
intensity that has been used widely in research settings where a quick index of 
pain is required and to which a numerical value can be assigned.12 The VAS 
consists of a 10-cm horizontal line, with the two endpoints labeled “no pain” and 
“worst possible pain”, respectively. The patient marked the 10-cm line at the 
point that corresponded to the level of pain intensity experienced at that time. 
The distance (in centimeters) from the low end of the VAS and the patient’s mark 
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was used as a numerical index of pain intensity. Pain was assessed with patients 
at rest (VAS-R) at 1, 2, 3, 6, 12, 24, 36 and 48 hours after surgery. Pain was also 
assessed after standardized mobilization (VAS-M) at 24 and 48 hours by asking 
patients to roll from a supine to a side-lying position and perform two maximal 
inspirations before rating their pain.
 
McGill Pain Questionnaire
The McGill Pain Questionnaire (MPQ) was developed by Melzack 13 to obtain 
quantitative and qualitative measures of the experience of pain. The MPQ yields 
two global scores, the pain rating index and the present pain intensity, which 
have been found to provide valid and reliable measures of pain.12,13 The pain 
rating index is the sum of the rank values of the words chosen from 20 sets of 
qualitative words, with each set containing two to six adjectives that describe the 
sensory, affective and evaluative properties of pain. The lists of pain descriptors 
are read to the patients, who are asked to choose the word in each category that 
best describes their pain at the moment. The present pain intensity is rated on a 
scale of 0-5 as follows: 0 = none, 1 = mild, 2 = discomforting, 3 = distressing,
4 = horrible and 5 = excruciating. The MPQ was administered at 24 and 48 hours 
after surgery.
Pressure Threshold Meter
Sensitivity to mechanical pressure around the surgical wound was assessed using 
a Pressure Threshold Meter (PTM) (Pain Diagnostics and Thermography Inc, 
Great Neck, NY, USA). The PTM is a force gauge with a rubber tip (1 cm2 in 
diameter) and a 10-kg range in 0.1-kg divisions. The PTM is used to obtain 
quantitative assessments of muscle/deep tissue tenderness in response to applied 
pressure.14 The pain perception threshold (PPT) was determined by applying 
pressure and recording (in kg cm-2) the level at which the patient ﬁ rst reported 
pain. The patient then rated, on a 10-cm VAS, the intensity of the pain induced 
by the PTM. Baseline PPTs were obtained from the left and right of midline on 
the abdomen at the level of Th9 on the morning of surgery before the operation. 
Postoperatively, PPTs were obtained 5 cm from the left and right edges of the 
wound dressing at 24 and 48 hours after surgery.
Assessment of adverse effects
Sedation
Postoperative sedation was assessed at 1, 2, 3, 6, 12, 24, 36 and 48 hours after 
surgery using a ﬁ ve-point modiﬁ ed sedation scale (0 = alert and orientated,
1 = awake but drowsy, 2 = sleeping but arousable by verbal commands,
3 = sleeping but arousable by tactile stimuli and 4 = comatose).15
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Nausea and vomiting
Postoperative nausea and vomiting were assessed at 1, 2, 3, 6, 12, 24, 36 and 48 
hours after surgery. Nausea was measured using a 10-cm horizontal VAS with 
endpoints labeled “no nausea” and “extreme nausea”. At the end of the study a 
retrospective over all nausea score was obtained using the same scale. Vomiting 
was assessed as present or absent.
Pruritus
Postoperative pruritus was assessed at 1, 2, 3, 6, 12, 24, 36 and 48 hours after 
surgery using a 10-cm horizontal VAS with endpoints labeled “no itching” and 
“extreme itching”. 
Other adverse effects
The presence of insomnia, dizziness, nervousness and dry mouth was assessed at 
24 and 48 hours after surgery using a four-point scale (0 = none, 1 = mild,
2 = moderate, 3 = severe). 
Patient satisfaction
A four-item satisfaction questionnaire was administered at the end of the study to 
all patients (1 = very dissatisﬁ ed; 2 = somewhat dissatisﬁ ed; 3 = somewhat 
satisﬁ ed; 4 = very satisﬁ ed). Patients rated their satisfaction with the care they 
received from their physician, nurses and other staff and their pain control and 
overall hospital experience.
Analysis of plasma amantadine, morphine and morphine metabolites
For analysis of amantadine and morphine plasma concentrations, a venous blood 
sample was taken 1 hour before induction of anesthesia (before the second dose 
of amantadine was administered), immediately after skin closure and at 24 and 
48 hours after surgery. Blood samples were collected in 10-ml heparinized tubes 
and centrifuged immediately, and the plasma was removed and kept at –20º C 
until analysis. We used the method reported by Bras et al.16 for the analysis of 
amantadine. For quantiﬁ cation, plasma samples were extracted with toluene, 
converted to acetylamantadine and then analysed by gas chromatography using a 
nitrogen-speciﬁ c detector.
For analysis of morphine, morphine-3-glucoronide (M3G) and morphine-6-
glucoronide (M6G), plasma samples were extracted using a solid-phase 
extraction method described by Gerostamoulos and Drummer,17 with 
hydromorphone as the internal standard. After the extraction and reconstitution, 
samples were quantiﬁ ed by high-performance liquid chromatography with both 
electrochemical and ﬂ uorescent detection according to Meng et al.18
72
Effects of perioperative oral amantadine...Chapter 4
Statistical analysis
Data were analysed using the Statistical Package for the Social Sciences (SPSS 
for Windows, release 9.0; SPSS, Chicago, IL, USA) and Primer of Biostatistics 
(version 4.0; McGraw-Hill, New York, NY, USA).19 Background demographic 
data and clinical variables were compared using two-tailed t-tests (for continuous 
data) and Pearson chi-squared tests (for frequency data). No intent to treat 
analysis was performed.
Primary Outcome Measure
Cumulative morphine consumption was analysed by one-tailed t-test.
Secondary Outcome Measure
Morphine consumption between intervals bounded by assessments of VAS pain 
scores in rest (VAS-R) was analysed by t-tests using the Bonferroni type I error 
rate correction for multiple comparisons (/n). VAS-R, visual analogue pain 
scores after mobilization (VAS-M) and pain perception threshold (PPT) were 
analysed by analysis of variance (ANOVA) or analysis of covariance(ANCOVA) 
(using the baseline value as covariate). MPQ total pain rating index and MPQ 
present pain intensity were analysed by Mann-Whitney U test. Adverse effects 
and patient satisfaction scores were analysed by Pearson chi-squared test for two-
way tables. 
Variable Placebo Amantadine
Age, years 61 ± 7.2 59 ± 4.9
Height, cm 179 ± 6.1 178 ± 6.8
Weight, kg 83 ± 9.5 89 ± 16.8
Body Mass Index, kg m-2 26 ± 2.9 28 ± 4.3
Frequency of ASA status (I:II:III) 6 : 4 : 0 2 : 8: 1
Preoperative pain, % 30 36
No. of previous surgical procedures 2.1 ± 1.5 1.7 ± 1.1
Days between pre-admission and surgery 11 ± 7.3 10 ± 3.8
Baseline PPT, kg cm-2 8.3 ± 2.7 8.3 ±1.9
Table 1. Demographic and clinical information obtained at the preadmission visit. Data are mean ± SD unless 
otherwise stated. ASA = American Society of Anesthesiologists; PPT =  pain perception threshold
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Pharmacokinetic Analysis 
  
The clearance rate of morphine was calculated in those patients who did not use 
PCA morphine from 22 to 24 hours after surgery (three patients per group), 
assuming a steady state, and also for the group as a whole. This clearance rate 
was calculated by the ratio of the total PCA morphine used between 21 and 24 
hours and the resultant serum concentration of morphine measured at 24 hours 
after surgery. Clearance rate was normalized for body weight and compared 
between the amantadine and placebo groups by two-tailed t-test. Serum 
concentrations of morphine and its metabolites M3G and M6G were also 
compared between the groups by two-tailed t-test. All data presented are mean ± 
SD unless otherwise speciﬁ ed. P < 0.05 was considered statistically signiﬁ cant.
Results
Three patients were withdrawn from the study. One patient in the placebo group 
decided against participating in the study on the morning of surgery before the 
procedure. Another patient in the placebo group was given additional analgesics 
(non steroidal anti-inﬂ ammatory drugs) after surgery. One patient in the
amantadine group was withdrawn on the morning of the scheduled procedure 
because his surgery had been postponed. These three patients were not followed 
after withdrawal and their postoperative pain was treated as per the Acute Pain 
Service protocol. Therefore, data are available from 10 patients in the placebo 
group and 11 patients in the amantadine group. There were no signiﬁ cant 
differences between the groups in demographic and clinical variables (Tables 1 
and 2).
Variable Placebo Amantadine
Time between preoperative capsule and 
incision, min
101 ± 39.5 98 ± 37.7
Surgery duration, min 188 ± 73.8 169 ± 36.2
Time between between closure and arrival
in PACU, min
17.4 ± 6.4 22.9 ± 9.4
Total morphine during surgery, mg 12.5 ± 6.4 12.8 ± 4.6
Total fentanyl during surgery, µg 211 ± 28.7 224 ± 37.7
Fluid intake, ml 4550 ± 1531 4564 ± 871
Crystalloid intake, ml 3450 ± 1136 3527 ± 535
Colloid intake, ml 950 ± 284 955 ± 350
Blood loss, ml 1170 ± 596 980 ± 334
Urine output, ml 389 ± 343 334 ± 363
Table 2. Intraoperative data for the two groups. Data are mean ± SD. PACU = Post Anesthesia Care Unit
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Figure 1. Cumulative PCA morphine consumption. Statistically signiﬁ cant differences were noted at 
all time points except at 48 hours after surgery. * p < 0.05, † p = 0.0515, one-tailed t-test.
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Figure 2. PCA morphine consumption between intervals bounded by VAS pain assessments in rest. 
Statistically signiﬁ cant difference was found at 1 hour after surgery.
* p = 0.004, t-test with Bonferroni Type I error rate correction for multiple comparisons.
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Morphine Consumption and Pain Scores
Cumulative morphine consumption was signiﬁ cantly lower in the amantadine 
group compared with the placebo group at all time points, except at 48 hours 
after surgery (p = 0.0515; Figure 1). The mean difference of 24 mg represents a 
32% reduction in morphine consumption over the 48-hour period (amantadine: 
51.4 ± 24.0 mg; placebo: 75.3 ± 38.9 mg). Morphine consumption between 
intervals bounded by VAS-R pain assessments was signiﬁ cantly lower in the 
amantadine group compared with the placebo in the ﬁ rst hour after surgery
(p = 0.004) but not afterwards, although the latter group consistently required 
more morphine across the entire study period (Figure 2). VAS-R pain scores did 
not differ signiﬁ cantly between the groups over time consistent with the 
appropriate use of the PCA pump (Figure 3). The number of patients reporting 
bladder spasm pain was signiﬁ cantly lower in the amantadine group at 48 hours 
(p = 0.02) and the pain was less intense (Table 3). In addition, at 48 hours after 
surgery, sensitivity around the surgical wound as measured with pressure 
algometry was signiﬁ cantly lower in the amantadine group compared with the 
placebo group (p = 0.04; Table 3). Signiﬁ cant differences between the groups 
were not found in the MPQ scores at any time point (data not shown).
Adverse effects and satisfaction scores
The incidence of adverse drug effects did not differ signiﬁ cantly between the 
groups (data not shown). At the end of the study, all patients reported being 
“somewhat” or “very” satisﬁ ed with the quality of care they received across the 
ﬁ ve satisfaction indicators. The only indicator that showed a signiﬁ cant 
difference between the groups was satisfaction with pain control. All patients in 
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Figure 3. Pain VAS scores at rest (VAS-R). No statistically signiﬁ cant differences were noted.
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Assessment Time Pain Measure Placebo Amantadine
24 h VAS-M pain, cm 4.8 ± 2.5 4.1 ± 2.8
Bladder spasm pain
 No. of patients 3 0
 VAS pain (cm) 0.6 ± 0.3 0
Pressure Pain Threshold (PPT)
 PPT (kg cm-2) 3.9 ± 3.4 4.3 ± 2.5
 VAS pain at PPT (cm) 4.3 ± 2.6 4.1 ± 2.5
48 h VAS-M pain (cm) 3.3 ± 1.9 3.0 ± 1.9
Bladder spasm pain
 Number of patients *4 1
 VAS pain (cm) 2.7 ± 3.8 0.1
Pressure Pain Threshold (PPT)
 PPT (kg cm-2) 3.4 ± 2.6 3.5 ± 2.4
 VAS pain at PPT (cm) †4.3 ± 1.8 2.4 ± 1.2
Table 3. VAS-M, incidence and intensity of bladder spasm pain, PPT obtained 5 cm lateral to the wound dressing 
and VAS pain intensity in response to pressure. Data are mean ± SD unless otherwise stated.
* p = 0.02, placebo versus amantadine by Fisher exact test. † p = 0.04, placebo versus amantadine by ANOVA.
Time
Substance/Group
1 h before surgery At skin closure 24 h after
surgery
48 h after
surgery
Amantadine
Placebo
Amantadine
0.0 ± 0.0
275.9 ± 70.2
0.0 ± 0.0
803.4 ± 184.6
0.0± 0.0
563.5 ± 153.8
0.0 ± 0.0
366.5 ± 146.2
Morphine
Placebo
Amantadine
0.0 ± 0.0
0.0 ± 0.0
22.5 ± 7.3
34.9 ± 26.5
19.4 ± 7.9
22.0 ± 14.3
18.2 ± 8.8
19.0 ± 9.8
M3G
Placebo
Amantadine
0.0 ± 0.0
0.0 ± 0.0
123.0 ± 52.5*
74.1 ± 47.8
111.4 ± 105.8
46.0 ± 26.0
91.3 ± 103.6
38.0 ± 18.2
M6G
Placebo
Amantadine
0.0 ± 0.0
0.0 ± 0.0
36.2 ± 12.3
37.4 ± 23.7
22.7 ± 14.2
22.3 ± 7.7
24.8 ± 20.0
20.9 ± 6.9
Table 4. Plasma concentrations (ng ml-1) of amantadine, morphine, M3G and M6G. Data are mean ± SD.
* p = 0.048 placebo versus amantadine by two-tailed t-test. M3G = morphine-3-glucuronide; M6G = morphine-6-
glucuronide.
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the amantadine group reported being “very satisﬁ ed” with the quality of their 
pain control, compared with only 70% of the patients in the placebo group
(p = 0.05).
Pharmacokinetic analysis
Serum concentrations of morphine at the end of surgery tended to be higher in 
the amantadine group than in the placebo group (34.9 ± 26.5 ng ml-1 versus 22.5 ± 
7.3 ng ml-1, respectively), but this difference did not reach statistical signiﬁ cance. 
At 24 hours and 48 hours after surgery, serum levels of morphine were similar 
between the groups despite the amantadine group having received signiﬁ cantly 
less morphine. The plasma clearance of morphine at 21-24 hours after surgery 
was signiﬁ cantly lower in the amantadine group (0.68 ± 0.47 l hr-1 kg-1) than the 
placebo group (1.17 ± 0.55 l hr-1 kg-1) (p < 0.05). This was true for the sample as 
a whole and for the three patients per group who did not use PCA morphine from 
22 to 24 hours after surgery. The clearance values for the placebo group were 
identical to reference values in adults.20 The plasma concentrations of M3G at the 
end of surgery were signiﬁ cantly lower in the amantadine group (74.1 ± 47.8 ng 
ml-1) as compared to the placebo group (123.0 ± 52.5 ng ml-1) (p = 0.048). There 
were no signiﬁ cant differences between the groups in concentrations of M6G.
Discussion
The main ﬁ nding of this preliminary study is a reduction of cumulative morphine 
consumption in the amantadine group of 32% compared with the placebo group 
(Figure 1). Although a statistically signiﬁ cant difference could not be 
demonstrated at 48 hours after surgery (p = 0.0515), all other time-points (up to 
47 hours) showed p-values less than 0.05. Morphine consumption between 
intervals bounded by VAS-R pain assessments was signiﬁ cantly lower only in the 
ﬁ rst hour after surgery, although the patients in the placebo group consistently 
required more morphine at each interval across the entire study period (Figure 2). 
Furthermore, despite the fact that the total dose of morphine given during surgery 
was virtually identical between the groups, the amantadine group showed a 
signiﬁ cantly lower M3G concentration and a tendency for a higher morphine 
concentration at the end of surgery than did the placebo group. Taken together, 
these ﬁ ndings can be explained by a pharmacokinetic interaction between 
amantadine and morphine resulting in inhibition of the 3-glucuronidation of 
morphine. Because more than 50% of morphine is metabolized to M3G (and 
only about 10% to M6G),21 less 3-glucuronidation of morphine would result in 
higher morphine concentrations and lower M3G concentrations. This would 
increase the systemic exposure to a given dose of morphine, resulting in a greater 
analgesic effect and lower morphine requirements in the amantadine group. 
To further explore a possible pharmacokinetic interaction between amantadine 
and morphine, morphine plasma clearance was calculated at 21-24 hours after 
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surgery. A signiﬁ cantly lower morphine plasma clearance rate was found in the 
amantadine group, which, in conjunction with the above ﬁ ndings, implies that 
the 3-glucoronidation of morphine is inhibited by amantadine. A potential site of 
interaction between these two drugs is the renal tubular cell, since both morphine 
and amantadine share the organic cation transport system.22–24 Studies have shown 
that tubular secretion of morphine is 4-5 fold higher than its glomerular ﬁ ltration, 
which means that competitive inhibition of its tubular secretion may be 
important.24 To the best of our knowledge, the unexpected ﬁ nding of 
pharmacokinetic interactions between these drugs has not been sought or 
described before. It emphasizes the critical value of considering pharmacokinetic 
mechanisms when performing studies of drug interactions. 
At 48 hours after surgery, sensitivity around the surgical wound as measured with 
pressure algometry was signiﬁ cantly lower in the amantadine group compared 
with the placebo group. By applying pressure algometry 5 cm from the wound 
we hoped to mainly assess secondary hyperalgesia, although we recognize that 
this blunt stimulus could stretch the wound so that the measure may be 
confounded with primary hyperalgesia. Recently, it has been shown that opioids 
not only activate antinociceptive systems but also pronociceptive systems causing 
acute opioid tolerance and opioid induced hyperalgesia. These phenomena seem 
to stem from a common NMDA receptor dependent mechanism.4,5 It can be 
hypothesized that the lower morphine consumption in the amantadine group, 
produced by the pharmacokinetic interaction between amantadine and morphine, 
led to the development of reduced mechanical sensitivity around the surgical 
wound on the second postoperative day. However we cannot exclude the 
possibility that the NMDA receptor antagonist properties of amantadine may 
have contributed to a reduction in the development of acute opioid tolerance and/
or opioid induced hyperalgesia, resulting in lower morphine consumption and 
reduced mechanical sensitivity around the surgical wound.  Furthermore, there is 
evidence from animal studies that NMDA receptor antagonists inhibit spinal 
neuronal and reﬂ ex response to urinary bladder distension, suggesting an action 
of NMDA receptor antagonists on pain originating from the bladder.25,26 This 
might explain the ﬁ nding of the lower incidence of bladder spasm in the 
amantadine group.
In the present study, mean amantadine plasma concentrations ranged from 275 to 
803 ng ml-1 (Table 4). At these levels, amantadine mainly interacts with the 
NMDA receptor and higher levels are necessary for interactions with other 
receptors and/or neurotransmitter systems.9
Little has been published describing the use of amantadine for its analgesic 
properties and with one exception,27 these publications relate to treatment of 
chronic neuropathic pain and not acute postoperative pain.28,29 In contrast to the 
results of the present study, Gottschalk et al.27 did not ﬁ nd a postoperative opioid 
sparing effect when a single dose of 200 mg amantadine or saline was given 
intravenously 30 minutes before induction of general anesthesia in women 
undergoing abdominal hysterectomy. However, in that study, patients in the 
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amantadine group were younger than patients in the control group, raising the 
possibility that the opioid sparing effects of amantadine may have been offset by 
the increased opioid requirements typically seen in younger versus older 
patients,30 thereby leading to the absence of a difference in outcome between the 
two groups. In addition, patients in the amantadine group had signiﬁ cantly more 
intense preoperative pain on the day of surgery than did patients in the control 
group. The difference in preoperative pain intensity may have masked the effect 
of amantadine. Alternatively, the efﬁ cacy of amantadine may have been reduced 
in much the same way that presurgical pain has been found to be less responsive 
to preoperative treatment with analgesics, perhaps because central sensitization 
had already been established before surgery.31
Apart from the inﬂ uence of these confounding factors, there are two major 
differences between the present study and that of Gottschalk et al.27 that may 
explain the different outcomes; namely, the dosing schedule of amantadine 
(multiple doses versus single dose) and the sex of the patients. A higher dose of 
amantadine and its continuation after surgery might have yielded the same effects 
as in the present study. Further research is required to evaluate whether the 
opioid sparing effects we observed are sex related.  
The current study has several limitations. First, this pilot study enrolled a 
relatively small number of patients. This might explain why despite the 32% 
reduction in 48 hours morphine consumption in the amantadine group, no 
differences in morphine related side effects were found. Based on the data from 
this preliminary study, we calculated the sample size required for an adequately 
powered, larger-scale clinical trial comparing amantadine and placebo (SPSS 
Sample Power, release 1.0). Using a type I error rate of 5 % (two tailed), 
increasing the sample size to 32 patients per group would yield a power of 80% 
to detect a mean difference of 24 mg morphine (using a pooled SD of 33.4 mg) 
at 48 hours after surgery. A second limitation is that patients in this study were 
only followed up to 48 hours after surgery. The study cannot address the question 
of whether perioperative amantadine inﬂ uences pain and analgesic consumption 
in the longer term. The results of this pilot study should be conﬁ rmed in a larger 
trial using a more extensive method of assessing hyperalgesia (e.g. quantitative 
sensory testing) and a longer follow-up. Also, a formal pharmacokinetic study 
under strict steady state conditions should be performed to deﬁ nitely conﬁ rm our 
results.
In conclusion, perioperative oral amantadine, but not placebo, was associated 
with lower postoperative morphine requirements, less intense mechanical 
sensitivity around the surgical wound and a reduced incidence of bladder spasm 
pain in patients after radical prostatectomy. The unexpected ﬁ nding of a 
pharmacokinetic interaction between amantadine and morphine explains the 
ﬁ nding of lower postoperative morphine requirements, although additional 
pharmacodynamic effects involving the NMDA receptor may also be involved. 
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Introduction
It is now recognized that the N-methyl-D-aspartate (NMDA) receptor system 
plays a key role in the development of central sensitization,1,2 acute opioid 
tolerance and opioid-induced hyperalgesia.3,4 This has led to renewed interest in 
the use of clinically available drugs with NMDA receptor antagonist activity 
since the perioperative use of these drugs might enhance or improve the 
antinociceptive effects of opioids. Most studies in this ﬁ eld have used ketamine, 
magnesium or dextromethorphan (for review see McCartney et al.5). Other 
clinically available substances with antagonistic activity at the NMDA receptor 
have attracted much less attention.
One of these substances is amantadine (1-aminoadamantane). Amantadine was 
ﬁ rst synthesized 40 years ago 6 and is now primarily used for the treatment of 
Parkinson’s disease and as an antiviral drug. Kornhuber and co-workers 7,8 
showed that amantadine is a non-competitive, low afﬁ nity NMDA receptor 
antagonist. 
Recently, we reported preliminary results on the effects of perioperative use of 
amantadine in patients after radical prostatectomy.9 In this randomised, double-
blind, placebo-controlled study we showed that postoperative, cumulative 
morphine consumption was signiﬁ cantly lower in patients in the amantadine 
group compared with patients in the placebo group (32% reduction in morphine 
consumption over a 48 hour period). 
To further evaluate the effects of amantadine on morphine induced 
antinociception we set out to proﬁ le the effects of combining varying doses of 
amantadine with morphine on a tonic, noxious stimulation induced by formalin 
in rats. We hypothesized that amantadine, as an NMDA receptor antagonist, 
would enhance the antinociceptive activity of morphine in rats.
Materials and methods
All studies were conducted following the ethical guidelines of the International 
Association for the Study of Pain 10 and were approved by the Local Animal Care 
Ethics Committee. 
Animals and drugs
Male Sprague-Dawley rats (Harlan, Borchen, Germany) weighing 240–315 g 
were used. The animals were housed in standard rodent cages with sawdust 
bedding and food and water ad libitum. The housing room was air conditioned 
with a 12:12 h day:night cycle (lights on 7:00 AM). During the light period, 
background noise was provided by playing a conventional radio station. The 
same surrounding conditions were used in the room in which the experiments 
were done. 
Both amantadine-HCl (Johnson & Johnson Pharmaceuticals, Beerse, Belgium) 
88
Effects of pre-treatment with amantadine on morphine induced antinociception...Chapter 5
and morphine-HCl (Belgopia, Louvain-La-Neuve, Belgium) were dissolved in 
saline (0.9% NaCl; Baxter, McGraw Park, IL, USA) and freshly prepared before 
experimentation.
Formalin test
An automated formalin test assembly (Automated Nociception Analyser, 
University College, San Diego, CA, USA) as described and validated by Yaksh 
and co-workers 11 was used. This consists of a cylindrical Plexiglas container 
mounted above a transmitter-receiver coil assembly, which is contained within a 
plastic enclosure. A small metal band is glued (using cyanoacrylate, Loctite, 
Dublin, Ireland) to the left hind paw of the animal being tested. The transmitter 
under the test chamber produces an electromagnetic ﬁ eld; if the rat lifts his 
banded paw a signal is transmitted to the receiver. This signal is processed 
through an algorithm that determines ﬂ inch activity. The ﬂ inches are summed 
and stored over a selected collection interval for later analysis.   
Sixty minutes before the start of the formalin test, the animals were taken out of 
their cages, the metal bands were glued to their left hind paw and amantadine
(0 (vehicle), 12.5, 25 or 50 mg kg-1) was injected intraperitoneally (i.p.) in a 
volume of 1 ml kg-1. The animals were then housed in individual Plexiglas 
chambers to allow them to accommodate to the test chambers. Fifteen minutes 
before the start of the formalin test, morphine was injected subcutaneously (s.c.) 
(0 (vehicle), 0.31, 0.63, 1.25, 2.5 or 5 mg kg-1) in a volume of 0.1 ml kg-1. 
At the start of the test 50 µl of formalin 5% was injected into the dorsum of the 
banded paw. Data collection started immediately after the animal was placed 
inside the test chamber. Each animal’s ﬂ inch count values over 1 minute periods 
were collected for a total of 60 minutes (Figure 1). Eight animals were tested 
with each combination of amantadine and morphine: a total of 192 animals were 
tested (4 doses of amantadine times 6 doses of morphine times 8 rats).
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Figure 1. Summary of tests performed.
89
Chapter 5Effects of pre-treatment with amantadine on morphine induced antinociception...
⎥
⎦
⎤
⎢
⎣
⎡
⎥
⎦
⎤
⎢
⎣
⎡ −
−
+
t
 
t
t
ED
D 
E
EE+1
EEE =E G
*0
max0
max
Dose response analysis and construction of the isobolograms 
For data analysis, the two phases of the formalin test were deﬁ ned conservatively 
as follows; phase I (acute phase: 0–9 minutes post-formalin) and phase II (tonic 
phase: 10–60 minutes post-formalin). For dose response analysis in both phases 
the following equation was ﬁ tted to the data:
 (Equation 1)
E is the observed mean number of ﬂ inches as function of dose of the drugs. E0 is 
the mean number of ﬂ inches per minute in the absence of the two drugs (thus, 
morphine 0 mg kg-1 (vehicle) with amantadine 0 mg kg-1 (vehicle)) or the 
presence of only amantadine (thus, morphine 0 mg kg-1 (vehicle) with amantadine 
12.5, 25 or 50 mg kg-1). D is the drug dose. E starts at E0 and goes to its maximal 
effect (E
max
) with a sigmoid shape (if a logarithmic scale is used for the dose D on 
the x-axis). The parameter  determines the shape of the sigmoidal dose effect 
curve. The dose response curves for each rat were ﬁ rst calculated individually 
and then used to calculate the dose response curves for the groups. 
For rats that received only morphine, a target point Et was calculated at half of 
the E0, thus representing a 50% reduction in the number of ﬂ inches compared 
with the vehicle treated controls. This point was chosen as the target point for the 
other dose-response series in which morphine was combined with amantadine. 
EDt is the dose needed to reach Et. EDt and  were estimated by ﬁ tting Equation 
1 to the data using non-linear regression analysis. 
Subsequently, an isobologram was constructed for the target points for each 
phase using the actual EDt values. In an isobologram, the dose of each individual 
drug, needed to reach the chosen effect, is plotted on one of the axes. Each point 
plotted in the graph represents a pair of doses of the drugs needed for the effect 
when added in combination. If an experimentally determined data point lies on 
the straight line deﬁ ned by the two plotted points of the individual drugs, then the 
drug effects are purely additive (no interaction). If the point lies below this line 
of additivity, then there is synergy (supra-additivity). If it lies above this line, 
then there is antagonism (infra-additivity).12,13 The theoretical dose of morphine 
that would yield an additive interaction was also calculated; i.e., the dose of 
morphine that together with the ﬁ xed dose of amantadine would produce a point 
on the line of additivity. 
Rotarod test
Changes in motor performance were assessed using the automated accelerated 
rotarod (ENV-575 ﬁ ve station rotarod, MED Associates Inc., St. Albans, VT, 
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USA). Approximately two hours prior to drug administration, all animals 
performed 4 training runs to habituate them to the revolving drum. The fourth 
training run was taken as the control performance (pre-drug latency). During 
each run, the rod was set to accelerate from 4 to 40 rotations per minute over a 5 
minutes interval. The time to fall off the rod was taken as the latency expressed 
in seconds. A 300 second cut-off was employed.
To simulate the conditions in the formalin test, amantadine was injected i.p. in a 
volume of 1 ml kg-1 60 minutes before testing and morphine was injected s.c. in a 
volume of 0.1 ml kg-1 15 minutes before testing. The following drug 
combinations were tested (5 rats per group); amantadine 0 (vehicle), 25 mg kg-1 
or 50 mg kg-1 each with morphine 0 mg kg-1 (vehicle), amantadine 0 mg kg-1 
(vehicle) with morphine 1.25, 2.5 or 5 mg kg-1, amantadine 12.5 mg kg-1 with 
morphine 2.5 mg kg-1 and amantadine 25 mg kg-1 with morphine 1.25 mg kg-1. 
Each rat performed 4 runs at T = 0 (60 minutes after amantadine and 15 minutes 
after morphine injection), T = 20, T = 40 and T = 60 minutes (Figure 1). 
Disruption in performance, expressed as a percentage, is given as:14
 
(Equation 2)
Morphine assays
For determination of morphine concentrations in serum 56 rats were assigned at 
random to one of two groups and injected (volume 1 ml kg-1) with amantadine 25 
mg kg-1 i.p. (28 rats) or vehicle i.p. (28 rats). Forty-ﬁ ve minutes later, all animals 
were injected with morphine 1.25 mg kg-1 s.c. (volume of 0.1 ml kg-1). Fifteen 
minutes after morphine injection, 7 rats from each group were decapitated and 
the blood collected in Vacutainer® SSTTM tubes (Becton Dickinson, Meylan, 
France). Fifteen, 30 and 60 minutes thereafter this process was repeated using 7 
rats from each group at each time period. As such blood sampling covered the 
experimental conditions in the formalin and rotarod test (Figure 1). Thirty 
minutes after collection, the blood was centrifuged at 2700 rpm at room 
temperature, the serum separated and stored at –70° C until analysis.
Morphine was determined in serum by radioimmunoassay (Coat-a-Count® Serum 
Morphine, Diagnostic Products Corporation, Humbeek, Belgium). The lower 
limit of quantiﬁ cation of morphine was 8.8 nmol/l. Morphine-3-glucuronide, the 
main metabolite of morphine in rats, gives a cross-reaction of 0.35% with 
concentrations of 10,000 nmol/l or higher. Morphine is not metabolized to 
morphine-6-glucuronide in rats.15
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Figure 2. Graphic display showing the mean number of ﬂ inches per minute over time. The graphs 
show the effect of combining ﬁ xed doses of amantadine (0 (vehicle), 12.5, 25 or 50 mg kg-1) with 
varying doses of morphine and a ﬁ xed dose of morphine 0 mg kg-1 (vehicle) with varying doses of 
amantadine. Each point represents the mean from eight animals; for ease of viewing the 95% 
conﬁ dence intervals are not shown. A: amantadine, M: morphine. The numbers after the symbols A 
and M are the doses expressed in mg kg-1.
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Statistical analysis
 
GraphPad Prism® (version 4.01, GraphPad Software Inc., San Diego, CA, USA) 
was used for data ﬁ tting and statistical analysis. In the isobolograms, a t-test was 
used to determine whether the actual EDt of morphine was signiﬁ cantly different 
from the theoretical additive EDt. ANOVA with repeated measures, followed 
where appropriate by Tukey’s post-hoc analysis, was used to analyse the data 
from the rotarod test. The data from the morphine assays were analysed using the 
exponential decay program in Graphpad Prism®; an F-test was used to test 
whether the individual morphine decay curves were statistically different. 
Data are expressed as means with 95% conﬁ dence intervals. For signiﬁ cant 
differences a p-value lower than 0.05 was used.
Results
Formalin test
Figure 2 shows the mean number of ﬂ inches per minute over time for the 
different treatment groups (for ease of viewing the 95% conﬁ dence intervals are 
not shown). 
Equation 1 was ﬁ tted to the data. The target point (50% of E0) in rats that 
received only morphine was 13 (being 50% from 26) ﬂ inches per minute for 
phase I and 14 (being 50% from 28) ﬂ inches per minute for phase II. These 
points were chosen as the target points for the other dose-response series in 
which morphine was combined with amantadine. 
The results of the ﬁ t procedures were further analysed with the isobole method. 
In phase I two ﬁ tting procedures failed to reach convergence; the one for the 
amantadine only group and that for the morphine only group. In order to be able 
to apply the isobole method on the data of phase I nevertheless, a steep sigmoid 
curve with a ﬁ xed  of 10 was forced through the data of the amantadine only 
group. By choosing this high ﬁ xed value, the real dose needed for an effect is 
likely to be higher and thus any statement about synergistic interaction in phase I 
will be very conservative. In the morphine only group, the  was ﬁ xed to 1; this 
value was chosen to keep close to the mean ’s of the other morphine curves in 
this phase.
The actual EDt’s and the ’s of the two drugs and those of the combinations of 
the drugs, with the 95% conﬁ dence intervals, are given in Table 1. Since the 
target of 14 ﬂ inches per minute for phase II was higher than the E0 for the rats 
that received amantadine 50 mg kg-1 no EDt could be calculated for this group. 
The EDt’s are also given as the theoretical additive dose, i.e. that EDt of morphine 
that should emerge if the drugs were additive. Also, the fraction of the actual EDt 
from the theoretical additive EDt is given (Table 1).
To achieve a reduction in the number of ﬂ inches to the chosen target point in the 
second phase of the formalin test in rats, less morphine was needed in 
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amantadine pre-treated rats than expected according to an additive interaction, 
which means that there is a synergistic interaction. In rats pre-treated with 
amantadine 12.5 and 25 mg kg-1, respectively 53 and 60% less morphine was 
needed. These results are shown in Table 1 and in the isobolograms in Figure 3. 
Rotarod test
To evaluate the effects of amantadine and morphine and their interactions on 
motor activity, a rotarod test was used. The data revealed a signiﬁ cant overall 
time effect (F3,34 = 15.13, p < 0.001) and a signiﬁ cant time x amantadine dose 
interaction (F9,83 = 3.44, p = 0.001). The time x morphine dose interaction
(F9,83 = 0.967, p = 0.47) and the three-way interaction were not signiﬁ cant. 
Table 1. Results of the dose response analysis (by using Equation 1 (see text)) of the combination amantadine and morphine in phase I 
and phase II of the formalin test. E0 is the mean number of ﬂ inches per minute in the absence of the two drugs or the presence of only 
amantadine. EDt (mg kg-1) is the dose needed to reach the target point. This target point is 50% of the E0 in rats that received only 
morphine; for phase I the target point is 13 ﬂ inches per minute and for phase II it is 14 ﬂ inches per minute. These points were chosen as 
the target points for the other dose-response series in which morphine was combined with amantadine. The EDt is given as the actual 
value (EDt actual) and also as the theoretical additive value (EDt if additive). A t-test was used to compare the actual with the theoretical 
additive EDt’s and the resulting t- and p-values are given; p-values lower than 0.05 were regarded as being signiﬁ cant (highlighted in 
bold). Furthermore, the fraction of the actual EDt  from the theoretical additive EDt is given (EDt actual / EDt if additive). The parameter 
 determines the shape of the sigmoidal dose effect curve. Data are given with their 95% conﬁ dence intervals (CI 95%).
          
Drug 
(fixed dose) 
Drug 
(varying doses) 
 E0 
(CI 95%) 
EDt  
actual  
(CI 95%) 
EDt  
if additive 
(CI 95%) 
t-value p-value ED t actual 
EDt if additive 
(CI 95%) 
G 
(CI 95%) 
 
          
          
Phase I: 
0-9 minutes 
         
Amantadine 
0 mg kg-1  
Morphine  26 
(23-29) 
6.6 
(3.4-13) 
- - - - 1 
(fixed) 
Amantadine 
12.5 mg kg-1 
Morphine  26 
(23-29) 
3.8 
(2.0-7.4) 
5.2 
(2.7-10) 
0.60 0.28 0.73 
(0.38-1.4) 
1.1 
(0.25-1.9) 
Amantadine 
25 mg kg-1 
Morphine  26 
(23-29) 
2.8 
(1.2-6.7) 
3.8 
(1.6-9.0) 
0.42 0.34 0.74 
(0.38-1.4) 
0.8 
(0.10-1.4) 
Amantadine 
50 mg kg-1 
Morphine  22 
(17-27) 
1.5 
(1.0-2.2) 
1.0 
(0.7-1.5) 
1.18 0.13 1.4 
(0.96-2.1) 
1.7 
(0.66-2.8) 
Morphine 
0 mg kg-1 
Amantadine  26 
(23-29) 
59 
(50-70) 
- - - - 10 
(fixed) 
          
Phase II: 
10-60 minutes 
         
Amantadine 
0 mg kg-1 
Morphine  28 
(23-33) 
2.2 
(1.6-3.0) 
- - - - 1.3 
(0.67-2.0) 
Amantadine 
12.5 mg kg-1 
Morphine  28 
(25-30) 
0.7 
(0.5-1.1) 
1.6 
(1.0-2.4) 
2.45 0.020 0.47 
(0.24-0.80) 
1.3 
(0.51-2.0) 
Amantadine 
25 mg kg-1 
Morphine  27 
(25-29) 
0.4 
(0.3-0.6) 
1.0 
(0.5-1.7) 
2.13 0.033 0.40 
(0.16-0.77) 
1.3 
(0.52-2.1) 
Amantadine 
50 mg kg-1 
Morphine  11 
(4.1-16) 
- -  - - 3.1 
(0.19-6.4) 
Morphine 
0 mg kg-1 
Amantadine  28 
(25-30) 
46 
(36-57) 
-  - - 5.9 
(5.2-17) 
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Figure 3. Isobolograms for the combined effects of amantadine and morphine in phase I (panel A) 
and in phase II (panel B) of the formalin test. 
In both panels the thick line deﬁ nes the line of additivity with the dotted lines representing the 95% 
conﬁ dence interval. Synergy is present in phase II (panel B), since the data-points of the 
combinations lie below the additive line. A: amantadine, M: morphine. The numbers after the 
symbols A and M are the doses expressed in mg kg-1. M
all and Aall stands for all doses of amantadine 
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Post hoc analysis to investigate the time x amantadine dose interaction showed 
that the only signiﬁ cant difference was found at the ﬁ rst run when the disruption 
in the amantadine 50 mg kg-1 group was higher than that of the control group
(p < 0.05) (Figure 4).
Morphine assays
No differences were found in the slopes of the morphine elimination curves 
between the group that received amantadine 0 mg kg-1 (vehicle) with morphine 
1.25 mg kg-1 and the group that received amantadine 25 mg kg-1 with morphine 
1.25 mg kg-1 (one curve sufﬁ ced for both data sets: F 2,52 = 2.96, p = 0.06). The 
half-life in both groups was 42 minutes (95% CI: 35-51).
Discussion
In this study a synergistic effect between the clinically available NMDA receptor 
antagonist amantadine and the mu-opioid agonist, morphine, was found in the 
second phase of the formalin test in rats. At the tested doses, no evidence was 
found for amantadine induced motor impairment or for a pharmacokinetic 
interaction between amantadine and morphine.
The formalin test is widely used as a test for persistent pain. The formalin model 
of inﬂ ammatory pain is considered to be a better test of clinical pain compared 
with models based on thermal or mechanical stimuli.16,17 After the intraplantar 
injection of formalin in the hindpaw of the animal a biphasic response is 
typically observed. The ﬁ rst phase (in this study conservatively deﬁ ned as lasting 
from 0 to 9 minutes) is the response to direct chemical stimulation. Formalin 
releases excitatory amino acids, prostaglandins, nitric oxide and neuropeptides.18 
The release of excitatory amino acids activates NMDA receptors and a number of 
studies have indeed shown that the second phase (in this study conservatively 
deﬁ ned as lasting from 10 to 60 minutes) of the formalin test is NMDA receptor 
dependent.19-21 
Amantadine has a number of effects, which are produced by (dose-dependent) 
interactions with different receptors. When used as an antiparkinson agent, 
therapeutic serum concentrations of amantadine range from 5 to 14 µM; at these 
serum levels amantadine mainly interacts with the sigma and the NMDA 
receptor.7,8,22 Acute i.p. injection of 46 mg kg-1 of amantadine in rats leads to a 
serum level of 12 µM and a dose of amantadine of 50 mg kg-1 is considered to be 
the upper limit of relevant effects after acute administration in rats.8,23 Higher 
doses and serum levels are probably needed to see other (direct) effects such as 
those on the acetylcholine receptor 24 and especially the effects on dopamine-
release and uptake.25 However, many of these effects can also be found at the 
therapeutic serum concentrations but are then most likely secondary to a primary 
effect of amantadine on the sigma and the NMDA receptor.22,26-29 
The exact role of the sigma receptor in nociception is still not clear; animal 
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Figure 4. Effect of amantadine (panel A), morphine (panel B) and two combinations of amantadine 
with morphine (panel C) on rotarod performance in the rat. For ease of viewing the plotted data-
points have been shifted by 1.5 minute to the left or right where necessary. Data are presented as 
percentage disruption of pre-dose performance with 95% conﬁ dence intervals. For statistical analysis 
ANOVA with repeated measures followed by Tukey post-hoc analysis was used (* p < 0.05 versus 
time-matched vehicle control group). A: amantadine, M: morphine. The numbers after the symbols A 
and M are the doses expressed in mg kg-1.
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studies indicate that sigma receptors modulate NMDA receptor function 30 and 
opioid analgesia.31,32 Recently, it was found that the sigma receptor is involved in 
modulating dopaminergic transmission by amantadine.22 In this way it might also 
inﬂ uence nociception since dopamine itself has antinociceptive activity.33
There is a clear interaction between mu-opioid receptor activation and the 
NMDA receptor. Chen and Huang 34 showed that mu-opioid receptor agonists can 
produce a sustained increase in NMDA-activated currents by activating 
intracellular protein kinase C which potentiates the NMDA response by reducing 
the voltage-dependent Mg2+ block of NMDA receptor channels. This interaction 
is responsible for the induction of acute opioid tolerance and opioid-induced 
hyperalgesia; administering substances with NMDA receptor antagonist activity 
prior to the opioid reduces these pronociceptive effects of the opioid and 
enhances antinociceptive activity.3,4 
The data from the formalin test showed a synergistic effect between amantadine 
and morphine in the second phase of the formalin test. We calculated that, for the 
same effect on the number of ﬂ inches per minute, 53% and 60% less morphine 
was needed in rats pre-treated with amantadine 12.5 and 25 mg kg-1 respectively, 
when compared with vehicle treated controls (Table 1). In the ﬁ rst phase of the 
formalin test there was no synergistic effect of amantadine and morphine. 
Enhanced antinociceptive effects of morphine in the second phase of the formalin 
test in rats were also reported after systemic use of the NMDA receptor 
antagonist magnesium 35 and after spinal administration of the NMDA receptor 
antagonist AP-5.36 Since the doses tested here for amantadine fall within the 
range known to affect the NMDA receptor, the synergistic effects observed 
between amantadine and morphine are most likely a result of the NMDA 
receptor antagonist properties of amantadine. However, additional interactions 
(sigma-receptor?) cannot be ruled out. 
We used the rotarod test to assess any possible motor impairment induced by 
amantadine, morphine or the combination. Drugs with motor impairing 
capabilities have been shown to produce apparent antinociceptive effects in the 
formalin test 37 and the rotarod test has been used to show that NMDA receptor 
antagonists can have motor impairing effects.38 Amantadine in a dose of 50 mg 
kg-1 reduced rotarod performance only at the ﬁ rst run (at 60 minutes after 
injection of amantadine) but not thereafter. This diminished performance was 
observed in 3 of the 5 tested rats that fell off the rod after only 18, 21 and 43 
seconds respectively in their ﬁ rst run, whereas they performed considerably 
better in the following runs (especially in their third and fourth run, respectively 
100 and 120 minutes after amantadine injection). Repetition of this test using 50 
mg kg-1 amantadine in a second group of 5 animals revealed a similar degree of 
motor impairment (data not shown). Motor performance was not impaired at any 
of the other tested doses of amantadine, morphine and combinations of 
amantadine and morphine. 
It is not clear why the rats given the highest dose of amantadine performed 
poorly at their ﬁ rst run. All the animals were trained in the same way (see 
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Methods) and this training is necessary to learn the task of running on the 
rotarod; it also reduces stress, a factor negatively affecting the motor task.39 The 
training resulted in easy handling and stepping voluntarily from the hand of the 
experimenter onto the rotarod. It was however observed that only the rats 
injected with amantadine 50 mg kg-1 showed signs of increased reactivity and 
excitation (nervousness, frequent urination; especially when handled) and they 
no longer stepped voluntarily onto the rotarod. These animals seemed to be 
aroused or stressed which might explain the poor motor performance at their ﬁ rst 
run (at T = 0 which would be in the ﬁ rst phase of the formalin test right after 
injection of the formalin). In the three subsequent runs (at T = 20, T= 40 and
T = 60 minutes, which would be all in the second phase of the formalin test) 
these rats performed much better and there were no signs of motor impairment. 
Danysz and co-workers 40 evaluated the effects of amantadine on motor 
performance by measuring locomotor activity in the open ﬁ eld from 30 to 60 
minutes after an i.p. injection of amantadine (20, 60 and 200 mg kg-1). 
Amantadine revealed some inhibition of activity at 30 minutes at doses of 60 and 
200 mg kg-1 but not thereafter. Based on these ﬁ ndings, it seems likely that 
disruption in motor performance occurs only at doses of amantadine above the 
therapeutic range (≥ 50 mg kg-1).
When drugs are studied in combination, pharmacokinetic interactions have to be 
considered. In the present study, no differences were found in the serum levels of 
morphine between rats that received vehicle and morphine 1.25 mg kg-1 and rats 
that received amantadine 25 mg kg-1 and morphine 1.25 mg kg-1. The calculated 
half live in both groups was 42 minutes, which is in accordance with reported 
values.41 As such, it does not appear that a pharmacokinetic interaction between 
amantadine and morphine is responsible for the synergistic interaction observed 
between both drugs. However, a formal pharmacokinetic study with different 
combinations and doses of amantadine and morphine is needed to deﬁ nitely 
exclude any pharmacokinetic interaction. This is especially relevant since our 
results in humans showed a possible pharmacokinetic interaction between 
amantadine and morphine.9 
In conclusion, pre-treatment with amantadine resulted in a synergistic interaction 
with morphine in the second phase of formalin test in rats. The rotarod test 
showed that this effect was not caused by changes in motor behaviour. The 
results of a (limited) pharmacokinetic interaction study made a direct kinetic 
interaction between the two drugs as the sole explanation for the observed effect 
unlikely. As such, the increased antinociceptive activity of morphine in 
amantadine pre-treated rats appears to be the result of a pharmacodynamic 
interaction, involving the NMDA receptor.
Acknowledgements
Thanks to Dr. J. Lerou and Prof. Dr. J. Katz for their helpful comments on the 
manuscript.
99
Chapter 5Effects of pre-treatment with amantadine on morphine induced antinociception...
References
1.  Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency 
dependent potentiation of deep rat dorsal horn nociceptive neurones following C ﬁ bre 
stimulation. Neuropharmacology 1987;26:1235-8.
2.  Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent 
on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury 
pain hypersensitivity states. Pain 1991;44:293-9.
3.  Celerier E, Rivat C, Jun Y, Laulin JP, Larcher A, Reynier P, Simonnet G. Long-lasting 
hyperalgesia induced by fentanyl in rats: preventive effect of ketamine.
Anesthesiology 2000;92:465-72.
4.  Laulin JP, Maurette P, Corcuff JB, Rivat C, Chauvin M, Simonnet G. The role of ketamine in 
preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance.
 Anesth Analg 2002;94:1263-9.
5.  McCartney CJ, Sinha A, Katz J. A qualitative systematic review of the role of N-methyl-D-
aspartate receptor antagonists in preventive analgesia. Anesth Analg 2004;98:1385-400.
6.  Davies WL, Grunert RR, Haff RF, McGahen JW, Neumayer EM, Paulshock M, Watts JC, Wood 
TR, Hermann EC, Hoffmann CE. Antiviral activity of 1-adamantanamine (amantadine).
 Science 1964;144:862-3.
7.  Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA 
receptor antagonists with neuroprotective properties. J Neural Transm Suppl 1994;43:91-104.
8.  Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G. Aminoadamantanes as NMDA 
receptor antagonists and antiparkinsonian agents-Preclinical studies.
 Neurosci Biobehav Rev 1997;21:455-68.
9.  Snijdelaar DG, Koren G, Katz J. Effects of perioperative oral amantadine on postoperative pain 
and morphine consumption in patients after radical prostatectomy: results of a preliminary study. 
Anesthesiology 2004;100:134-41.
10.  Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. 
Pain 1983;16:109-10.
11.  Yaksh TL, Ozaki G, McCumber D, Rathbun M, Svensson C, Malkmus S, Yaksh MC. An 
automated ﬂ inch detecting system for use in the formalin nociceptive bioassay.
 J Appl Physiol 2001;90:2386-402.
12.  Berenbaum MC. What is synergy? Pharmacol Rev 1989;41:93-141.
100
Effects of pre-treatment with amantadine on morphine induced antinociception...Chapter 5
13.  Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response 
surface perspective. Pharmacol Rev 1995;47:331-85.
14.  Kesingland AC, Gentry CT, Panesar MS, Bowes MA, Vernier JM, Cube R, Walker K, Urban L. 
Analgesic proﬁ le of the nicotinic acetylcholine receptor agonists, (+)-epibatidine and ABT-594 in 
models of persistent inﬂ ammatory and neuropathic pain. Pain 2000;86:113-8.
15.  Milne RW, Nation RL, Somogyi AA. The disposition of morphine and its 3- and 6-glucuronide 
metabolites in humans and animals, and the importance of the metabolites to the 
pharmacological effects of morphine. Drug Metab Rev 1996;28:345-472.
16.  Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the 
method. Pain 1992;51:5-17.
17.  Abbott FV, Franklin KB, Westbrook RF. The formalin test: scoring properties of the ﬁ rst and 
second phases of the pain response in rats. Pain 1995;60:91-102.
18.  Yaksh TL. Preclinical models of nociception. In: Anesthesia: Biologic Foundations. Edited by 
Yaksh TL, Lynch C, Zapol WM, Maze M, Biebuyck JF, Saidman LJ. Philadelphia, Lippincott-
Raven, 1997:685-718.
19. Chaplan SR, Malmberg AB, Yaksh TL. Efﬁ cacy of spinal NMDA receptor antagonism in 
formalin hyperalgesia and nerve injury evoked allodynia in the rat.
 J Pharmacol Exp Ther 1997;280:829-38.
20.  Kim SJ, Thomas KS, Calejesan AA, Zhuo M. Macromolecular synthesis contributes to 
nociceptive response to subcutaneous formalin injection in mice.
Neuropharmacology 1998;37:1091-3.
21.  Yukhananov R, Guan J, Crosby G. Antisense oligonucleotides to N-methyl-D-aspartate receptor 
subunits attenuate formalin-induced nociception in the rat. Brain Res 2002;930:163-9.
22.  Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, Hermans E. Involvement of the sigma 1 
receptor in the modulation of dopaminergic transmission by amantadine.
 Eur J Neurosci 2004;19:2212-20.
23.  Quack G, Hesselink M, Danysz W, Spanagel R. Microdialysis studies with amantadine and 
memantine on pharmacokinetics and effects on dopamine turnover.
 J Neural Transm Suppl 1995;46:97-105.
24.  Matsubayashi H, Swanson KL, Albuquerque EX. Amantadine inhibits nicotinic acetylcholine 
receptor function in hippocampal neurons. J Pharmacol Exp Ther 1997;281:834-44.
101
Chapter 5Effects of pre-treatment with amantadine on morphine induced antinociception...
25.  Toide K. Effects of amantadine on dopaminergic neurons in discrete regions of the rat brain. 
Pharm Res 1990;7:670-2.
26.  Stoof JC, Booij J, Drukarch B, Wolters EC. The anti-parkinsonian drug amantadine inhibits the 
N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non- 
competitive way. Eur J Pharmacol 1992;213:439-43.
27.  Fisher A, Biggs CS, Starr MS. Differential effects of NMDA and non-NMDA antagonists on the 
activity of aromatic L-amino acid decarboxylase activity in the nigrostriatal dopamine pathway 
of the rat. Brain Res 1998;792:126-32.
28.  Li XM, Juorio AV, Qi J, Boulton AA. Amantadine increases aromatic L-amino acid 
decarboxylase mRNA in PC12 cells. J Neurosci Res 1998;53:490-3.
29.  Deep P, Dagher A, Sadikot A, Gjedde A, Cumming P. Stimulation of dopa decarboxylase activity 
in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of 
amantadine. Synapse 1999;34:313-8.
30.  Monnet FP, Debonnel G, Junien JL, de Montigny C. N-methyl-D-aspartate-induced neuronal 
activation is selectively modulated by sigma receptors. Eur J Pharmacol 1990;179:441-5.
31.  Chien CC, Pasternak GW. Sigma antagonists potentiate opioid analgesia in rats.
 Neurosci Lett 1995;190:137-9.
32.  Mei J, Pasternak GW. Sigma1 receptor modulation of opioid analgesia in the mouse.
 J Pharmacol Exp Ther 2002;300:1070-4.
33.  Shimizu T, Iwata S, Morioka H, Masuyama T, Fukuda T, Nomoto M. Antinociceptive mechanism 
of L-DOPA. Pain 2004;110:246-9.
34.  Chen L, Huang LY. Protein kinase C reduces Mg2+ block of NMDA-receptor channels as a 
mechanism of modulation. Nature 1992;356:521-3.
35.  Begon S, Pickering G, Eschalier A, Dubray C. Magnesium increases morphine analgesic effect in 
different experimental models of pain. Anesthesiology 2002;96:627-32.
36.  Nishiyama T. Interaction between intrathecal morphine and glutamate receptor antagonists in 
formalin test. Eur J Pharmacol 2000;395:203-10.
37.  Rosland JH, Hunskaar S, Hole K. The effect of diazepam on nociception in mice.
 Pharmacol Toxicol 1987;61:111-5.
102
Effects of pre-treatment with amantadine on morphine induced antinociception...Chapter 5
38.  Boyce S, Wyatt A, Webb JK, O’Donnell R, Mason G, Rigby M, Sirinathsinghji D, Hill RG, 
Rupniak NM. Selective NMDA NR2B antagonists induce antinociception without motor 
dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn.
 Neuropharmacology 1999;38:611-23.
39.  Rozas G, Guerra MJ, Labandeira-Garcia JL. An automated rotarod method for quantitative drug-
free evaluation of overall motor deﬁ cits in rat models of parkinsonism.
 Brain Res Protoc 1997;2:75-84.
40.  Danysz W, Essmann U, Bresink I, Wilke R. Glutamate antagonists have different effects on 
spontaneous locomotor activity in rats. Pharmacol Biochem Behav 1994;48:111-8.
41.  Zheng M, McErlane KM, Ong MC. High-performance liquid chromatography-mass 
spectrometry-mass spectrometry analysis of morphine and morphine metabolites and its 
application to a pharmacokinetic study in male Sprague-Dawley rats.
J Pharm Biomed Anal 1998;16:971-80.
 
103
Chapter 6aParenteral administration of low dose ketamine for...
Chapter 6
Case series6

105
Chapter 6aParenteral administration of low dose ketamine for...
Chapter 6a
Parenteral administration of low dose ketamine for the 
 treatment of  neuropathic pain in cancer patients
Lee Kong PE, Snijdelaar DG, Crul BJ
Adapted from: Parenterale toediening van lage doseringen
ketamine ter behandeling van neuropathische pijn bij patiënten 
met kanker. Ned Tijdschr Geneeskd 2002;146:2556-8
 
6a

107
Chapter 6aParenteral administration of low dose ketamine for...
Introduction
Adequate treatment of pain in terminal cancer patients can be a major challenge 
especially when the pain cannot, or can no longer, be controlled with high doses 
of opioids. This phenomenon can occur in the presence of a neuropathic 
component to the pain, which is known to be less responsive to treatment with 
opioids. In these patients, the anesthesiologist may be called upon to perform 
more invasive pain therapies to bring the pain under control. These more invasive 
approaches include insertion of an intrathecal or epidural catheter for the 
continuous administration of local anesthetics and opioids or an ablative 
procedure such as percutaneous chordotomy. However these treatments usually 
cannot be performed immediately; the patient must be admitted and OR-
facilities, ﬂ uoroscopy and skilled personnel must be available. A major problem 
is how to achieve acceptable pain relief while awaiting these more invasive pain 
therapies.
We present 3 terminal cancer patients with neuropathic pain. Acceptable pain 
relief could not be obtained despite high doses of opioids. The patients were 
scheduled for more invasive treatments and were administered a continuous 
parenteral infusion of low dose ketamine.
Case reports
Patient A was a 52-year-old woman with skeletal metastases from bladder 
carcinoma. She suffered from a continuous somatic pain in the lower abdominal 
region and an intermittent neuropathic pain which radiated to both of her legs. 
Pain was assessed using an 11 point Numeric Rating Scale (NRS) where 0 
represented “no pain” and 10 represented “worst possible pain”. The patient’s 
pain remained poorly controlled (NRS ranged from 6 to 9) despite multiple 
treatments including epidural analgesia and use of opioids (intravenous morphine 
by patient-controlled analgesia (PCA) and transdermal fentanyl totalling 590 mg 
of morphine equivalents per day) co-administered with other analgesic drugs 
(paracetamol, diclofenac, amitriptyline and carbamazepine). The patient was 
scheduled for insertion of an intrathecal catheter and in the meantime a 
subcutaneous infusion of ketamine 15 mg per hour (3.3 µg kg-1 min-1) was started. 
A few hours after the start of ketamine infusion, the patient reported signiﬁ cant 
pain relief with a NRS of 4. In the days thereafter opioid consumption 
(controlled by the patient through PCA) was reduced to 80 mg of morphine 
equivalents per day. The patient reported being very satisﬁ ed with this method of 
relieving her pain and a NRS of 4 was acceptable for her. After consultation with 
her family doctor, the initial plan to insert an intrathecal catheter was abandoned 
and it was decided to continue with the treatment of ketamine at home. The 
ketamine was administered subcutaneously through a 22G butterﬂ y needle and 
this was replaced every three days by the home care nurse in consultation with 
the family doctor.  
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The administration of ketamine was continued until the death of the patient, three 
weeks after she was discharged from the hospital. During this time the dose of 
ketamine was gradually increased (guided by the pain complaints of the patient) 
to a ﬁ nal dose of 45 mg per hour (10 µg kg-1 min-1). The anesthesiologist 
maintained regular telephone contact with the patient, her family doctor and the 
home care nurse. Psychomimetic adverse effects (hallucinations, bad dreams, 
confusion or feelings of unreality) or other adverse effects such as itchiness, 
nausea or dizziness were not reported by the patient or the treating professionals.
Patient B was a 54-year-old man with metastatic thyroid carcinoma. He 
experienced a continuous somatic and intermittent neuropathic pain in his right 
shoulder and arm, caused by tumor growth into the brachial plexus. He was 
admitted to the hospital and treated initially with opioids (intravenous morphine 
via PCA plus transdermal fentanyl totalling 495 mg of morphine equivalents 
daily) co-administered with a variety of other analgesic agents including 
paracetamol, diclofenac and amitriptyline. It was decided to insert a cervical 
epidural catheter and while awaiting the epidural treatment, he was started on an 
intravenous infusion of ketamine 10 mg per hour (2.2 µg kg-1 min-1) which 
resulted in a signiﬁ cant reduction in pain; from a NRS which varied between 7 
and 10 to a NRS of 3. Total daily opioid consumption was eventually reduced to 
130 mg of morphine equivalents per day.  
The patient was satisﬁ ed with the pain relief he was getting from the ketamine-
opioid combination and the insertion of the cervical epidural catheter was 
cancelled. The patient was discharged home with a subcutaneous administration 
of ketamine which was monitored by the home care nurse and his family doctor. 
Over the course of the next three weeks until his death, the ketamine infusion 
was gradually increased to 20 mg per hour (4.7 µg kg-1 min-1) with satisfactory 
pain control. No adverse effects were reported. 
Patient C was a 40-year-old man with a non-Hodgkin’s lymphoma with 
continuous somatic and intermittent neuropathic pain in the left leg caused by 
tumor growth into the lumbar plexus. He was scheduled for insertion of an 
intrathecal catheter. At the time of assessment, the patient was receiving opioids 
(slow release oral morphine, dextromoramide as needed and PCA morphine 
which totalled 480 mg of morphine equivalents per day) in combination with 
other analgesics (paracetamol, amitriptyline en carbamazepine). Despite the use 
of these drugs the patient rated his pain as a 10 on the 0-10 NRS.
Intravenous ketamine was started at a dose of 10 mg per hour (2 µg kg-1 min-1) 
and was increased the same day to 15 mg per hour (3.3 µg kg-1 min-1). This 
resulted in a dramatic relief of pain to a NRS of only 0.5. Opioid consumption 
stabilized at 420 mg of morphine equivalents a day. Because of the relative long 
life expectancy of this patient it was decided to go ahead with the insertion of the 
intrathecal catheter. This resulted in complete pain relief (NRS score of 0) and 
discontinuation of the ketamine.  
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Patient Morphine 
equivalents (mg 
day-1) before start 
of ketamine
Start dose of 
ketamine
(µg kg-1 min-1)
Duration of 
ketamine 
treatment (days)
Maximum dose 
of ketamine
(µg kg-1 min-1)
Morphine 
equivalents 
(mg day-1) 
after start of 
ketamine
Deﬁ nitive 
therapy
A 590 3.3 21 10 80 Ketamine
B 495 2.2 21 4.7 130 Ketamine
C 480 2 6 3.3 420 Intrathecal 
catheter
Table 1. Daily use of opioids (calculated as morphine equivalents), dose and duration of ketamine treatment and 
deﬁ nitive therapy for the three presented patients.
Discussion
There is now ample evidence that the NMDA receptor is involved in the 
processes underlying central sensitization and in the development of opioid 
tolerance.1,2 Central sensitization and opioid tolerance are two of many factors 
which may be responsible for the pain in cancer patients despite use of high 
doses of opioids. This is especially true in cases where there is a neuropathic 
component to the pain. The use of substances that act to block the NMDA 
receptor-ion channel complex can be useful if the pain cannot be sufﬁ ciently 
controlled using high dose opioids alone. One of the most useful of these 
substances is ketamine.
Ketamine has been widely used as an anesthetic and analgesic agent for the last 
35 years. It proved valuable in military and trauma medicine, especially in the 
treatment of pain in the hypotensive and severely injured patient. Its usefulness 
however was limited by its undesirable psychic side effects when administered 
intravenously at doses of 2-3 mg kg-1.
Since its introduction into clinical practice, a number of studies have looked at 
possible mode of actions of ketamine. It is now know that ketamine interacts 
with the NMDA receptor, opioid receptors, monoaminergic receptors, nicotinic 
and muscarinic cholinergic receptors, Ca2+ channels, GABA receptors and Na+ 
channels. However ketamine has the highest afﬁ nity for the NMDA receptor and 
it is the interaction with the NMDA receptor that is considered to be the most 
signiﬁ cant mode of action of ketamine.3,4 
Low doses of ketamine have been successfully used in the treatment of acute 
(postoperative) pain.5 Also a number of case reports and case series have been 
published describing the use of low doses of ketamine in the treatment of chronic 
neuropathic pain and cancer pain.6-8,9
The present case-reports show that the use of a continuous, intravenous or 
subcutaneous infusion of low dose ketamine (starting dose of 2-5 µg kg-1 min-1) 
can provide adequate pain relief in cancer patients who have not responded to 
high dose opioid therapy. In patients A and B the use of ketamine led to a 
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signiﬁ cant reduction in pain as well as to a considerable decline in their need for 
opioids (see Table 1). The treatment with ketamine in these two patients was 
continued at home. A portable infusion pump and a 22G subcutaneously placed 
butterﬂ y needle were used. The needle was renewed every three days by the 
home care nurse. In patient C signiﬁ cant pain relief could be reached by using 
ketamine pending more deﬁ nitive invasive pain therapy. 
No adverse effects were reported with these low doses of ketamine. Local itch 
around the subcutanueous needle was not reported.10 By replacing the needle 
every three days, the development of local skin irritation was probably 
minimized. Other adverse effects of ketamine such as psychomimetic effects, 
nausea or dizziness were not reported.
This method of using ketamine seems suitable for covering the period between 
initial assessment and the initiation of a more invasive pain therapy that cannot 
be performed on the spot and must be scheduled. However the administration of 
a continuous, low-dose infusion of ketamine can also be used to further reduce 
residual pain after invasive pain therapy. As shown in patients A and B the 
administration of ketamine can also be continued at home. In the home situation 
the subcutaneous route is preferred over the intravenous route since the care and 
changing of the needles can be left to the home care nurse.   
In this case-series, we used racemic ketamine which is a mixture of two 
enantiomers, s(+)- and r(-)-ketamine. Studies of the isolated enantiomers of 
ketamine in animals and humans show the s(+)-isomer to be a more potent 
analgesic and to cause fewer psychomimetic adverse effects than the r(-) form of 
the racemate.11,12 These differences between the two enantiomers are mainly based 
on differences in pharmacodynamics; different studies showed that the
s(+)-enantiomer binds to the NMDA receptor more readily than does the
r(-)-enantiomer.13 The recent introduction of s(+)-ketamine into the Dutch market 
offers the possibility to use even lower doses in patients unresponsive to high 
dose opioids therapy.
In conclusion, the parenteral administration of low dose (racemic) ketamine is an 
easily available, minimally invasive and effective addition to the treatment with 
opioids of neuropathic pain in terminal cancer patients.
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Introduction
Phantom limb pain is a referred neuropathic pain condition, perceived to arise 
from the part of the body that was amputated. The mechanisms of phantom limb 
pain remain unknown; both peripheral and central factors seem to be important. 
Recently Flor et al.1 postulated that a somatosensory pain memory and altered 
homonuclar structure in the somatosensory cortex may underlie phantom limb 
pain and that peripheral factors may sustain this memory. Suggested therapies 
include pharmacological agents (e.g. anti-depressive drugs, anti-epileptic drugs, 
calcitonin), behavioral interventions, transcutaneous electrical nerve stimulation, 
invasive techniques (e.g. epidural blockade, sympathectomies, dorsal root entry 
zone lesion, spinal cord stimulation, motor cortex stimulation) and even 
electroconvulsive therapy.2-5 In a signiﬁ cant percentage of amputees adequate 
pain relief cannot be achieved, which makes the search for an effective therapy a 
priority. Not one of the many published treatments for phantom limb pain has 
been shown convincingly to be effective, necessitating the publication of even 
small case series.3 We report four patients with phantom limb pain refractory to 
multiple treatment strategies. The patients received methadone and all reported at 
least adequate relief of their phantom limb pain symptoms.
Case reports
Patient 1
This patient was a 49-year old woman who had a right above-elbow amputation 
due to arterial vascular occlusion of the right arm. After the amputation, she 
suffered stump pain which subsided within a few days. Two weeks after surgery, 
the patient began complaining of phantom hand pain which she described as 
feeling ice-cold and cramped. This pain increased in intensity over the following 
months despite treatment with transcutaneous electrical nerve stimulation and 
medication (non-steroidal anti-inﬂ ammatory drugs, opioids (oral slow release 
morphine), carbamazepine, amitryptiline and calcitonin). 
Oral methadone was started six months after amputation. At that time, the patient 
rated her average phantom limb pain severity on a Visual Analogue Scale (VAS) 
as 7/10. Two days after the start of 5 mg methadone bid, the pain intensity 
decreased to a VAS score of 4/10. After 4 weeks, during which time the 
methadone dose was gradually increased to 7.5 mg bid and 10 mg an, she 
reported no pain during the day and a VAS score of 4/10 in the evening. On 
follow-up, four months after the start of methadone, the patient reported the 
absence of pain during the day and variable pain intensity in the evening ranging 
from a VAS score of 4-8/10. 
116
Methadone for phantom limb painChapter 6b
Patient 2
The second patient was a 47-year old woman who suffered from adenocarcinoma 
of unknown origin, with metastases to the right femur and to the brain. Because 
of the metastatic cancer in her right femur she had a right upper leg amputation.
Postoperatively the patient reported mild stump pain which lasted for two days. 
After one week she started suffering phantom leg pain. Pain treatment consisted 
of medical therapy (opioids (intramuscular nicomorphine, transdermal fentanyl), 
amitriptyline, carbamazepine, valproine-acid and calcitonin).
Four weeks after amputation a course of oral methadone was started. She rated 
her phantom limb pain intensity at a 6/10 prior to the start of methadone. An 
initial dose of oral methadone 2 mg bid was gradually increased to 6 mg bid and 
8 mg an over a period of three months. At a three-month follow-up, the patient 
reported substantial relief of the phantom limb pain which she rated at 3/10.    
Patient 3
The patient was a 21-year old man who underwent a left above-the-knee 
amputation because of a Complex Regional Pain Syndrome type 1 of the left 
lower leg and foot. Two days after surgery, the patient started suffering severe 
phantom limb pain, rating the intensity as a 9-10/10 on a VAS. He also reported 
severe stump pain, rating it as a 7/10. Initially the patient was treated with non-
steroidal anti-inﬂ ammatory drugs, tramadol, opioids (intramuscular 
nicomorphine, oral slow release morphine, transdermal fentanyl), amitriptyline 
and gabapentin. Two weeks after amputation, oral methadone was started at a 
dose of 2 mg tid. Within three days the patient reported diminished phantom limb 
pain but no relief of the stump pain. The dose of methadone was increased to 5 
mg qid over the next few days, and after one week, the patient rated both his 
phantom and stump pain intensity at 4/10. At this time, other opioids and 
gabapentin were discontinued, and the patient was maintained on methadone 5 
mg qid until follow-up.
On follow-up, two months later, the patient reported a VAS pain score of 4/10 for 
both his phantom and stump pain.
Patient 4
This patient was a 27-year old woman who had a right upper arm amputation, 
because of recurrent upper arm luxation due to the Ehlers-Danlos syndrome. 
Immediately after the amputation she suffered severe phantom hand pain which 
she described as a burning and cramping sensation. Stump pain was only present 
during the ﬁ rst four days postoperatively.   
Medical treatment of her phantom limb pain consisted of non-steroidal anti-
inﬂ ammatory drugs, opioids (oral slow release morphine, transdermal fentanyl), 
amitriptyline, carbamazepine, several injections of calcitonin and a continuous 
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intravenous infusion of a low-dose ketamine. After 4 weeks of ketamine 
treatment, the patient still rated her phantom limb pain as 8/10. Ketamine was 
discontinued and oral methadone 4 mg tid was started. After two days, the patient 
reported pain relief. Over a period of two weeks, the methadone was gradually 
increased to 10 mg qid. At that time the patient reported a VAS-score of 3/10.
Four months later, during which time the methadone was continued, she rated her 
phantom limb pain at 5/10. An attempt to reduce the methadone dose failed 
because of a subsequent increase in the severity of her phantom limb pain.
Discussion
Methadone is a drug that was developed more than 40 years ago. It is now 
mainly used both as a maintenance drug for opioid dependence and in the 
treatment of pain, mostly cancer pain.6 Some important characteristics of 
methadone are its lack of known metabolites, the long and unpredictable half-
life, excellent absorption following oral and rectal administration and its low 
cost. Because of its unpredictable half-life, methadone must be titrated carefully 
in each individual to avoid overdose.                    
Four cases are presented in which methadone reduced phantom limb pain. In all 
cases other medication, including opioids, did not result in satisfactory pain 
relief. No signiﬁ cant methadone related adverse effects were noted in the four 
patients which we attribute to the low doses and the slow titration rate. 
True phantom limb pain is a neuropathic pain in which the process of central 
sensitization may play an important role.7,8 The N-methyl-D-aspartic acid 
(NMDA) receptor-ion channel is thought to be important in the development of 
central sensitization and substances that block this receptor can be effective in 
the treatment of pain.9,10
In animal studies methadone acts as an opioid agonist as well as an NMDA 
receptor antagonist although it is not clear that the NMDA receptor antagonist 
activity has any signiﬁ cance.11,12 Still, a synergistic action between the opioid 
agonist activity and NMDA receptor antagonist activity of methadone might 
contribute to its effectiveness in the treatment of phantom limb pain. In this 
respect it is remarkable that in patient 4, the continuous infusion of ketamine did 
not produce any pain relief, whereas methadone dramatically decreased the 
phantom limb pain from an 8/10 to a 3/10. 
In addition to its effects at the mu-opioid receptor and the NMDA receptor, 
methadone appears to inhibit serotonin reuptake.13 It is known that serotonin 
plays a role in a variety of pain syndromes. The inhibition of serotonin reuptake 
may therefore contribute to the analgesic effect of methadone in phantom limb 
pain although it has to be mentioned that other serotonin reuptake inhibitors 
failed to produce pain relief in our patients.
There are several limitations to the present case series. The series was 
nonrandomized, uncontrolled and unblinded and the follow-ups were limited to 
between two and four months. The possibility of a placebo response cannot be 
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ruled out, but we think this is less likely since patients had been refractory to 
multiple other treatments. The limited follow-up times raise the possibility that 
the improvements we observed reﬂ ected the natural course of phantom limb pain 
since the intensity and duration of phantom limb pain episodes appear to 
diminish during the ﬁ rst year after amputation.14,15 Nevertheless, prospective 
studies show that the incidence of phantom limb pain is between 59% and 70% 
one to two years after amputation and cross-sectional survey studies indicate that 
between 78% and 85% of amputees continue to experience signiﬁ cant phantom 
limb pain more than 25 years after amputation.3,14,15 Phantom limb pain occurs in 
the majority of amputees and an effective treatment has yet to be found. In our 
opinion before considering invasive treatments, it is advisable to try oral 
methadone. We realise that opioid therapy for chronic non-cancer pain remains 
controversial because of concerns about tolerance and addiction. Depending on 
the severity of the pain, body weight of the patient and history of opioid use, we 
suggest starting with a low dose of methadone (e.g., 2 to 5 mg bid or tid) and 
slowly titrate upwards until satisfactory pain relief is reached or intolerable side 
effects noted.
Conclusion
Oral methadone was effective in reducing phantom limb pain intensity in four 
patients. All patients had been tried on a variety of other analgesic agents without 
effect. Given the high incidence of phantom limb pain and the immense suffering 
the pain engenders, it is imperative that effective treatments be found. A 
prospective, controlled clinical trial evaluating the efﬁ cacy of methadone for 
phantom limb pain and addressing the issues of tolerance and addiction would be 
appropriate to verify our observations.
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Opioids are widely used in the treatment of acute and chronic pain. In general, 
they are quite effective in the symptomatic treatment of pain when administered 
in the appropriate way and dose. However, their effectiveness can be offset by the 
development of tolerance and/or hyperalgesia, their reduced efﬁ cacy in certain 
types of pain syndromes (e.g. central neuropathic pain), and the occurrence of 
adverse effects. Since the NMDA receptors are involved in many nociception 
related processes it was hypothesized that it would be beneﬁ cial to combine 
opioids with substances with NMDA receptor antagonist properties in an effort 
to modulate (and hopefully improve) opioid induced analgesia.
In this thesis, three clinically available drugs with NMDA receptor antagonist 
properties ((s(+)-)ketamine, amantadine, methadone) have been evaluated for 
their effect on opioid induced analgesia. The results of the studies performed 
with these drugs will now be discussed, the original research questions answered 
and future perspectives given.
Ketamine
Two clinical trials using ketamine were conducted to evaluate if this clinically 
available NMDA receptor antagonist could improve opioid efﬁ cacy in acute pain 
settings and improve long term outcomes. Special attention was given to the 
optimal timing of the administration of ketamine. 
Does pre-emptive analgesia using intravenous fentanyl plus low dose (racemic) 
ketamine, versus intravenous fentanyl alone, for radical prostatectomy under 
general anesthesia produce short term or long term reductions in pain or 
analgesic use? 
In Chapter 2 the use of (racemic) ketamine in combination with the opioid 
fentanyl in radical prostatectomy patients is described. The objective of this 
study was to evaluate short (up to 72 hours after surgery) and long term (two 
weeks and six months after surgery) effects on pain and analgesic use of the 
administration of the ketamine/fentanyl combination started before or after 
incision, in comparison with a control group (only fentanyl). The main 
hypothesis was that the pre-emptive use (pre-incisional administration of an 
analgesic agent versus its post-incisional administration) of the combination of 
ketamine and fentanyl would reduce postoperative consumption of morphine. 
The results of this study indicated that cumulative postoperative morphine 
consumption was not different between the groups at 72 hours after surgery. 
Only on the third postoperative day (49 to 72 hours after surgery) a slight 
reduction in hourly morphine consumption was found. This is, however, not 
considered to be a clinical signiﬁ cant effect since pain scores (VAS, MPQ), 
measurement of hyperalgesia (by von Frey ﬁ laments) and the items scored 
during the two-week (pain scores (VAS), hyperalgesia (von Frey)) and six month 
(Follow-Up Pain Questionnaire) follow-up did not differ among the three 
treatment groups. It can be concluded that using the combination of low dose 
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ketamine and fentanyl, according to the classical pre-emptive analgesia design 
and deﬁ nition, is clinically not useful in radical prostatectomy patients with 
regard to opioid sparing, improved opioid efﬁ cacy or long term outcome. 
Since results from other studies suggested that more clinically meaningful results 
might be obtained by (1) extending the infusion of ketamine to cover a longer 
period of nociceptive activity over the per- and postoperative phase,1 (2) using the 
s(+)-enantiomer of ketamine,2 (3) administration of ketamine before opioids are 
given 3 and (4) possibly also by using morphine as the intraoperative opioid,4 the 
study as presented in Chapter 3 was performed. 
What is the effect of preventive analgesia by using intra- and postoperative low 
dose s(+)-ketamine plus morphine on postoperative pain and analgesic 
consumption after radical prostatectomy?
The objective of the study presented in Chapter 3 was to evaluate the preventive 
use of s(+)-ketamine (e.g. starting administration of s(+)-ketamine before 
induction of anesthesia (and before the opioids are given) with continuation into 
the postoperative period). This study incorporates many of the above suggestions: 
(1) s(+)-ketamine was used and started before the opioids were given,
(2) morphine was selected as the intraoperative opioid (fentanyl was only used at 
induction of anesthesia) and (3) s(+)-ketamine was continued for 48 hours after 
surgery. The same study population (men undergoing radical prostatectomy) was 
used as in the study presented in Chapter 2. The results demonstrated that the 
preventive use of s(+)-ketamine resulted in a clinically signiﬁ cant reduction in 
the consumption of morphine postoperatively together with a reduction in pain 
scores over the 48 hours. However no differences were found in the incidence of 
adverse effects or in hyperalgesia (as measured with pressure algometry at 24 
and 48 hours after surgery). This study did not evaluate other potentially 
meaningful short term (e.g. time to ambulate, resumption of dietary intake) or 
long term (e.g. residual pain) clinical outcomes.
It can be concluded from the two studies presented in Chapters 2 and 3, that the 
use of ketamine and opioids in the pre-emptive way (pre-incisional 
administration of an analgesic agent versus its post-incisonal administration) is 
not a useful clinical approach, and that a preventive approach (starting 
administration before induction of anesthesia with continuation into the 
postoperative period) has a clear morphine sparing effect postoperatively. 
However, further studies using other clinical populations and larger sample sizes 
are needed to determine if the preventive approach is a clinically useful strategy.
McCartney et al.5 recently reviewed studies on the perioperative use of clinically 
available NMDA receptor antagonists. Ketamine was co-administered with 
opioids in a preventive design in 18 studies; ketamine produced a signiﬁ cant 
preventive analgesic beneﬁ t in 8 of the 18 included studies. Interestingly, in the 8 
positive studies a direct analgesic beneﬁ t occurred in the early postoperative 
period, while of the 10 negative studies, 6 did not demonstrate any direct 
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analgesic effect of the intervention. Patients enrolled in the included studies 
underwent a variety of surgical procedures; there was no effect of surgical type 
on the success of preventive intervention. Thus, there remain a number of 
questions which need to be answered on the preventive, perioperative use of 
combining ketamine and opioids:
1. How long after surgery must ketamine administration be continued to have a 
maximal preventive effect? 
In the studies presented in Chapters 2 and 3 ketamine is administered for 72 and 
48 hours after surgery respectively. This is in accordance with other studies in 
which ketamine is administered postoperatively.6 The time point of 48 or 72 
hours is usually chosen because at that point most patients can be taken off 
opioids and need only non-opioid analgesic drugs to manage their residual pain. 
It is not known whether extending the administration of ketamine beyond 48-72 
hours would be of any beneﬁ t to surgical patients. Kissin 7 argued that the 
surgically induced inﬂ ammatory injury (as a reaction to damaged tissue) plays a 
dominant role in central sensitization processes. Since, especially after major 
surgery, the inﬂ ammatory response lasts longer than 72 hours,8 continuation of 
ketamine beyond this time point might indeed be of further beneﬁ t to the patient.
2. Is s(+)-ketamine better than racemic ketamine? 
Only a direct, head-to-head, comparison of the preventive use of a combination 
of s(+)-ketamine with an opioid versus racemic ketamine with the same opioid 
versus a placebo control group (opioid only) in a surgical patient population can 
deﬁ nitely answer this question. To date, no such study has been published.
3. Ketamine and fentanyl and/or morphine or other opioids?
In the study presented in Chapter 2 fentanyl was the only intraoperative opioid 
used. In the study in Chapter 3 a single dose of fentanyl was used during 
induction of anesthesia and morphine was used for the remainder of the 
procedure. In both studies morphine was used as the postoperative opioid. As 
already discussed in Chapter 2 Hofmann et al.4 found that epidural ketamine 
potentiated epidural morphine but not epidural fentanyl; the choice of opioid 
might thus be important.
4. Which type of surgeries or patient-groups beneﬁ t the most from the preventive 
use of ketamine and what is the inﬂ uence of the preventive use of ketamine on 
long term outcome, especially on the development of chronic pain syndromes?
In the studies presented in Chapter 2 and 3 only patients scheduled for radical 
prostatectomy were enrolled. This type of surgery was chosen because it is 
standardized, major surgery that is performed frequently in the elderly male 
patient; this makes the study population homogeneous and suited for 
postoperative pain studies. The data from the study presented in Chapter 2 show 
an overall incidence of pain of 10.5% of the patients at six months follow-up. 
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This pain was perceived as mild (VAS between 2.3 and 3.4) and only in one 
patient did it interfere with daily activity (see table 7, Chapter 2). Although 
Haythornthwaite et al.9 reported a much higher incidence of mild pain following 
radical prostatectomy surgery (49% of their patients had pain at 3 months and 
36% had pain at 6 months), severe chronic pain seems unlikely after radical 
prostatectomy. This might, of course, be an additional explanation for why we 
did not ﬁ nd a difference in residual pain at the six month follow-up for the 
patients presented in Chapter 2.
There are, however, a number of surgeries that are known for their high incidence 
of developing (severe) chronic pain syndromes. 
After mastectomy, retrospective studies suggest a prevalence of post-mastectomy 
pain syndrome between 20 and 65% of breast cancer survivors.10 These patients 
report a continuous neuropathic pain in the axilla, medial upper arm and lateral 
chest wall starting shortly after surgery. The pain is characterised by paroxysms 
of lancinating pain against a background of burning, aching and tight 
sensations.11 
Post-thoracotomy pain is deﬁ ned as pain on the chest around the incision scar 
that persists for longer than 2 months postoperatively, or that recurs after having 
disappeared for a while, but that is not related to the recurrence of a tumor or to 
an infection. Pertunnen et al.12 found that the incidence of chronic post-
thoracotomy pain was 80% at 3 months, 75% at 6 months and 61% one year after 
surgery and that chronic post-thoracotomy pain interfered with the patient’s 
normal daily life in more than half of the patients. It is reported that early post-
operative pain after thoracotomy is the only factor that signiﬁ cantly predicted 
long term post-thoracotomy pain.13
As already discussed in Chapter 6b, prospective studies showed that the 
incidence of phantom limb pain is between 59% and 70% 1 to 2 years after 
amputation.14,15 Amputees suffering from preoperative limb pain may have a 
higher incidence of phantom pain after amputation.15
Other surgical procedures such as cholecystectomy and inguinal herniotomy, are 
also known to have a high risk of developing chronic pain.16
Further clinical trials should focus on the effects of preventive use of ketamine 
with opioids on the development of chronic pain syndromes in patients scheduled 
for mastectomy, thoracotomy, amputation, cholecystectomy or inguinal 
herniotomy. 
Another group of patients that could potentially beneﬁ t from the preventive use 
of ketamine is the opioid-dependent patient presenting for surgery. It is usually 
difﬁ cult to optimise anesthetic and especially analgesic care in these patients.17 
As discussed in Chapter 1, the use of opioids can lead to tolerance and 
hyperalgesia due to NMDA receptor mediated mechanisms, and the use of an 
NMDA receptor antagonist such as ketamine might therefore prove useful.18,19 
However, thus far only case reports have been published on the use of ketamine 
for management of acute pain in opioid-dependent patients.20,21
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Besides its use in the surgical population, the use of ketamine was also evaluated 
in the treatment of neuropathic pain secondary to cancer.
 
Can a continuous parenteral infusion of low dose (racemic) ketamine effectively 
be used in the treatment of neuropathic pain (uncontrolled by high doses of 
opioids) in terminal cancer patients?
In chapter 6a a case series study is presented on the use of subcutaneously 
administered (racemic) ketamine in patients with neuropathic cancer pain. It was 
shown that in selected patients the continuous administration of ketamine can be 
very useful in this otherwise difﬁ cult to treat pain syndrome. Bell et al.22 
evaluated the evidence for the use of ketamine in cancer pain. Only four 
randomised, controlled studies were identiﬁ ed, of which two were excluded due 
to poor quality. The two studies that met the inclusion criteria concluded that 
ketamine improves morphine treatment in cancer pain. For non-cancer pain, 
Hocking and Cousins 23 concluded that the evidence for the efﬁ cacy of ketamine 
is moderate to weak, but that in situations where standard analgesic options have 
failed, ketamine is a reasonable “third line” option. 
As shown in Chapter 6a, the continuous intravenous or subcutaneous 
administration of ketamine is feasible at home. However, other routes of 
administration, especially transdermal, nasal or oral, can have obvious 
advantages versus intravenous or subcutaneous administration.24-27 Randomised, 
controlled trials (using (s(+)-)ketamine) of high quality with larger numbers of 
patients and clinically relevant routes of administration are needed to further 
clarify the possible beneﬁ cial role of ketamine in neuropathic pain patients.
Amantadine
A human, clinical, pilot study and a preclinical study in rats were performed 
using amantadine.
What is the effect on postoperative pain and opioid consumption of amantadine 
given orally over the perioperative period in patients undergoing radical 
prostatectomy?
In Chapter 4 the results are presented of a pilot study on the effects of 
perioperative, preventive use of amantadine in patients undergoing radical 
prostatectomy. It was shown that perioperative use of amantadine (400 mg before 
surgery and a total of 300 mg after surgery) resulted in a 32% reduction in 
postoperative morphine consumption. Much to our surprise, a possible 
pharmacokinetic interaction was found between amantadine and morphine, 
perhaps explaining the main ﬁ nding of lower morphine consumption in the 
amantadine group. In addition, a reduced mechanical sensitivity around the 
surgical wound and a lower incidence of bladder spasm pain was found in 
patients of the amantadine group. This would suggest that pharmacodynamic 
interactions, involving the NMDA receptor, likely also contributed to the positive 
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outcomes observed with amantadine in this study.
What are the effects of pre-treatment with amantadine on morphine induced 
antinociception during second phase formalin responses in rats?
In Chapter 5 the possible effects of pre-treatment with amantadine on morphine 
induced antinociception were assessed in rats using a formalin test. The rotarod 
test was used to assess possible motor impairment to exclude aspeciﬁ c behavioral 
effects, as a possible explanation of any observed antinociceptive effects in the 
formalin test. In addition, and as a result of the pharmacokinetic interaction 
observed in humans (Chapter 4), serum morphine concentrations were measured 
to evaluate possible pharmacokinetic interactions between amantadine and 
morphine. The performed experiments revealed a clear synergistic effect between 
amantadine and morphine during the second phase of the formalin test. To obtain 
a comparable level of antinociception in the second phase of the formalin test, 53 
and 60% less morphine was needed in rats pretreated with amantadine 12.5 and 
25 mg kg-1 respectively, as compared to vehicle treated controls. There were no 
signs of motor impairment in this phase and no evidence was found for a 
pharmacokinetic interaction. A pharmacodynamic interaction involving the 
NMDA receptor is therefore the most likely explanation of the opioid sparing 
effects of amantadine in this test.
In both studies presented in Chapter 4 and 5, a morphine sparing effect was 
found by combining amantadine with morphine. It is, however, not clear if this 
effect can be explained via pharmacodynamic factors (Chapter 5), 
pharmacokinetic factors, or a combination of both (Chapter 4). A formal 
pharmacokinetic study under strict steady state conditions should be performed 
to conﬁ rm or reject our preliminary results in humans. 
Currently, a large-scale randomised, blinded, prospective clinical study is being 
conducted to further evaluate the early and late effects of preventive use of 
amantadine in surgical patients.
Methadone
Methadone is an opioid with intrinsic NMDA antagonist properties. In order to 
evaluate whether methadone would be effective in chronic neuropathic pain it 
was tried in patients with phantom limb pain.
 
Can methadone effectively be used in the treatment of phantom limb pain?
In chapter 6b a case series is presented on the use of methadone in patients with 
phantom limb pain. A low dose of 2 to 5 mg bid or tid was slowly titrated 
upwards to obtain pain relief. In all 4 cases an effective reduction in phantom 
limb pain was seen. The favorable results in our patients led us to conclude that a 
trial with oral methadone should be included in the treatment plan for these 
patients. Other authors have now also conﬁ rmed the efﬁ cacy of methadone in the 
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treatment of neuropathic pain in an open, prospective study and a randomised 
trial.28,29 However, to date no prospective trials have been published evaluating the 
efﬁ cacy of methadone speciﬁ cally for phantom limb pain.
The studies presented in this thesis emphasize the NMDA receptor antagonist 
properties of ketamine, amantadine and methadone. However as mentioned 
above and/or discussed for ketamine in Chapter 2, 3 and 6a, for amantadine in 
Chapter 4 and 5 and for methadone in Chapter 6b, these drugs have multiple 
other sites of actions which may also have contributed to the observed effects. 
Ketamine interacts with multiple binding sites (e.g. opioid receptors, 
monoaminergic receptors, nicotinic and muscarinic cholinergic receptors, Ca2+ 
channels, GABA receptors, Na+ channels) but enough evidence is available to 
consider the NMDA receptor antagonist properties of ketamine as its primary 
mode of action.30,31
In the clinically relevant dose range amantadine, mainly interacts with the sigma 
and the NMDA receptor.32-34 As discussed in Chapter 5, the exact role of the 
sigma receptor with regard to pain and its interaction with opioids has not been 
elucidated, while the NMDA receptor antagonists properties of amantadine are 
better deﬁ ned. 
Methadone is an unique drug since it combines mu-opioid receptor agonist 
activity with NMDA receptor antagonist activity in one drug.35 This dual action 
makes it particularly useful for the treatment of chronic, neuropathic pain. 
Furthermore, methadone inhibits the reuptake of serotonine which further 
potentially adds to its pain relieving properties.36 
It is noteworthy that all three clinically available NMDA receptor antagonist 
drugs used in this thesis were already in clinical use before they have been found 
to inhibit the NMDA receptor. Interestingly, they are all low-afﬁ nity, non-
competitive NMDA antagonists, which might explain their favorable side-effect 
proﬁ le (when, of course, used in the appropriate dose).37 In contrast, high afﬁ nity, 
non-competitive NMDA receptor antagonist such as MK-801 and phencyclidine 
have not proved successful in clinical use because of their severe psychomimetic 
side effects.38
For the three clinically available NMDA receptor antagonists used in this thesis 
the following can be concluded:
Ketamine
• Pre-emptive analgesia using intravenous fentanyl plus low dose (racemic) 
ketamine does not produce clinically meaningful short term or long term 
reductions in pain or analgesic use in patients after radical prostatectomy. 
• The preventive use of intra- and postoperative low dose s(+)-ketamine plus 
morphine reduces postoperative morphine consumption and results in lower 
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pain scores at rest in patients after radical prostatectomy.
• The parenteral administration of low dose (racemic) ketamine is an easily 
available, minimally invasive and effective addition to the treatment with 
opioids of neuropathic pain in terminal cancer patients.
Amantadine
• The results from a pilot-study show that perioperative oral amantadine is 
associated with lower postoperative morphine requirements, less mechanical 
sensitivity around the surgical wound and a reduced incidence of bladder 
spasm pain in patients after radical prostatectomy.
• The combined use of amantadine and morphine results in a synergistic 
interaction between these two drugs in the second phase of the formalin test 
in rats.
Methadone
• Oral methadone can be effective in reducing phantom limb pain intensity in 
humans.
The general conclusion is that the combined use of opioids and clinically 
available NMDA receptor antagonists can, under certain conditions, reveal an 
opioid sparing effect in acute pain and can help in relieving neuropathic pain. 
The future clinical beneﬁ ts of these effects remain to be determined. 
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This thesis concerns the effects of combining opioids with clinically available 
NMDA receptor antagonists in the treatment of acute and chronic pain.
Chapter 1 includes a general introduction to the subject of this thesis. Opioids are 
widely used in the treatment of pain. There are, however, a number of problems 
with the use of opioids, such as, the development of tolerance, the development 
of an abnormal pain response (hyperalgesia), their reduced effectiveness in 
(central) neuropathic pain, and troublesome adverse effects, such as nausea and 
vomitting.
These problems might be resolved, or at least attenuated, by the combined use of 
opioids and clinically available drugs with N-methyl-D-aspartate (NMDA) 
receptor antagonist properties. The NMDA receptor plays a key role in the 
development of opioid induced tolerance, opioid induced hyperalgesia, central 
sensitization and neuropathic pain syndromes. In this thesis the effects of three 
clinically available NMDA receptor antagonists were studied: ketamine (the 
racemic form and its s(+)-enantiomer), amantadine and methadone.
The primary aim of the study presented in Chapter 2 is to evaluate postoperative 
pain and morphine consumption after pre-emptive use of fentanyl plus (racemic) 
ketamine. A secondary aim is to evaluate possible long term effects (two weeks 
and six months after surgery) of the treatment schedules on the transition of acute 
to chronic pain. In this study men undergoing radical prostatectomy under 
general anesthesia were randomly assigned in a double-blinded manner to one of 
three groups. All patients received intravenous (i.v.) fentanyl (0,5 µg kg-1) 10 
minutes before incision. This was immediately followed by an i.v. bolus dose 
(0.2 ml kg-1) and an i.v. infusion (0.0025 ml kg-1 min-1) of 1 mg ml-1 ketamine 
(group 1) or normal saline (groups 2 and 3). Seventy minutes after incision, the 
ﬁ rst infusion was stopped and the patients received again i.v. fentanyl (all 
groups) with a second i.v. bolus dose/infusion of saline (groups 1 and 3) or 
ketamine (group 2). The second infusion was stopped after 80 minutes. 
Furthermore all patients received i.v. fentanyl (1 µg kg-1) every 80 minutes 
starting 5 minutes before induction of anesthesia. Pain at rest and after 
mobilization, von Frey pain thresholds and cumulative morphine consumption 
using patient-controlled analgesia (PCA) were assessed up to 72 hours after 
surgery.
A total of 143 patients completed the study (group 1: n = 47; group 2: n = 50; 
group 3: n = 46). Cumulative PCA morphine (mean ± SD) did not differ 
signiﬁ cantly among the groups (group 1: 92.3 ± 45.9 mg, group 2: 107.2 ± 58.4 
mg, group 3: 103.6 ± 50.4 mg; p = 0.08 for group 1 versus group 2, and group 1 
versus group 3). However, on day 3 (49 to 72 hours after surgery), the hourly rate 
(mean ± SEM) of morphine consumption was signiﬁ cantly lower (p < 0.0009) in 
group 1 (0.61 ± 0.013 mg h-1) than group 2 (0.86 ± 0.011 mg h-1) and group 3 
(0.89 ± 0.008 mg h-1). This amounted to 6 mg less of morphine over 24 hours for 
the patients in group 1, which is considered to be not clinically relevant. Pain 
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scores and von Frey pain thresholds did not differ signiﬁ cantly among groups. 
Two week and six month follow-ups did not reveal signiﬁ cant group differences 
in pain incidence, pain intensity, disability or mental health. 
It is concluded that pre-incisional, low dose administration of a combination of 
fentanyl and ketamine does not result in a clinically meaningful reduction in pain 
or morphine consumption when compared with post-incisional administration of 
fentanyl and ketamine or a control condition which only received fentanyl.
Chapter 3 presents the results of a study evaluating the effects on postoperative 
pain and morphine consumption of the administration of s(+)-ketamine (100 µg 
kg-1 bolus and a continuous infusion of 2 µg kg-1 min-1 intraoperatively, and 
combined with PCA morphine (morphine 1 mg ml-1, s(+)-ketamine 0.5 mg ml-1)  
postoperatively) and morphine, when compared to the administration of saline 
and morphine. In this randomised, double-blind, prospective study a total of 28 
male patients undergoing radical prostatectomy were studied. Morphine 
consumption (PCA), pain scores, sensitivity to mechanical pressure around the 
surgical wound (pressure algometry) and adverse effects were recorded for 48 
hours after surgery.
Cumulative PCA morphine consumption (mean ± SD) was signiﬁ cantly lower in 
the ketamine/morphine group (47.9 ± 26.2 mg) than in the saline/morphine group 
(73.4 ± 34.8 mg; p = 0.049). Pain scores at rest were signiﬁ cantly lower in the 
ketamine/morphine group across the 48-hour study period (p = 0.01). No 
signiﬁ cant differences were found in pressure algometry measurements or in the 
occurrence of adverse effects. 
The results of this study show that low dose s(+)-ketamine given during and after 
radical prostatectomy reduces PCA morphine consumption by 34% at 48 hours 
after surgery and lowers pain scores at rest. However no differences were found 
in hyperalgesia (as measured with pressure algometry) or in the incidence of 
adverse effects. 
The aim of the pilot study presented in Chapter 4 is to evaluate the effects of 
perioperative oral amantadine on postoperative pain and morphine consumption. 
Amantadine is known to be a non-competitive NMDA receptor antagonist and 
may be useful in preventing postoperative central sensitization, acute opioid 
tolerance and opioid-induced hyperalgesia thereby decreasing pain and/or 
morphine requirements. Twenty-four patients scheduled for radical 
prostatectomy were given oral amantadine in a randomised, double blind, 
placebo controlled manner. A total of 400 mg of amantadine was given before 
surgery and 100 mg was given at 8, 20 and 32 hours postoperatively. After 
surgery patients received i.v. PCA with morphine for 48 hours. Wound pain 
intensity, sensitivity to mechanical pressure around the surgical wound (pressure 
algometry), the number of patients reporting bladder spasm pain, adverse effects 
and patient satisfaction were assessed. Blood samples were drawn for analysis of 
amantadine, morphine and the morphine metabolites (M3G and M6G).
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The results revealed that the cumulative morphine consumption (mean ± SD) was 
signiﬁ cantly lower in the amantadine group at all time points (except at 48 hours, 
p = 0.0515) resulting in a 32% reduction over the 48 hours period (amantadine: 
51.4 ± 24.0 mg; placebo 75.3 ± 38.9 mg). Furthermore, 48 hours after surgery, 
visual analogue pain scores to pressure applied near the wound were signiﬁ cantly 
lower in the amantadine group (2.4 ± 1.2) than in the placebo group (4.3 ± 1.8;
p = 0.04). In addition, the number of patients reporting bladder spasm pain was 
signiﬁ cantly lower in the amantadine group (p = 0.02). Despite the same amount 
of morphine given during surgery, the plasma concentration of M3G was found 
to be signiﬁ cantly lower at the end of surgery in the amantadine group 
(amantadine: 74.1 ± 47.8 ng ml-1; placebo 123.0 ± 52.5 ng ml-1, p = 0.048). 
Furthermore pharmacokinetic analyses showed that the plasma clearance of 
morphine at 21-24 hours after surgery was also signiﬁ cantly lower in the 
amantadine group (p < 0.05). 
It is concluded that the results of this pilot study suggest that perioperative oral 
amantadine reduces postoperative opioid consumption mainly by 
pharmacokinetic mechanisms, although additional pharmacodynamic 
interactions may also be involved.
Intrigued by the ﬁ ndings from the study on perioperative use of amantadine, an 
animal study was performed (presented in Chapter 5) to proﬁ le the possible 
effects of amantadine (0, 12.5, 25 or 50 mg kg-1 i.p.) pre-treatment on morphine 
(0, 0.63, 1.25, 2.5 or 5 mg kg-1 s.c.) induced antinociception in rats. The 
(automated) formalin test (5% formalin, 50 µl) was used to assess if amantadine 
enhances the antinociceptive activity of morphine. Possible motor impairment 
was assessed with a rotarod test. Morphine was measured in serum of 
amantadine or vehicle treated rats to search for pharmacokinetic interactions 
between amantadine and morphine. 
Isobolographic analysis provided evidence for a synergistic interaction between 
amantadine and morphine in the second phase of the formalin test. For the same 
effect on the number of ﬂ inches per minute, 53% and 60% less morphine was 
needed in rats pre-treated with amantadine 12.5 and 25 mg kg-1 respectively. No 
evidence was found to indicate that amantadine induced motor impairment at the 
doses potentiating morphine during the second phase of the formalin test. There 
was also no evidence for a pharmacokinetic interaction between amantadine and 
morphine.
Since the second phase of the formalin test is dependent on NMDA receptor 
activation it was concluded that an antagonistic activity of amantadine at the 
NMDA receptor most likely contributes to the synergistic interaction observed 
between amantadine and morphine in rats. 
Chapter 6a presents our experiences with the use of continuous low dose infusion 
of i.v. or subcutaneous (racemic) ketamine in the treatment of neuropathic pain in 
cancer patients. Neuropathic pain that could not be alleviated adequately by 
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administration of opioids was treated with parenteral ketamine in three patients; 
a 52-year-old woman with skeletal metastases from bladder carcinoma, a 54-
year-old man with metastasized thyroid carcinoma and a 40-year-old man with 
non-Hodgkin’s lymphoma. Pending invasive therapy, the three patients were 
given a continuous low dose infusion of i.v. or subcutaneous ketamine (2-5 µg kg 
min-1) in addition to the analgesic drugs they were receiving. 
The pain in the ﬁ rst two patients responded so well to ketamine that it was 
decided to waive the invasive pain treatment and to continue the ketamine 
infusion at home until death. In the third patient, the addition of ketamine 
resulted in an adequate level of analgesia during the waiting period for a more 
invasive treatment involving insertion of an intrathecal catheter. These results 
suggest that the parenteral administration of low dose (racemic) ketamine is an 
easily available, minimally invasive and effective addition to the treatment with 
opioids of neuropathic pain in terminal cancer patients.
The objective of the case series presented in Chapter 6b was to determine if 
severe phantom limb pain could be reduced with oral methadone, an opioid with 
NMDA receptor blocking properties. Four patients with severe, intractable 
phantom limb pain refractory to multiple treatment modalities were treated with 
oral methadone. Oral methadone was administered starting with a low dose of 2 
to 5 mg bid or tid and slowly titrated upward to achieve pain relief. 
Methadone was effective in reducing phantom limb pain intensity in all four 
presented patients. It is concluded that administration of oral methadone may be 
of value in the treatment of phantom limb pain; controlled clinical trials would be 
appropriate to verify this observation.
A discussion of the overall results, together with further perspectives, is given in 
Chapter 7. It was concluded that the concept of pre-emptive analgesia (by using 
fentanyl plus low dose (racemic) ketamine before versus after incision) is not a 
useful clinical approach, but that a preventive approach (by using s(+)-ketamine 
started before induction of anesthesia with continuation into the postoperative 
period) might be a more clinically useful strategy. 
The results from a pilot study showed that the perioperative, preventive use of 
amantadine was associated with lower postoperative morphine requirements, less 
intense mechanical sensitivity around the surgical wound and a reduced 
incidence of bladder spasm pain in patients after radical prostatectomy. An 
animal study revealed that the combined use of amantadine and morphine 
resulted in a synergistic interaction between these two drugs in the second phase 
of the formalin test in rats. It is however not clear if the effects found with the 
use of amantadine can be contributed to pharmacodynamic factors, 
pharmacokinetic factors or a combination of both.
For patients with neuropathic pain it was found that the parenteral administration 
of low dose ketamine is an easily available and minimally invasive alternative for 
the treatment of neuropathic pain in terminal cancer patients, and that oral 
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methadone can be effective in reducing phantom limb pain intensity in humans.
In conclusion the work presented in this thesis indicates that combined use of 
opioids and clinically available NMDA receptor antagonists can, under certain 
conditions, reveal an opioid sparing effect in acute pain and can help in relieving 
neuropathic pain. The future clinical beneﬁ ts of these effects remain to be 
determined. 
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Dit proefschrift gaat over de effecten van het gecombineerd gebruik van opioïden 
en klinisch beschikbare N-methyl-D-aspartaat (NMDA) receptor antagonisten bij 
de behandeling van acute en chronische pijn.
Hoofdstuk 1 is een introductie tot het onderwerp van het proefschrift. Opioïden 
zijn een veelgebruikt middel bij de behandeling van pijn. Er zijn echter een 
aantal problemen bij het gebruik van opioïden, waaronder de ontwikkeling van 
tolerantie, de ontwikkeling van een abnormale pijnrespons (hyperalgesie), 
verminderde effectiviteit bij de behandeling van (centrale) neuropathische pijn, 
en het optreden van hinderlijke bijwerkingen, zoals bijvoorbeeld misselijkheid en 
braken. 
Stelling van het onderzoek was dat deze problemen kunnen worden opgelost, of 
ten minste verminderd, door het gecombineerd gebruik van opioïden en klinisch 
bruikbare middelen met een antagonistische werking op de NMDA receptor. De 
NMDA receptor speelt een belangrijke rol in het ontstaan van opioïd-
geïnduceerde tolerantie, opioïd-geïnduceerde hyperalgesie, centrale sensitisatie 
en neuropatische pijnsyndromen. In dit proefschrift zijn de effecten van drie 
klinisch beschikbare NMDA receptor antagonisten bestudeerd: ketamine (het 
racemisch mengsel en de s(+)-enantiomeer), amantadine en methadon.
Het eerste doel van de studie, zoals gepresenteerd in hoofdstuk 2, is het evalueren 
van de effecten van het gecombineerd, pre-emptief gebruik van fentanyl en 
(racemisch) ketamine op postoperatieve pijn en morﬁ negebruik. Een tweede doel 
is de evaluatie van mogelijke lange termijn effecten (twee weken en zes maanden 
na de operatie) van de behandelschema’s op de overgang van acute, 
postoperatieve pijn in chronische pijn. In deze dubbelblinde studie zijn mannen, 
die een radicale prostatectomie onder algehele anesthesie ondergingen, 
gerandomiseerd in drie groepen. Alle patiënten kregen, 10 minuten voor incisie, 
intraveneus (i.v.) fentanyl (0,5 µg kg-1) toegediend, meteen gevolgd door een i.v. 
bolusinjectie (0.2 ml kg-1) en een continue infusie (0.0025 ml kg-1 min-1) van 1 mg 
ml-1 ketamine (groep 1) of fysiologische zout (groep 2 en 3). Zeventig minuten na 
incisie werd de eerste infusie gestopt en kregen de patiënten wederom i.v. 
fentanyl (alle groepen) en een i.v. bolusinjectie/continue infusie van fysiologisch 
zout (groep 1 en 3) of ketamine (groep 2). De tweede infusie werd gestopt na 80 
minuten. Bovendien kregen alle patiënten elke 80 minuten i.v. fentanyl (1 µg kg-1) 
toegediend; de eerste gift werd gegeven 5 minuten voor inductie van de 
anesthesie. Pijn in rust en na mobilisatie, meting van pijndrempels middels von 
Frey ﬁ lamenten en het cumulatief morﬁ negebruik (patiënt gecontroleerde 
analgesie (PCA)) werden bepaald tot 72 uur na de operatie. 
De onderzochte populatie omvatte 143 patiënten (groep 1: n = 47; groep 2:
n = 50; groep 3: n =  46). Er bleken geen signiﬁ cante verschillen te zijn tussen de 
groepen in cumulatief PCA morﬁ negebruik (gemiddeld ± SD) (groep 1: 92.3 ± 
45.9 mg, groep 2: 107.2 ± 58.4 mg, groep 3: 103.6 ± 50.4 mg; p = 0.08 voor 
groep 1 versus groep 2 en groep 1 versus groep 3). Alleen op dag 3 (49 tot 72 uur 
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na operatie) was het morﬁ negebruik per uur (gemiddelde ± SEM) signiﬁ cant 
lager (p < 0.0009) in groep 1 (0.61 ± 0.013 mg h-1) in vergelijking met groep 2 
(0.86 ± 0.011 mg h-1) en groep 3 (0.89 ± 0.008 mg h-1). Dit kwam neer op een 
reductie in morﬁ negebruik van 6 mg per 24 uur voor de patiënten in groep 1, wat 
wordt beschouwd als een klinisch niet-relevante reductie. Pijnscores en bepaling 
van de pijndrempels met behulp van von Frey ﬁ lamenten lieten geen signiﬁ cante 
verschillen zien tussen de groepen. Er bleek evenmin sprake te zijn van een 
verschil in incidentie en intensiteit van pijn en in lichamelijk of psychisch 
functioneren bij de follow-up na twee weken en na zes maanden. 
De conclusie is dat het toedienen van een combinatie van fentanyl en een lage 
dosis (racemisch) ketamine, voor versus na incisie, niet resulteert in een klinisch 
relevante vermindering van pijn en morﬁ negebruik, ten opzichte van een 
standaard behandeling middels het toedienen van alleen fentanyl.
Hoofdstuk 3 presenteert de resultaten van een studie naar de effecten van het 
gebruik van s(+)-ketamine (100 µg kg-1 bolus en een continue infusie van 2 µg
kg-1 min-1 intraoperatief, en gecombineerd met PCA morﬁ ne (morﬁ ne 1 mg ml-1, 
s(+)-ketamine 0.5 mg ml-1) postoperatief) en morﬁ ne, ten opzichte van het 
gebruik van fysiologisch zout en morﬁ ne, op postoperatieve pijn en het totale 
postoperatieve morﬁ negebruik. Deze gerandomiseerde, dubbel blinde, 
prospectieve studie omvatte 28 patiënten, die een radicale prostatectomie 
ondergingen. Morﬁ negebruik (PCA), pijnscores, gevoeligheid voor mechanische 
druk rond de chirurgische wond (druk algometrie) en incidentie van bijwerkingen 
werden bepaald tot 48 uur na de operatie.
Cumulatief PCA morﬁ negebruik (gemiddelde ± SD) was signiﬁ cant lager in de 
ketamine/morﬁ ne groep (47.9 ± 26.2 mg) in vergelijking tot de fysiologisch zout/
morﬁ ne groep (73.4 ± 34.8 mg; p = 0.049). De pijnscores in rust waren 
signiﬁ cant lager in de ketamine/morﬁ ne groep over de gehele periode van 48 uur 
(p = 0.01). Er werden geen signiﬁ cante verschillen gevonden in de algometrie-
metingen of in de incidentie van bijwerkingen. 
De resultaten van deze studie laten zien dat de toediening van een lage dosis 
s(+)-ketamine, gegeven tijdens en na een radicale prostatectomie, resulteert in 
een afname van het PCA morﬁ negebruik met 34% (48 uur na de operatie) en in 
lagere pijnscores. Er werden echter geen verschillen gevonden in hyperalgesie, 
zoals gemeten met druk algometrie, of in de incidentie van bijwerkingen.
Het onderzoek (pilot studie), zoals gepresenteerd in hoofdstuk 4, beoogt het 
evalueren van de effecten van perioperatief, oraal toegediend amantadine op 
postoperatieve pijn en morﬁ negebruik. Amantadine is een niet-competitieve 
NMDA antagonist en is daarom mogelijk bruikbaar voor de preventie van 
postoperatieve centrale sensitisatie en preventie van acute opioïd-geïnduceerde 
tolerantie/hyperalgesie. Dit zou dan kunnen resulteren in een verminderd 
morﬁ negebruik en/of betere pijnstilling. In deze gerandomiseerde, dubbelblinde 
en placebo gecontroleerde studie, kregen 24 patiënten, die een radicale 
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prostatectomie ondergingen, oraal amantadine toegediend. In totaal 400 mg 
amantadine werd gegeven voor de operatie en 100 mg op 8, 20 en 32 uur na de 
operatie. Gedurende 48 uur na de operatie gebruikten de patiënten i.v. morﬁ ne 
(PCA). Op vaste tijden werden de intensiteit van de wondpijn, de gevoeligheid 
voor mechanische druk rond de chirurgische wond (druk algometrie), het aantal 
patiënten met pijn ten gevolge van blaaskrampen, de bijwerkingen en de 
tevredenheid van de patiënten gescoord. Ook werden bloedmonsters genomen 
voor het bepalen van plasma concentraties van amantadine, morﬁ ne en morﬁ ne 
metabolieten (M3G en M6G).
Het cumulatieve morﬁ negebruik (gemiddelde ± SD) was signiﬁ cant lager in de 
amantadine groep op alle tijdstippen (behoudens op 48 uur, p = 0.0515). Dit 
resulteerde in een  reductie van 32% in het morﬁ negebruik over de periode van 
48 uur (amantadine: 51.4 ± 24.0 mg; placebo 75.3 ± 38.9 mg). De pijnscore, 
gemeten tijdens het toepassen van druk algometrie rond de wond, was signiﬁ cant 
lager in de amantadine groep (2.4 ± 1.2) dan in de placebo groep (4.3 ± 1.8;
p = 0.04). Tevens was het aantal patiënten met pijn door blaaskrampen signiﬁ cant 
lager in de amantadine groep (p = 0.02). Aan het eind van de operatie werd een 
signiﬁ cant lagere plasma concentratie voor M3G gemeten (amantadine: 74.1 ± 
47.8 ng ml-1; placebo 123.0 ± 52.5 ng ml-1, p = 0.048), terwijl dezelfde 
hoeveelheid morﬁ ne was gegeven tijdens de operatie. Een farmacokinetische 
analyse liet zien dat de plasmaklaring van morﬁ ne tussen 21 en 24 uur na de 
operatie signiﬁ cant lager was in de amantadine groep (p < 0.05).
De resultaten van deze (pilot) studie suggereren dat het perioperatief gebruik van 
amantadine, het postoperatief gebruik van morﬁ ne met name reduceert door 
farmacokinetische mechanismen. Farmacodynamische interacties zijn echter niet 
uitgesloten.
Nieuwsgierig gemaakt door de bevindingen uit het onderzoek naar het 
perioperatief gebruik van amantadine, is een dierexperimentele studie opgezet 
(hoofdstuk 5). In deze studie zijn de mogelijke effecten van voorbehandeling met 
amantadine (0, 12.5, 25 of 50 mg kg-1 i.p.) op morﬁ ne (0, 0.63, 1.25, 2.5 of 5 mg 
kg-1 s.c.) geïnduceerde antinociceptie onderzocht in ratten. De (geautomatiseerde) 
formalinetest (5% formaline, 50 µl) is gebruikt om te onderzoeken of amantadine 
de antinociceptieve effecten van morﬁ ne verhoogt. Mogelijke motorische 
bijwerkingen zijn onderzocht met de rotarodtest. Morﬁ ne is gemeten in serum 
van met amantadine of placebo voorbehandelde ratten, ten einde te kunnen 
beoordelen of er farmacokinetische interacties zijn tussen amantadine en 
morﬁ ne. 
Isobolograﬁ sche analyse leverde het bewijs voor een synergistische interactie 
tussen amantadine en morﬁ ne in de tweede fase van de formalinetest. Voor 
eenzelfde effect op het aantal “ﬂ inches” (terugtrekkingen van de poot van de rat) 
per minuut, was respectievelijk 53 en 60% minder morﬁ ne nodig in ratten, die 
waren voorbehandeld met amantadine 12,5 en 25 mg kg-1. Bij het gebruik van 
deze doseringen amantadine werd geen effect op de motoriek gezien. Ook was er 
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geen bewijs voor een farmacokinetische interactie tussen amantadine en morﬁ ne.
Daar de tweede fase van de formalinetest afhankelijk is van activatie van de 
NMDA receptor werd geconcludeerd dat een antagonistische werking van 
amantadine op de NMDA receptor, de meest waarschijnlijke verklaring is voor 
de synergistische interactie tussen amantadine en morﬁ ne in ratten. 
Hoofdstuk 6a presenteert onze ervaringen met het gebruik van een continue i.v. 
of subcutane toediening van een lage dosis (racemisch) ketamine in de 
behandeling van neuropathische pijn bij kankerpatiënten. Neuropathische pijn, 
die niet voldoende verlicht kon worden middels het gebruik van opioïden, werd 
behandeld met parenterale toediening van ketamine bij drie patiënten: een 52-
jarige vrouw met een naar het skelet gemetastaseerd blaascarcinoom, een 54-
jarige man met een gemetastaseerd schildkliercarcinoom en een 40-jarige man 
met een non-Hodgkin-lymfoom. In de overbruggingsperiode tot een invasieve 
behandeling werd gestart met de continue i.v. of subcutane toediening van een 
lage dosis ketamine (2-5 µg kg-1 min-1). Dit als aanvulling op de analgetica die al 
werden gebruikt. 
Bij de eerste twee patiënten was de pijnstilling dermate goed dat werd afgezien 
van verdere invasieve behandeling. Gekozen werd voor het voortzetten van de 
ketaminetoediening in de thuissituatie. Bij de derde patiënt kon door de 
toevoeging van ketamine een adequate pijnstilling bereikt worden in de 
overbruggingsperiode tot invasieve behandeling met een intrathecale catheter.
De conclusie luidt dat de parenterale toediening van een lage dosis (racemisch) 
ketamine een makkelijk beschikbare, minimaal invasieve en effectieve 
toevoeging is aan de behandeling met opioïden van neuropathische pijn bij 
terminale kankerpatiënten.
De case serie, zoals gepresenteerd in hoofdstuk 6b, beoogt het effect van oraal 
gebruik van methadon (een opioïd met NMDA receptor antagonistische 
activiteit) te bepalen op ernstige fantoompijn. Vier patiënten met ernstige 
fantoompijn, die niet hadden gereageerd op diverse voorafgaande therapieën, zijn 
behandeld met methadon. Methadon werd gestart in een lage dosis van 2 tot 5 
mg (2–3 x daags) en dit werd langzaam verhoogd tot pijnstilling optrad. 
Methadon was effectief in het verminderen van de intensiteit van de fantoompijn 
in alle vier patiënten. De conclusie luidt dat het oraal gebruik van methadon van 
waarde kan zijn in de behandeling van fantoompijn. Gecontroleerde, klinische 
trials zijn nodig om onze waarneming te bevestigen.
Hoofdstuk 7 is een discussie over alle onderzoeksresultaten met suggesties voor 
verder onderzoek.
Geconcludeerd werd dat het concept van pre-emptieve analgesie (middels het 
toedienen van fentanyl in combinatie met (racemisch) ketamine, voor versus na 
de incisie) geen klinisch zinvolle benadering is, maar dat een preventieve 
benadering (middels het gebruik van s(+)-ketamine gestart voor inductie van 
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anesthesie met voortzetting in de postoperatieve periode) mogelijk een klinisch 
zinvolle strategie is.
De resultaten van een pilot studie laten zien dat het perioperatieve, preventieve 
gebruik van amantadine in radicale prostatectomie-patiënten leidde tot een lager 
postoperatief morﬁ negebruik, minder intense mechanische gevoeligheid rond de 
chirurgische wond en een lagere incidentie van pijn ten gevolge van blaaskramp. 
Een dierexperimentele studie in ratten liet een synergistische interactie zien 
tussen amantadine en morﬁ ne in de tweede fase van de formalinetest. Het is 
echter nog niet duidelijk of de gevonden effecten van het gebruik van amantadine 
verklaard kunnen worden vanuit farmacodynamische factoren, farmacokinetische 
factoren of een combinatie van beiden.
Bij patiënten met neuropathische pijn werd gevonden dat de parenterale 
toediening van een lage dosis ketamine een makkelijk beschikbare, minimaal 
invasieve en effectieve aanvulling is voor de behandeling van neuropathische pijn 
in kankerpatiënten en dat het oraal gebruik van methadon effectief kan zijn in het 
reduceren van fantoompijn.
De verschillende onderzoeken leiden tot de conclusie dat een gecombineerd 
gebruik van opioïden en klinisch bruikbare NMDA receptor antagonisten, onder 
bepaalde voorwaarden, een opioïdsparend effect heeft bij acute pijn en helpt in 
het verlichten van neuropathische pijn. Verdere klinische voordelen van deze 
effecten moeten nog worden vastgesteld.
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the supervisors of my thesis.
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inzet en strijd voor het (opnieuw) creëren van een onderzoeksklimaat binnen de 
afdeling Anesthesiologie. Jos, naast je welverdiende Radboudpluim krijg je van 
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Johnhnson & Johnson Pharmaceutical Research and Development te Beerse 
(België) ben ik veel dank verschuldigd voor hun hulp bij de praktische 
uitvoeringen van de dierexperimentele studies.
Tineke van Rijn, je noemt je zelf “dataverslaafd” en als toediener van allerlei 
potentieel verslavende stoffen gaf ik je dus de data van de dierexperimentele 
studies. Hiermee heb jij een belangrijke bijdrage geleverd aan hoofdstuk 5.
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AMPA  alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
an  ante noctum 
ANCOVA analysis of covariance
ANOVA  analysis of variance
ASA  American Society of Anesthesiologists
bid  twice a day (Latin: bis in die)
C  centigrade(s)
Ca  calcium
cm  centimeter(s)
CNS  central nervous system
FUPQ  Follow-Up Pain Questionnaire
g  gram(s)
GABA  gamma-aminobutyric acid
h  hour(s)
i.p.  intraperitoneal(ly)
i.v.  intravenous(ly)
K  potassium
kg  kilogram(s)
l  liter(s)
log  logarithm
m  meter(s)
M3G  morphine-3-glucoronide
M6G  morphine-6-glucoronide
mg  milligram(s)
Mg  magnesium
MHI  Mental Health Inventory
µg  microgram(s)
µM  micromolar
min  minute(s)
ml  milliliter(s)
mm  millimeters(s)
MPQ  McGill Pain Questionnaire
N2O  nitrous oxide
Na  sodium
NK  neurokinin
NMDA  N-methyl-D-aspartate
nmol  nanomoles
NRS  numeric rating scale
NSAID’s non-steroidal anti-inﬂ ammatory drugs
O2  oxygen
OR  operating room
PACU  Post Anesthesia Care Unit
PCA  patient-controlled analgesia
PCP  phenylcyclidine
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PKC  protein kinase C
PPI  present pain intensity
PPT   pain perception threshold
PRI  pain rating index
PT  pain threshold
PTM   Pressure Threshold Meter
qid  4 times a day (Latin: quater in die)
rpm  rotations per minute
s.c.  subcutaneous(ly)
SD  standard deviation
SEM  standard error of the mean 
SPSS  Statistical Package for the Social Sciences
STAI  Spielberger State-Trait Anxiety Inventory
T  time(point)
Th  thoracic
tid  three times daily (Latin: ter in die)
TT  touch threshold
VAS  visual analogue scale
VAS-M  visual analogue scale after mobilization
VAS-R  visual analogue scale in rest
VRS  verbal rating scale
WHO  World Health Organization
